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Abstract
Malignant hyperthermia (MH) is the most common cause of unexpected 
death due to general anaesthesia using common volatile anaesthetic agents. It is an 
autosomal dominant pharmacogenetic abnormality of skeletal muscle with a high 
degree of genetic and clinical variability. It is associated with elevated calcium ion 
levels in skeletal muscle cells. Apparently it is caused by defect in a calcium 
release channel, encoded by theRYRJ gene which is located on chromosome 19q.
Studies show only around 50% of MH families are linked to the RYR1 gene 
so that heterogeneity for this abnormality is suggested. Further studies proved 
more genes or a candidate regions such as chromosome 7q, 3q are involved in 
malignant hyperthermia susceptibility.
In this search for more understanding of the malignant hyperthermia 
disorder and for identifying the gene or genes which may be causative in MH, 
some UK MH families for the RYR1 gene and other candidate regions were 
studied. Furthermore based on reports of the correlation between MH and 
mutations in the RYR1 gene in 19-linked families the screening of UK MH families 
for three mutations from eight putative causative mutations in the RYR] gene was 
carried out.
The ultimate goal of this MH project has been to identify individuals 
susceptible to MH in advance of anaesthesia. Genetic analysis by direct mutation 
testing or linkage analysis potentially offers an alternative non-invasive and 
accurate test for diagnosis of MH susceptibility. However once the linkage
relationships are firmly established, they provide a sensitive, non-invasive 
technique for the presymptomatic diagnosis of MH.
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Chapter one
Introduction
Malignant Hyperthermia, MH, is perhaps the commonest cause of 
unexpected death in patients due to general anaesthesia using common volatile 
anaesthetic agents (Ellis and Halsall 1980). Malignant hyperthermia is an 
autosomal dominant pharmacogenetic abnormality and life threatening disorder of 
skeletal muscle with a high degree of genetic and clinical variability (Denborough 
et al 1962; Britt et al 1969). It is an inherited condition that occurs in humans and 
some species of domestic animals, such as dog, horse and swine (Gronert 1980; 
Britt 1987). It can be triggered by a variety of factors, such as stress, anaesthetic 
drugs and skeletal muscle relaxants (Wingard 1974).
1.1 History of malignant hyperthermia (MH)
Malignant hyperthermia was reported for the first time in humans by 
Denborough and Lovell in Australia (1960). They reported an accelerated 
metabolism during anaesthesia, in a 21-year-old man, who survived after an 
episode of extreme hyperpyrexia. Subsequent investigation revealed that he had 
lost 10 relatives since 1922 as a result of anaesthesia and in three of these cases 
where records were available high body temperature was associated with the death. 
For this anaesthesia they used volatile anaesthetic agents, halothane and nitrous 
oxide. The family history of the young man suggested this condition had been
2transmitted as an autosomal dominant with reduced penetrance (Denborough et al 
1962).
Further case reports were published and muscle rigidity, hyperthermia, 
tachycardia and other symptoms of malignant hyperthermia as a result of general 
anaesthesia were described (Saidman et al 1964; Thut and Davenport 1966; Lavoie 
1966; Davies and Graves 1966). In subsequent MH studies treatment schemes and 
hypotheses of its aetiology, its relationship to other metabolic and muscle diseases 
such as central core disease (CCD) and neuroleptic malignant syndrome have been 
described. These raised the possibility that in previous years some of the sudden 
deaths which had occurred during or immediately after anaesthesia associated with 
high fever might have been caused by malignant hyperthermia susceptibility. The 
word “malignant” before hyperthermia or hyperpyrexia was used for the first time 
by Gordon in his description of the disorder (Gordon 1966).
MH is not a disease with unique symptoms, a unique hereditary pattern and 
a singular aetiology. It does not necessarily occur during the first anaesthesia (Britt 
et al 1969). Halsall et al (1979) reported one patient who had had 13 previous 
general anaesthetics without any apparent problem before experiencing an MH 
crisis and subsequently was identified as MH susceptible. Therefore the 
occurrence of an MH episode is dependent on the background susceptibility of 
subjects and other possible environmental factors, and for this reason MH 
susceptibility is considered to exhibit autosomal dominance with reduced 
penetrance. During dental and other minor surgery using anaesthetic vapour for a 
brief exposure time, MH is usually not a complication. Unfortunately compared
with most muscular disorders MH does not have any phenotypic key features and 
the phenotype remains cryptic until a susceptible individual is exposed to triggering 
anaesthetic agents. It is generally believed that a defect in calcium regulation of 
muscle contraction and metabolism is responsible for this abnormality (Britt and 
Kalow 1970b; Mickelson et al 1986; Carrier et al 1991; Nelson 1991; Iaizzo et al
1988) although the precise mechanism is not known.
1.2 An animal model of MH
A condition similar to MH in some features, called porcine stress syndrome 
(PSS) has been recognised in some races of pigs including the Dutch, Landrace, 
Poland China, and Pietrain breeds. This syndrome in predisposed pigs is induced 
by stress such as separation, shipping, weaning, fighting, coitus, slaughter, and heat 
in addition to exposure to volatile anaesthetics. Porcine MH or PSS presents with 
shortness of breath, associated with rapid increase in body temperature, metabolic 
acidosis, muscle rigidity, and death (Gronert 1980; Mabry et al 1981). PSS in 
addition to death can have serious economic consequences in the pork industry. It 
causes hypermetabolism in skeletal muscle which results in the deterioration of the 
muscle so that the carcass yields an unsuitable quality of pork (Briskey 1964). This 
meat has little commercial value and it is described as pale, soft and exudative pork 
(PSEP).
In attempts to further understand the syndrome the relations between PSS 
as a disorder of muscle and rigidity during suxamethonium-halothane anaesthesia 
(Hall et al 1966) and nitrous oxide-halothane anaesthesia (Harrison et al 1968) in
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susceptible pigs have been investigated. Discoveries on the clinical, metabolic and 
biochemical changes in susceptible pigs with MH have demonstrated its 
importance as an animal model for the human phenotype. It was ideal for 
experiments on pathophysiology and identification of susceptible individuals which 
could not be carried out in humans (Berman et al 1970).
The finding of the role of altered skeletal muscle sarcoplasmic reticulum,
SR ryanodine receptor in susceptible pigs compared with controls and the 
implication of a biochemical abnormality of the SR calcium release channel as the 
cause of MH was an important step towards understanding the aetiology of 
malignant hyperthermia susceptibility or PSS (Mickelson et al 1986; 1988;
Eravasti et al 1991). This is supported by molecular genetic evidence where a 
mutation in the gene encoding the skeletal muscle ryanodine receptor in susceptible 
pigs was reported. The susceptibility to PSS in pigs, unlike MH in humans, is an 
autosomal recessive trait and transmitted by a single gene, Hal (Andresen and 
Jensen 1977; Reik et al 1983) which is located on chromosome 6 (Hartbitz et al 
1990).
1.3 MH signs and symptoms
A human MH crisis is indicated by a spectrum of symptoms, which are 
categorised in eight groups ranging from the classic cases described as fulminant, 
with frequency less than 10% (Rosenberg 1988), to those with mild or unusual 
presentation (Ellis et al 1990; Halsall and Ellis 1993). Although atypical physical 
appearance of MH susceptible individuals is not proven, anecdotal evidence exists
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to suggest that MH susceptible (MHS) individuals tend to be well built, muscular 
and also may have a greater muscle bulk and power than normal (Britt 1974; Ellis 
1980). The MH diversity of different clinical presentations of MH may reflect 
differences in anaesthetic techniques used in different countries and centres.
Indeed MH is associated with a variable combination of different characteristics. 
Conclusions about specific signs are difficult to determine and as a syndrome the 
clinical and biochemical symptoms can be categorised as below.
1.3.1 Clinical aspects:
Following administration of an inhalational agent with or without 
suxamethonium (succinylcholine) the clinical characteristics of MH may appear in 
susceptible individuals and early recognition of the symptoms is vital to successful 
management of the patient. The classic presentation begins after a few minutes 
with an increase in heart rate (tachycardia) and arterial CO), respiratory acidosis 
and tachypnoea and are the earliest signs of MH. Muscle rigidity, especially 
masseter muscle spasm or jaw rigidity, have been described as the most common 
clinical signs of MH with an incidence of 50 - 64%, but the appearance of masseter 
muscle spasm is not correlated with MH in every patient. MH has also been 
described in anaesthesia in association with muscle diseases, such as myotonia 
congenita (Ellis and Halsall 1984). Muscle rigidity can occur without 
hyperthermia and also hyperthermia can happen without rigidity in 20% of MH 
cases (Kalow 1970; Rosenberg and Fletcher 1994). The MH symptoms may occur 
at any time during anaesthesia and even afterwards in the recovery period.
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In an MH episode an increase in body temperature of 2-6°C per hour up to a 
temperature of 43°C is not uncommon (Kalow 1970; Keaney and Ellis 1971; 
Gronert 1980). Body temperature may begin to rise a few minutes after the 
initiation of the earliest signs of MH or may be delayed for a longer time and may 
even only be observed post operatively in the recovery room. Generally it is a 
relatively late sign of the syndrome if it occurs at all (Rosenberg and Fletcher
1994). The rise in body temperature reflects an imbalance between the heat 
production and heat loss. This results from skeletal muscle hypermetabolism 
which is related to the high concentration of Ca2+ in the myoplasm (Nelson et al 
1983; Mickelson et al 1988). This phenomenon gives rise to an increase in cardiac 
output and consequently to tachycardia.
1.3.2 Biochemical signs
The loss of intracellular calcium balance which is initiated by triggering 
agents in susceptible individuals and the attempts of muscle cells to restore normal 
levels of Ca2+ ions leads to the consumption of large amounts of ATP to provide
enough energy for sarcoplasmic reticulum Ca~+ pumps. This rapid ATP
2_ |_
consumption in re-establishing the resting Ca balance requires an extreme 
increase of muscle metabolism to five or six times the basal level. This excessively 
high metabolic rate, described as a metabolic storm, results in malignant 
hyperthermia symptoms, increase in body temperature, acidosis, tachycardia, 
increased oxygen consumption and muscle rigidity. Depletion of ATP can induce 
muscle membrane permeability to potassium ions, and results in hyperkalaemia. 
This elevated serum potassium level may contribute to the production of cardiac
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arrhythmia including asystole (Hopkins and Ellis 1995; Rosenberg 1988). In 
addition, increasing muscle permeability causes increased serum levels of creatine 
phosphokinase and other muscle enzymes like lactate dehydrogenase (LDH) and 
aspartate amino transferase (Rutberg et al 1983). The induced derangement after 
an acute MH episode will continue by breakdown of muscle fibres and the increase 
in myoglobin excretion causes damage in renal tubules.
1.4 Triggering agents
As mentioned before, PSS can be induced in susceptible pigs by different 
factors but in humans MH is triggered by volatile anaesthetic drugs, and possibly 
the depolarising muscle relaxant, suxamethonium. Some workers also consider 
that a few cases may be induced by injection of some intravenous anaesthetics such 
as propofol, opioids and barbiturates although it is a controversial matter (Strazis 
and Fox 1993; Dripps et al 1988). Fruen et al (1995) reported that propofol does 
not activate ryanodine receptor Ca2+ channels of normal or MH susceptible pigs. 
Wingard (1974, 1981) argued that stress could also precipitate MH in humans but 
supportive evidence is lacking. It is well known that inhalation anaesthetic drugs 
including halothane, diethyl ether, methoxyflurane, enflurane, isoflurane, 
desflurane, sevoflurane, and chloroform (Ellis and Halsall; 1980; Ellis 1992; 
Hopkins and Ellis 1995; Rosenberg and Fletcher 1994) and some depolarising 
muscle relaxants like suxamethonium (Hall et al 1966) may act as triggering agents 
in malignant hyperthermia induction.
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For safe anaesthesia, nitrous oxide, local anaesthetic, intravenous 
anaesthetics, sedatives and non-depolarising relaxants do not trigger MH (Halsall 
and Ellis 1993; Rosenberg and Fletcher 1994).
1.5 Frequency and incidence of MH
Apart from the spectrum of expression of the clinical features of MH there 
seems to be great variation from individual to individual, and even in the same 
individual at different times to susceptibility and response to triggering agents in 
predisposed individuals (Halsall et al 1979; Ellis et al 1986). Thus uneventful 
anaesthesia with exposure to triggering agents does not exclude the possibility of 
malignant hyperthermia susceptibility. This makes the exact determination of the 
prevalence of malignant hyperthermia susceptibility difficult. Currently the 
frequency of MH crises is estimated to be between 1 in 40 000 and 1 in 50 000 
general anaesthetics in the North American and European populations (Kalow 
1970; Ellis and Halsall 1980; Ellis et al 1986; Halsall and Ellis 1993; Strazis and 
Fox 1993). It is suggested that the frequency of MH susceptibility is 1 in 5000 in 
the general population of the UK (West 1996). The discrepancy between 
frequencies may arise from the following factors : lack of a unique practical 
anaesthetic method in different centres; brief exposure time (duration of 
anaesthesia which may be insufficient time to induce MH); type of triggering 
agents used, for example, in more than 90% of operations, the standard triggering 
agents are used (Campling et al 1993). In addition, susceptibility and the use of 
non-volatile anaesthetic drugs are involved in expression of the malignant 
hyperthermia phenotype (King et al 1972; Ellis 1980). Halsall et al (1979)
supposed the probability of MH developing in susceptible patients is 44% on each 
occasion of exposure to triggering agents.
In general anaesthesia the estimated frequency of MH in children and young 
adults is higher than for other age groups and so it is supposed that the MH 
phenotype may be affected by age. Studies show the age range of the majority of 
index cases is between 3-19 years (McPherson and Taylor 1982; Halsall and Ellis 
1993). This higher incidence of MH crises in childhood may also be influenced by 
many factors, which may reflect a reduced penetrance of MHS with increasing age 
illustrated in fig 1.1 (redrawn from Halsall and Ellis 1993).
Despite MH being an autosomal dominant trait it appears that more males 
than females suffer from the clinical reaction. This may be a reflection of different 
life styles, for example the higher number of males than females who present with 
trauma, which is one of the most common reasons for anaesthesia between the ages 
of 10-30 years (Halsall et al 1979; McPherson and Taylor 1982) although the death 
rates for both sexes being the same and IVCT reveals approximately equal numbers 
of both sexes and being susceptible to MH. As illustrated in fig 1.1 the frequency 
of individuals experiencing MH is reduced in the over 30 year age groups for both 
sexes. This may be caused by reduction in sensitivity to anaesthetic drugs with 
advancing age (Kalow 1970). In conclusion, the susceptibility to MH, although not 
a sex-linked disease, may be a sex influenced trait. Other environmental factors 
may also influence the onset of an MH episode, such as stress, premedication 
trauma and exercise (Wingard 1974; Ellis and Halsall 1980; Halsall et al 1979; 
Strazis and Fox 1993; Britt and Kalow 1970a). MH susceptibility is reported in all
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Fig 1.1 The sex and age distribution of probands betweenl 971-1984 
(Leeds). Redrawn from Ellis et al (1986)
0-9 10-19 20-29 30-39 40-49 50-59 60-69
Age of probands
Fig 1.1 MH crises predominate in the 10-19 year age group and are considerably 
more prevalent in males than females. The frequency of MH crises decrease with 
increasing age. Possible reasons for these observations are discussed in section 1.5.
racial groups but is more common in the Caucasian population (McPherson and 
Taylor 1982) and is particularly high in the Japanese population.
1.6 Treatment
The frequency of mortality as a result of an MH episode was reported at 
70% in 1970 (Halsall and Ellis 1993) and at present, although it has not been 
eliminated, it is less than 10% (Strazis and Fox 1993). In reducing mortality and 
successful treatment of susceptible individuals, the early recognition of an 
impending MH crisis is very important. With regard to malignant hyperthermia as 
a life threatening disorder and the lack of a generally applicable pre-anaesthetic 
screening method for MH susceptibility, the knowledge of anaesthetists of the early 
symptoms of an MH episode, and rapid response by terminating the anaesthetic 
process, is critical. In this procedure the elimination of the volatile drugs from the 
body, enhanced by hyperventilation, and intravenous dantrolene therapy are the 
main methods of treatment. Dantrolene is believed to stop the release of calcium 
from the sarcoplasmic reticulum by blocking the calcium release channel, 
controlling high temperature and muscle rigidity regardless of causes (Gronert et al
1988). It is very important in the successful treatment of an MH crisis and has 
reduced the MH caused death rate in anaesthesia (Ellis et al 1974; Kolb et al 
1982). If treatment is delayed, the development of muscle rigidity and restriction 
of the blood supply to muscle cells causes pathological development and leads to 
the crucial stage which becomes irreversible. In addition to cessation of surgery 
and dantrolene therapy in recovery after an MH episode, hyperventilation (95% of 
oxygen, 5% C 0 2) and active cooling with an electric cooling blanket or iced water,
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and intravenous infusion with ice-cold fluids (mannitol) is necessary (Halsall and 
Ellis 1993; Rosenberg and Fletcher 1994).
Patients who develop the symptoms of MH may die within minutes from 
ventricular fibrillation, within hours from pulmonary oedema or coagulopathy, or 
within days from neurological damage or obstructive renal failure if treatment is 
not initiated immediately. After successful treatment, they will be ill for several 
days from heavy loss of potassium, acidosis, unstable body temperature and severe 
muscle pain (Ellis 1980; MacLennan 1992) and will require intensive care therapy. 
Longer term symptoms such as muscle pain may continue for several weeks (Ellis 
and Halsall 1980).
In conclusion, the following steps are vital in preventing an MH episode 
from becoming irreversible. At first the administration of triggering agents, must 
be stopped and then injection of dantrolene sodium (l-10mg / per kg of body 
weight) administered intravenously. The next step is active body cooling, at this 
step one may cool the body sufficiently to inhibit the MH response at the cellular 
level, and finally in the recovery period , frequent observation of the body 
temperature, biochemical signs and attention is necessary.
1.7 Identification of susceptible individuals
Many methods have been described in the literature for MH diagnosis but 
only two methods are currently used, and these are the creatine phosphokinase 
activity (CK) measurement and the In Vitro Contracture Test (IVCT).
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1.7.1 The measurement o f CK
Serum creatine phosphokinase (CK) activity is increased in many MH- 
susceptible individuals but in others it is normal (Isaacs and Barlow 1970; Gronert 
1980). Efforts to use concentration of CK as an indicator in MH susceptibility 
prediction have been made (Issacs and Barlow 1970) but with insufficient 
sensitivity and specificity to be used as a screening test in malignant hyperthermia 
diagnosis. The increase of CK in several diseases which are not related to MH, and 
the variability of CK levels in MHS individuals (Ellis et al 1975) and also CK 
increase after exercise (Ellis et al 1972) renders it of little value as a screening test 
(Ellis 1992). As an initial screening test, a high level of CK in some susceptible 
families to MH can be used in making a decision on priority of individuals for 
investigation by muscle biopsy.
In conclusion, it is supposed that the estimate of serum CK appears 
unreliable and so it cannot be used in susceptible patients as a predictive test, 
although the patients with high values of CK, 10 000-20 000 units per litre 
(whereas the normal range is 200-220 units) after anaesthesia have more chance of 
susceptibility to MH especially when it is 20 000 units or more per litre. In some 
susceptible families, high resting levels of CK may correlate with malignant 
hyperthermia susceptibility (Kalow 1970; King et al 1973; Ellis et al 1972; 1975; 
0rding 1988; Rosenberg 1988).
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1.7.2 In Vitro Contracture Test (IVCT)
The limitation of using the biochemical tests and also the lack of 
phenotypic symptoms to predict malignant hyperthermia susceptibility before 
general anaesthesia makes the in vitro contracture test IVCT a “gold standard” test 
in malignant hyperthermia diagnosis. The IVCT has been widely accepted by most 
European testing centres. It remains the most reliable and acceptable method in 
identifying MH susceptibility although it is time-consuming, expensive and 
invasive and for these reasons is not appropriate as a population-screening test. In 
addition, viability and type of muscle used, and some known myopathies, also 
influence the IVCT results. An IVCT protocol was established by Kalow et al, 
who reported that muscle from malignant hyperthermia susceptible individuals is 
more sensitive to caffeine (Kalow et al 1970; Kalow et al 1977). In the following 
year the sensitivity of muscle to halothane was described (Ellis et al 1971; Ellis et 
al 1972; Ellis and Harriman 1973). Nowadays two main protocols for IVCT are 
used in MH investigation Units. These are the European protocol used by all 
members of the European Malignant Hyperthermia Group (EMHG 1984; 1985) 
and the North American protocol (Larach 1989).
The North American method, Caffeine Halothane Contracture Test (CHCT) 
differs in a few aspects from the European test. 0rding and Bendixen (1992) have 
reported an agreement of 78%-88% between results from the two protocols. The 
North American method is not performed by EMHG because it produces both false 
positive and negative results (MacKenzie et al 1991; Ellis 1992; Isaacs and 
Badenhorst 1993; Larach 1993; Wedel and Nelson 1994). The CHCT is carried
out according to the protocol supported by the North American Malignant 
Hyperthermia Registry (NAMHR). This group was formed to establish uniformity 
in testing among laboratories from Canada and United States (Larach 1989). In 
this method two tests are required. These are the exposure of muscle strips to 3% 
(v/v) halothane alone and exposure to incremental caffeine concentrations (CSC) 
alone. In addition to these tests, there are two optional tests. These are exposure of 
muscle strips to a combination of both 1% halothane and incremental caffeine 
concentrations, and the other one is using 2% halothane alone. The abnormal 
contracture responses or MH susceptibilities identified as :
A positive response is defined by a contracture of more than 0.2 - 0.7g 
(dependent upon the individual laboratory) on exposure to 3% halothane for 10 
minutes.
Abnormal contracture response to 2mM caffeine or caffeine specific 
contracture (CSC) at <4mM and induction of 0.2 g tension or more or the 
development of lg  contracture after exposure to a concentration of ImM or less 
caffeine in presence of 1% halothane (Larach 1989; Melton et al 1989).
In this test protocol a few points need consideration. Firstly, the range of 
values for abnormality response is determined by each laboratory. This means that 
the threshold for deciding diagnosis of MHS and MHN is variable and this could 
underlie the false positive and negative results from individual centres. Secondly, 
while the combined test may increase sensitivity in some cases, it may result in 
decreased specificity (Wedel and Nelson 1994). Thirdly in the North American 
protocol, contracture response to halothane alone, caffeine alone or the combined
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challenge is indicative of MH susceptibility. At the recent NAMHR 5th MH 
Biopsy Standards Conference Meeting acceptance of the MHE group defined by 
the European protocol as an intermediate between MHS and MHN was 
recommended (Iaizzo and Lehmann-Horn 1995). This step if accepted may help in 
reaching an agreement on an international protocol.
In Europe the in vitro contracture test is carried out according to the 
updated European standardised protocol which was adopted by the European 
Malignant Hyperthermia Group or EMHG in 1984 and updated in 1985 (EMHG 
1984; 1985; Ellis 1984; Ellis et al 1986; Ellis 1992). In this test, muscle biopsy 
specimens measuring 3cm, 0.4cm, and 0.2cm are taken from the motor point of the 
vastus interims muscle under general or regional anaesthesia. The fascicles are 
immediately placed in oxygenated (95% O2 and 5% CO2) modified Krebs solution 
(NaCl 118.1mM, KH2Po4 1.2mM, KC1 3.4mM, MgSo4, 0.8mM, N aH C 03 25mM, 
glucose 11.1 mM, CaC^ 2.5mM and pH 7.4) at room temperature prior to 
contracture testing. The time from biopsy to the completion of all tests should not 
exceed 5 hours. The bundles of living muscle at 37°C in a tissue bath are exposed 
to the different doses of triggering agents, caffeine (0.5mM, I mM, 2mM, 3mM, 
4mM and 32mM) and halothane (0.5%, 1%, and 2%) to produce a sustained 
increase of at least 0.2g in baseline tension.
From the results of IVCT, the patients may be classified into three 
diagnostic groups, MHS, MHN, and MHE, based on the responses to contracture 
inducing agents. MHS indicates that the individual is susceptible to malignant 
hyperthermia, with abnormal responses to both caffeine (2mM or less) and
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halothane(2% or less) in the muscle contracture test (fig 1.2). MHN or normal 
individuals have no abnormal response to either halothane (2% or less) or caffeine 
(2mM or less) (fig 1.3). MH equivocal or MHE individuals show a positive 
response to caffeine (MHEC) or halothane (MHEh) but not both. The MHE 
category allows maximum specificity to be assigned to the MHS and MHN 
phenotypes. For clinical purposes MHE individuals are advised that they are 
sensitive to halothane (EMHG 1984; 1985) but for investigative purposes they are 
regarded as equivocal. In addition to halothane and caffeine in contracture tests, 
use of ryanodine may be useful in distinguishing between the MHN and MHE 
classes (Wappler et al 1994; 1996). The ryanodine test appears to be more 
sensitive than the caffeine test in distinguishing between MHS and MHN (Halsall 
and Ellis 1993) and may become an integral part of the IVCT protocol. When a 
suspected clinical reaction is observed, all probands except those under 10 years 
old, or patients who have died, should be tested for MH susceptibility. In these 
situations the diagnosis of MH status may be obtained indirectly by testing both the 
parents.
In an interesting review of the reliability of the IVCT (based on European 
protocol), 65 subjects who survived a clinical episode of fulminant reaction of MH 
have been investigated with the IVCT. Of these, 89% (58) have been designated 
susceptible and -11%  equivocal (4 MHEh and 3 MHEC) with no MHN (P. M. 
Hopkins, pers. comm.).
Although IVCT is at present the only accurate and reliable method for MH 
diagnosis it is not an ideal test for the following reasons. A sizeable muscle biopsy
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a) Halothane concentrations : —» 0.5% 1% 2%
sj' '1' 'I'
b) Caffeine concentrations :
3mM 2mM l.5mM ImM 0.5mM
Fig 1.2 The effect of different concentrations of a) halothane (0.5, 1, 2 and 3%) and b) 
caffeine (0.5, 1, 1.5, 2, 3. 4 and 32 mM) on muscle samples from individual no. 2134, who 
shows positive contracture to halothane and caffeine at 0.5% and 0.5mM respectively and 
is therefore diagnosed as MHS.
a) Halothane concentrations :
0.5 1% 2%
vL 4 /  vi*
b) Caffeine concentrations
1.5mM 2 1 n.VI 3mM 4mM 32mM
X J, -I X 'I
Fig 1.3 The effects of a) halothane (0.5, 1 and 2%) and b) caffeine (0.5mM to 
32mM) on muscle samples from individual 1879 who shows no contracture to 
halothane and caffeine and is therefore diagnosed as MHN.
is required which has to be taken using anaesthetic and involves hospitalisation of 
the patient. This protocol is an expensive test that needs at least two nights stay in 
hospital, and a special laboratory and expert staff. It is possible that the variability 
and fibre types of muscle (type I and II) used influence the test results because the 
muscle bundles are a mixture of slow (type I) and fast (type II) muscle fibres 
(Gallant and Goetti 1989; Sudo 1995). IVCT is not absolutely specific, for 
example, false positive results have been obtained for patients with other known 
myopathies.
Although it is claimed that the fibre composition has an influence on 
halothane and caffeine contractures in cat, rat, and swine muscles (Brownell and 
Szabo 1982; Nelson and Schochet 1982), further studies indicate that the 
composition does not influence the discrimination between MHS responses in 
contracture test results in human biopsies (Heiman-Patterson et al 1987). Of 
course the halothane sensitivities for a given muscle fibre type (I or II) are different 
between MHS and MHN patients, but both types of MHS fibres had a significantly 
lower threshold compared with normal fibres (Adnet et al 1994). In conclusion the 
effects of fibre types on response to halothane or caffeine is a controversial subject 
and more experiments are necessary. The report of false negative results in young 
children (Issacs and Bandenhorst 1993; Hopkins and Ellis 1995) is another 
disadvantage of IVCT. Because of these problems, muscle biopsy testing of young 
children is seldom performed; not only it is undesirable to take the samples but also 
because the immature muscle frequently gives erratic responses in this test (Ellis et 
al 1986).
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1.8 MH and other diseases
Most patients who have been identified as MH susceptible do not show any 
other disease related to it. However in some cases the association between MH and 
a second disease is reported (Denborough et al 1962; Steers et al 1970; Ellis et al 
1971; Harriman et al 1973), for example the association of MH with 
neuromuscular disorders has been recognised since 1970 (Isaacs and Barlow 1970). 
Some diseases which have been associated with MH are as follows :
Central core disease (CCD) in muscle fibres was first described by Shy 
and Magee (1956) in five members from a family pedigree with three generations. 
The association of this apparently rare myopathy with MH was reported by 
Denborough et al (1973). It is a slow or non-progressive morphological myopathy 
which affects the normal development of muscle fibres in affected individuals from 
birth. CCD appears in patients with quite variable clinical features, ranging from 
being asymptomatic to severely disabled as result of muscle weakness. CCD is 
inherited as an autosomal incomplete dominant genetic trait, and apparently more 
than one genetic factor is involved in manifestation of disease (Engel et al 1961; 
Denborough et al 1973) although in a study in nine CCD families no heterogeneity 
was reported (Schwemmle et al 1993). The CCD diagnosis depends upon the 
demonstration of poorly staining “cores” in a significant proportion of type I 
Skeletal muscle fibres (Denborough et al 1973). Significant pathological changes 
in sarcoplasmic reticulum and t-tubules and reduction in the number of triads in 
CCD families was reported by Hayashi et al (1989). Due to the wide clinical
variation it is not clear whether this reflects a high mutation rate, low penetrance or 
superficial diagnosis. In subsequent studies the abnormal contraction with IVCT in 
a CCD patient was reported by Brownell (1988). Islander et al ( 1995) suggested 
that the members of families with CCD could be at risk of being malignant 
hyperthermia susceptible. Co-segregation of MH with CCD has been described in 
patients using linkage studies with chromosome 19q markers (Kausch et al 1991) 
and based on this correlation it has been proposed that these two abnormalities are 
allelic (Kausch et al 1991). With the strong association between the RYR1 gene 
and surrounding markers on 19q 12-q 13.2, the RYR I gene is a likely candidate for 
CCD (Mulley et al 1991; Schwemmle et al 1993).
Neuroleptic malignant syndrome (NMS) is another rare disease which 
mimics some features of MH like muscle rigidity, high CK, increased body 
temperature and acidosis due to metabolic stimulation (Caroff et al 1987; Heiman- 
Patterson 1993). Triggering agents in NMS are neuroleptic drugs but not 
anaesthetic agents. This abnormality responds to dantrolene therapy although it is 
differentiated from MH by the IVCT (Ellis and Heffron 1985; Adnet et al 1980) 
and the time course of the onset of the syndrome which is hours to days in contrast 
with MH in which it is minutes (Rosenberg 1988; Renwick et al 1992). However, 
while the clinical manifestations of the two syndromes are similar, their underlying 
aetiology is different (Keck et al 1995).
Myotonia congenita (myotonia may be defined as a delayed relaxation of 
muscles) is a rare dominant trait characterised by muscle spasm after 
suxamethonium administration (King et al 1972; Heiman-Patterson et al 1988;
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Ellis 1981). Saidman et al (1964) described a patient with myotonia congenita 
who developed malignant hyperthermia after anaesthesia. In the treatment of these 
MH-like events, dantrolene may be a useful drug due to its effect on the excitation- 
contraction coupling mechanism (Ellis 1981). This abnormality is reported in a 
few cases of MH patients with positive IVCT (Heiman-Patterson 1988). Usually it 
is associated with muscle hypertrophy and its histological appearance also has 
similarities with the hypertrophied muscle fibres in MHS individuals, and greater 
variation of fibre size than normal (Ellis 1981).
Several other abnormalities have been reported with MH. King syndrome 
is a slowly progressive myopathy with short stature. The usual manifestation of 
this abnormality are fever and tachycardia and elevated CK levels. It begins in 
childhood and patients with King syndrome should be considered as MH 
susceptible. This abnormality has been reported in four unrelated boys (King and 
Denborough 1973) and in a girl by McPherson and Taylor (1981). In a few cases it 
has been reported in association with malignant hyperthermia.
Osteogenesis imperfecta: an association between MH and this 
abnormality has been suggested. Patients suffering from this abnormality may 
display increasing temperature during general anaesthesia although this alteration 
may have a different basis (Rampton et al 1984). In a survey of seven patients with 
osteogenesis imperfecta only one of them was MH susceptible using a North 
American protocol IVCT (Rosenberg 1988).
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Sudden infant death syndrome (SIDS) is a disorder with probably 
multiple aetiology reported in a few families associated with malignant 
hyperthermia susceptibility (Denborough et al 1982). Further studies have not 
confirmed the association between MH and SIDS (Ellis et al 1988).
Duchenne Muscular Dystrophy (DMD), is inherited as an X-linked 
recessive muscular dystrophy and is the commonest of the muscular dystrophies. 
During anaesthesia with halothane and or suxamethonium, tachycardia, 
hyperthermia, acidosis, hyperkalaemia, myoglobinuria and high level of CK have 
been reported (Ellis 1981; Ellis and Heffron 1985; Wang and Stanley 1986; 
Brownell 1988). The reactions, if detected early in their course, appear to be 
reversed by discontinuing the volatile drugs. Children with DMD may develop 
tachycardia and cardiac arrest post-operatively due to muscular weakness (Ellis and 
Heffron 1985). In some cases muscle biopsies from patients showed contracture 
on exposure to caffeine (Brownell et al 1983) and halothane (Rosenberg and 
Heiman-Patterson 1983). Becker Muscular Dystrophy (BMD) another type of 
muscular dystrophy with a few differences such as milder effects and later age of 
onset. Patients usually survive until middle life. DMD and BMD have both been 
shown to be due to defects of the gene coding for a sarcolemmal protein, 
dystrophin. This protein in very low levels protects the fibres (especially in 
skeletal muscle cells) from damage due to repeated contraction. This protein is 
present in an altered form in BMD patients but in nearly all DMD patients is 
absent. Almost all DMD patients have deletions in the dystrophin gene which give 
rise to alterations in the reading frame and change the coding sequence downstream
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of the mutation. These events consequently cause the DMD disease. But in 
comparison deletions which do not alter the reading frame induce BMD. There 
have been no recent reports of anaesthesia problems in BMD but muscle from a 
BMD patient has been shown to have abnormal IVCT response to halothane 
(Heiman-Patterson et al 1988).
Hyperkalaemic periodic paralysis (HyperPP) is caused by an autosomal 
dominant mutation in the a-subunit gene of adult skeletal muscle sodium channel, 
SCN4A which is located on chromosome 17q (Fontaine et al 1990). The mutations 
in this subunit may be causing masseter muscle rigidity and whole-body rigidity 
(symptoms of MH) using succinylcholine (Vita et al 1995). Some individuals with 
hyperPP show positive contracture using IVCT (Lehmann-Horn and Iaizzo 1990). 
An attack of hyperPP may be induced by different factors such as cold, fasting, 
sleep, infection and anaesthesia and may be treated by high sodium, low potassium, 
high carbohydrate diet, intravenous glucose and insulin (Ellis 1981; Hopkins and 
Ellis 1995). Hypokalaemic periodic paralysis (HypoPP) has been observed in a 
patient with MH-like reactions and a positive response to halothane using IVCT 
and may be due to deregulation of Ca2+ ( Lehmann-Horn and Iaizzo 1990; Lambert 
et al 1994). This abnormality is associated with a reduction in serum potassium 
concentration and is inherited as an autosomal dominant abnormality with full 
penetrance in males and incomplete penetrance in females. The locus for hypoPP 
is reported to be located on chromosome 1 at q 3 1 -32 (Fontaine et al 1994). An 
attack of hypoPP can be induced by anaesthesia and other factors such as heavy 
exercise, stress, or by eating a heavy meal especially if it contains a high proportion
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of carbohydrate. It can be treated with combined low sodium and high potassium 
therapy (Hopkins and Ellis 1995).
These abnormalities are clinically and genetically distinguishable from each 
other. Indeed the disorders mentioned reported to coexist with MH are infrequent 
and do not represent a typical presentation of MH. On the other hand the positive 
IVCT results in other myopathies than MH are not specific and may be based on 
pathophysiological mechanisms different from MH (Heytense/ al 1992). In 
conclusion the patient with either myopathy or related conditions such as hernia, 
strabismus and orthopaedic abnormalities must be considered to be at a greater risk 
than the general population, or on the other hand they may be predisposed to MH if 
exposed to the appropriate triggers (Ellis et al 1972; McPherson and Taylor 1981). 
However these associations may be coincidental and are independently inherited.
1.9 Aetiology of MH
A genetic abnormality which leads to MH causes a primary lesion in the 
skeletal muscles. This is because muscle rigidity is one of the first macroscopic 
signs of an impending MH episode, and also the muscle relaxant dantrolene blocks 
development of the syndrome, and in addition many susceptible individuals and 
most pigs have elevated muscle-specific serum creatine phosphokinase activity 
(Hall et al 1976; Isaacs and Barlow 1970; Harrison 1971; Gronert et al 1976; 
Heffron and Mitchell 1975). In an attempt to find the possible primary abnormality 
in MH the relation between it and the sympathetic nervous system was studied. In 
a well-designed study, Gronert et al (1977) showed that the changes in the
26
metabolic rate in susceptible pigs are unrelated to abnormalities of the central or 
sympathetic nervous system (Artru and Gronert 1980; Gronert et al 1988). Finally 
these indications of a myogenic aetiology have given rise to a very large number of 
studies of the biochemical basis of MH using muscle from susceptible pigs and 
human muscle biopsies.
1.9.1 The role o f  Ca2+
The main cause of malignant hyperthermia induction is an alteration in 
mechanisms that control and maintain Ca2+ homeostasis and its low cytoplasmic 
concentration in skeletal muscle (Lopez et al 1985; Heffron 1988). Lopez et al 
(1988) in a study measured free Ca2+ during and after an MH episode, and also, 
using dantrolene, proved that the concentration of Ca2+ increased in swine MH 
skeletal muscle fibres and reduced after dantrolene administration. Calcium 
release from the sarcoplasmic reticulum SR, the main store of Ca2+ in skeletal 
muscle is induced by membrane depolarisation. Three membranes, the 
sarcolemma, the sarcoplasmic reticulum membrane and the mitochondrial 
membrane are involved in intracellular calcium in muscle. These membranes 
through their constituent proteins act together in controlling calcium movements 
during the coupled processes of excitation and contraction coupling.
Furthermore proteins like the dihydropyridine receptor function co- 
ordinately to regulate the transduction of depolarisation signals from the 
sarcolemma to the intracellular calcium store and to effect the release of calcium 
into the sarcoplasm. Mutation in any one of the genes encoding these proteins
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could conceivably lead to the abnormality in Ca2+ regulation found in MH muscle 
(Lopez et al 1988; Iaizzo et al 1988). Increased free Ca2+ in the myoplasm could 
result from increased release of Ca2+ from the SR, increased release of Ca2+ from
o  i
mitochondria, or an increased entry of Ca through the sarcolemma from the 
extracellular fluid. Although uptake of Ca2+ from the sarcoplasm by the SR by 
calcium pumps is important in calcium regulation, in surveys of calcium pumps in 
MH susceptibility, experiments in halothane positive and negative pigs indicated 
no causative role for the calcium pump which is responsible for calcium re-uptake 
against a concentration gradient (Louis et al 1992).
Iaizzo et al (1989) reported that the development in MHS muscle 
contracture is not related to alterations in the surface membrane caused by 
anaesthetic agents (Iaizzo and Lehmann-Horn 1989). Furthermore depolarisation 
is not required for contracture development in porcine MHS fibres (Gallant 1988). 
They indicated that Ca2+ significantly increases during a clinical episode with no 
change in the resting membrane potential Vm (Lopez et al 1986; 1988). The lack 
of detectable change in Vm during the increase in intracellular calcium 
concentration in an MH episode demonstrates that this increase is not membrane- 
potential dependent and therefore depolarisation does not appear to be related to 
induction of the syndrome in pigs.
In a well designed study using pig cells, halothane did not alter the resting 
membrane potentials of MHS or MHN surface membranes but it alters the 
electrical properties action potential (raise, peak and fall) of the muscle fibres. 
These effects were more pronounced in MHS skeletal muscle fibres but were not
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related to the occurrence of a contracture (Iaizzo et al 1989). Based on many
aetiological studies of MH, attention has focused on the SR as the probable site of
2+the lesion. This is because the increasing Ca concentration is fundamental to 
induction of the MH crisis and SR is the main store of Ca2+ for release and re­
uptake. Therefore it is likely that any defect in SR could give rise to an MH 
episode (Denborough et al 1973; Gronert et al 1979).
1.9.2 Sarcoplasmic reticulum and RYR1
The sarcoplasmic reticulum is the main store of intracellular calcium, 80% 
of the Ca2+ in skeletal muscle, and therefore plays the main role in calcium 
homeostasis in muscle (Artru and Gronert 1980). Transfer of the neural 
stimulation and depolarisation of the sarcolemma, the action potential, via the t- 
tubule to the terminal cistern of the SR and consequent release of calcium initiates 
the excitation-contraction coupling. The sequence of the different events leading to 
the contraction of the cell in response to the nerve influx is called excitation- 
contraction coupling.
Two processes are involved in excitation-contraction coupling, first 
depolarisation of the motor end plate occurs in response to acetylcholine released 
from the nerve ending, and second, this causes a transient membrane permeability 
resulting in an influx of sodium and efflux of potassium. As a result, during 
excitation-contraction coupling, transmission of the electric potential from the 
sarcolemma propagates in muscle to the t-tubules to the SR. This process is 
believed to occur at triadjunctions where the t-tubules and SR membranes are
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close together and gives rise to a massive calcium release into the myoplasm of 
muscle fibre. This step is believed to result from a conformational change in the 
dihydropyridine receptor and direct physical coupling between two calcium 
channels (for explanation of the E-C coupling the two following hypotheses are 
ruled out as the main mechanisms, Ca2+ induced Ca2+ release which causes direct 
activation of the RYR channel by extracellular calcium ions via the t-tubule, and 
the role of second messenger for E-C coupling in skeletal muscle fibres) (Marty et 
al 1994; Ronjat 1995). The next step causes actin and myosin filaments to interact 
and produce the contracture (fig 1.4). A defect of the SR could cause impaired re­
uptake of calcium from or uncontrolled release of calcium into the aqueous 
sarcoplasm. A number of independent physiological studies comparing halothane- 
positive with halothane-negative pigs of different breeds have detected an 
abnormality in calcium release from SR as the primary cause of MH (Nelson et al 
1983; Ohnishi et al 1983; Mickelson et al 1986; O’Brien 1986). Alteration in the 
properties of the MHS calcium channel ryanodine receptor protein due to the 
halothane sensitivity gene (Hal locus), results in a modified SR calcium release 
channel activity and elevated rate of Ca2+ release from vesicles of the SR in MHS 
individuals.
The ryanodine receptor, the sarcoplasmic reticulum calcium-sensitive 
calcium release channel protein, has been identified as the key protein involved in 
the regulation of SR Ca2+ release. Its function is regulated by Ca2+, ATP, Mg2+, 
inositol 1, 4 and 5-trisphosphate (IP3) and calmodulin. Thus an abnormality in the 
ryanodine receptor protein or these factors might alter pharmacological sensitivities 
and gating properties of the SR Ca2+ release channel. RYR or ryanodine receptor
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Fig 1.4 A proposed relation between Ca2+ ions and different factors which are 
involved in excitation-contraction coupling.
The process initiates when the nerve impulse reaches the sarcolemma causing 
depolarisation of the membrane. The generalised depolarisation of the sarcolemma 
activates the voltage-gated calcium channels of the t-tubules. These events activate 
the ryanodine receptor at the sarcoplasmic reticulum and calcium is released 
(different mechanisms such as calcium-induced calcium release are involved in 
calcium release, section 1.9.2) into the myoplasm. The increase in myoplasmic 
calcium concentration causes the myofibrils in the muscle cell to contract. The 
abnormality in the factors which are involved in excitation-contraction coupling 
(such as DHPR or dihydropyridine receptor in the t-tubule and ryanodine receptor or 
RYR in the sarcoplasmic reticulum) may give rise to malignant hyperthermia 
(adapted from MacLennan 1992).
binds and is blocked by ryanodine, a plant alkaloid (used as an insecticide). This is 
a homotetrameric complex, made from identical subunits, located in the SRI
membrane projecting into the myoplasm at the junction of the SR and T-tubules. 
Finding out more about the skeletal muscle ryanodine receptor (RYR) was 
achieved by Lai et al (1988). They purified the channel protein from rabbit SR and 
reconstituted it as a functional unit in a lipid bilayer. It consists of two domains, a 
junctional foot which spans the 10-20nm gap between the sarcoplasmic reticulum 
terminal cisternae and transverse tubule membranes, and transmembrane domain 
in the SR membrane. RYR has been purified from skeletal muscle as a 30S protein 
complex composed of four identical polypeptides of about 5000 amino acids.
It has been suggested that in mammals at least three distinct/?}7/? genes exit 
and they show differential tissue expression, RYR I is present in skeletal muscle. 
RYR2 is expressed in cardiac muscle and brain but not in skeletal muscle.
Therefore this gene is not considered to be a potential candidate in MH because the 
model of potential-induced calcium release in skeletal muscle is not compatible 
with RYR2 defects (Ogawa 1994). The^?i7?3 gene appears to be expressed in a 
wide range of tissues including skeletal muscle (Giannini et al 1992) and has been 
proposed as a possible candidate gene in malignant hyperthermia susceptibility.
Comparison of sarcoplasmic reticulum samples from halothane sensitive 
and insensitive pigs suggests that RYR binds ryanodine with higher affinity in MH- 
susceptible than normal SR (Lai et al 1988; Mickelson et al 1988). It appears to 
bind when the calcium release channel is in the open configuration and blocks the 
channels open (Mickelson et al 1989). Furthermore comparison of homozygous
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halothane sensitive and halothane insensitive pigs with heterozygous pigs showed 
that the SR isolated from the heterozygous pigs has Ca2+ release properties 
intermediate between those of halothane positive and halothane negative animals 
(Gallant et al 1989). As a result heterozygous pigs do not exhibit a typical 
halothane positive response to triggering agents. One explanation for this 
observation is that there is a mixed population of RYR 1 channels in the 
heterozygous pigs with 0, 1, 2, 3 or all 4 of the subunits being of the mutant type. 
Therefore there may be adequate normal channels to avoid ryanodine blocking. 
Ca2+ flux through a heterotetrameric channel with less than four affected subunits 
may not be altered sufficiently to precipitate an MH crisis. Indeed the Ca“+ release 
channels in heterozygous pigs can be assembled from mutant and normal subunits 
that combine to form heterotetrameric channels (Shomer et al 1995). The SR from 
pigs heterozygous for the halothane-sensitivity gene, however, demonstrates 
intermediate values for the rate of calcium release and affinity for tritiated 
ryanodine. Thus alteration in SR Ca2+ release and ryanodine binding in pigs 
comparing only one copy of the halothane-sensitivity gene demonstrates a distinct 
intermediate phenotype and indicates a truly heterozygous state (Mickelson et al
1989).
These studies using SR vesicles and muscle bundles indicate that both 
MHS and normal SR Ca2+ release channel genes are expressed in the muscle of 
heterozygous pigs (Gallant et al 1989). However, SR from heterozygous pigs has 
more affinity for ryanodine, a lower threshold for contraction (Gallant and Jordan 
1996), and intermediate properties in Ca2+ release compared with SR from normal 
pigs.
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In conclusion these intermediate responses to triggering agents are further 
proof that the ryanodine receptor is the main cause of gene in halothane sensitivity 
in pigs.
1.9.3 T-tubule and DHPR
In skeletal muscle the 1,4 dihydropyridine receptor (DHPR) acts as the 
voltage sensor and calcium channel located on the transverse tubule (t-tubule) 
membrane which is a part of the sarcolemma. The t-tubules are the internal tubular 
membrane systems which are orientated transversely with respect to the fibre axis 
(Caspar Ruegg 1988). They function as an L-type voltage-dependent calcium 
channel and transducer of membrane depolarisation of the interior of the muscle 
fibre, and so fulfil a critical role in excitation-contraction coupling (E-C) and in 
sarcoplasmic calcium regulation. The DHPR functions primarily as a voltage 
sensor in E-C coupling and exhibits voltage-gated Ca2+ channel activity although 
the entry of extracellular Ca2+ is not required for skeletal muscle contracture 
(Catteral and Striessing 1992). Moreover it is suggested that the DHPR complex is 
a binding site for dantrolene sodium which acts to block calcium release in 
malignant hyperthermia therapy. The DHPR is comprised of a hetero-pentameric 
protein involved in excitation-contraction coupling. The purified DHPRs are 
composed of five polypeptide subunits, 0Ci, 012, (3, 8 and y.
1.9.4 Mitochondria
There is no report of a significant causative role of mitochondrial defects in 
malignant hyperthermia induction but they may be involved in the progress of the
syndrome once initiated. Many of the changes observed in mitochondria have also 
been seen in other myopathies and are probably non-specific manifestations of the 
disease process (Gronert and Heffron 1979). Furthermore Britt et al ( 1973) 
reported no difference between normal and MH mitochondria in regard to 
respiratory function, and later Gronert and Heffron (1979) stated that mitochondrial 
respiration is not greatly impaired in MH, if at all.
1.9.5 Miscellaneous
It is considered that the skeletal muscle CRC (calcium release channel) is 
not strongly voltage gated, and cannot be activated directly by membrane potential 
changes in the transverse tubule or SR membranes. Therefore the action potential 
at the t-tubule / SR junction for calcium release activation from SR needs a 
chemical or physiological signal. Among the factors being investigated to account 
for calcium release and MH induction, low molecular weight compounds including 
Ca2+ and inositol 1,4,5-trisphosphate have been considered as second messengers 
in this process (Fletcher et al 1995a) and intermediates which affect Ca2+ release.
1.9.5.1 Inositol trisphosphate
1,4,5-inositol trisphosphate, IP3, is an intracellular second messenger which 
acts in calcium release from intracellular stores of a variety of cell systems, 
including the sarcoplasmic reticulum of skeletal muscle (Berridge and Irvine 1989) 
and then it serves as the chemical messenger of excitation-contraction coupling. It 
is a product of the hydrolysis of phosphatidylinositol 4,5-bisphosphate and causes 
Ca2+ release from non-mitochondrial intracellular stores, sarcoplasmic reticulum
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(Henzi and MacDermott 1992). In addition release of calcium from sarcoplasmic 
reticulum suggests IP3 may cause opening of dihydropyridine sensitive calcium 
channels in animal models (Vilven and Coronado 1988). The IP3 receptor is 
located in the sarcoplasmic reticulum membrane and shows some homology with 
the ryanodine receptor.
The increase of IP3 concentration in MHS samples is demonstrated in 
human and pig skeletal muscle, and thus the pathophysiological role of inositol 
trisphosphate in MH development is considerable especially as it is reported that 
halothane inhibits the hydrolysis of IP3 in swine (F o s te red / 1989; Scholz et al 
1991; Scholz et al 1993; 1995). In attempts to identify MHS susceptible 
individuals, using IP3 as an indicator and measurement of IP3 and IP3 5- 
phosphatase activity, there were no significant results (Foster 1993; Scholz et al
1995).
1.9.5.2 Calcium pump
As mentioned before (section 1.9.1), changes in the Ca2+-ATPase are not 
believed to play a primary role in the pathogenesis of MH in pigs. This suggestion 
was supported in humans (Everts et al 1992; McSweeney and Heffron 1990).
1.9.5.3 Calmodulin
The function of calmodulin as a biological regulator and Ca2+ receptor is 
linked to the level of free Ca2+ in the cell and there is evidence that it may be 
involved in the control of the movements of cellular Ca2+. It is formed from a
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single polypeptide with four high affinity Ca2+ binding sites. In different studies it 
has been shown that the calcium release is independent of calmodulin inhibition 
(Holland et al 1992; Marjanen et al 1984). Although finding the relationship 
between this protein and MH susceptibility was reported, this is not probably the 
site of halothane action on sarcoplasmic reticulum (O’Sullivan and Heffron 1995).
1.9.5.4 Phospholipase A2
This enzyme has been suggested to be involved in MH induction. The 
increased sarcoplasmic Ca2+ may activate membrane-associated phospholipases 
(Heffron 1988). Consequently increased activity of phospholipases may result in 
increased membrane permeability resulting in fatty acid liberation. The enhanced 
activity of phospholipase A2 can cause increased Ca2+ release from mitochondria 
which causes increased Ca2+ release from the sarcoplasmic reticulum. This 
procedure is called calcium induced Ca-+ release (Ellis and Heffron 1985 ).
1.10 The genetics of MH
1.10.1 The genetics o f  MH
The mode of MH inheritance as an autosomal dominant has been confirmed 
by pedigree analysis and results of family screening using them vitro contracture 
test (Ellis et al 1986). The chance of transmission of the susceptibility allele by an 
affected individual to each offspring based on Mendelian principles is 50%. The 
malignant hyperthermia abnormality in susceptible individuals appears with 
reduced penetrance and variable expressivity (Britt er al 1969). In this section
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possible causative genes and their mutations which may be involved in MH 
susceptibility are described.
1.10.2 Genetic mapping o f RYR1 in pigs and humans
The general clinical and biochemical characteristics of MH syndrome in 
humans and pigs are similar (Berman et al 1970; Britt and Kalow 1970b), and so it 
is possible that a similar gene or genes may be responsible for MH in humans and 
pigs. Genetic mapping in the pig showed that the Hal locus, the causative gene in 
PSS or halothane sensitivity, is tightly linked to the phosphohexose isomerase 
locus, phi, also known as glucose phosphate isomerase, gpi (Andresen and Jensen 
1977). These loci were observed to be linked with the S and H blood group loci 
and glucose phosphate dehydrogenase, pgd. The gene order was deduced to be S- 
(phi-Hal) - H - po2 - pgd. This linkage group was located near the centromere of 
porcine chromosome 6, at pl2-q21 (Archibald and Imlah 1985; Harbitze? al 1990). 
In humans gpi has been mapped to the q 12-13.2 of region of chromosome 19q and 
this region shows homology with the centromere region of pig chromosome 6 
(Davies et al 1988). Previous studies by Mickelson et al had indicated that the 
skeletal muscle SR calcium release channel in halothane sensitive pigs is abnormal 
and this calcium channel is the product of the Hal gene (Mickelson et al 1988;
1989). At this time MacKenzie et al (1990) reported that the human skeletal 
muscle ryanodine receptor is located on chromosome 19 in the region 19cen-ql3.3.
Linkage studies in humans between MHS and markers that span 19q 12-
13.2 in three large Irish families indicated co-segregation of the MHS gene and the 
related polymorphic markers surrounding the RYR I gene from the GPI gene region
38
(McCarthy et al 1990). In this region two genes were suggested as candidates for 
MH susceptibility. These were RYR] and the hormone-sensitive lipase gene 
(MacLennan et al 1990; Levitt et al 1990). Identification of RYR1 as the candidate 
gene was demonstrated by the observation of tight linkage between the calcium 
release channel and the hal locus in pigs (Harbitz et al 1990, Otsu et al 1991). 
MacLennan et al (1990) reported that the polymorphic markers for the RYR1 gene 
co-segregate with human MH susceptibility. Confirmation of MHS linkage to 
19q 13 has been obtained by two groups in Germany and Britain (Deufelef al 1992; 
Ball et al 1993). Co-segregation of MHS and RYR1 in human families (Healy et al 
1991; McCarthy et al 1990; Ball et al 1991; Couch et a l l  991 b; Stewart et al 1991) 
combine with physiological data indicated that theR Y R l gene is a highly likely 
candidate for the MH susceptibility, and basic defects in {he RYR I gene underlie 
the MH episode (Davies 1990). In addition close linkage was demonstrated in pigs 
between the halothane sensitivity locus and polymorphic microsatellites flanking 
the porcine calcium release channel gene (Bolte? al 1991).
1.10.2.1 Mutations in the RYR] gene
Linkage between theR YR I gene and MH made it imperative to initiate a 
search for sequence differences between MH and normal individuals. For the first 
time in a comparison of the RYR I cDNA sequence of MH (Pietrain ) and normal 
(Yorkshire) pigs a single amino acid change was reported (Fujii et al 1991).
Indeed the large size of the skeletal muscle ryanodine receptor gene with more than 
204kb makes it probable that many different mutations could occur to give rise to 
the MHS phenotype.
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The RYR cDNA is over 15000 base pairs long, arranged in 105 exons, two 
of which show alternative splicing, and encodes an RYR1 protein with 5035 amino 
acids (Zorzato et al 1990; Phillips and MacLennan 1995).
In a study of the sequence of the RYR 1 gene, Fujii et al (1991) found 18 
single nucleotide differences between halothane positive and halothane negative 
pigs but no evidence for small insertions, deletions or internal stop codons. Only 
one of these sequence variants, the C1843T resulted in an amino acid change, 
substitution of Arg615 by Cys and was considered to be a possible causative 
mutation. This mutation was investigated in blood samples from more than 450 
animals (halothane positive, homozygote pigs and halothane negative) from six 
breeds of pigs, and it can account for all cases of MH in swine (Fujii et al 1991; 
Otsu et al 1991; 1994). In a survey of human MHS, Gillarde? al (1991) observed 
conversion of C1840 to T (Arg614 to Cys) in a single MH family of thirty five 
families investigated. As a result it was proposed as a causative gene for malignant 
hyperthermia susceptibility. To date eight potentially pathological mutations and 
further polymorphisms in the RYR1 gene have been reported in MHS and CCD 
individuals. In a well designed study, Gillard et al (1992) reported twenty-one 
polymorphic sequence variants in the RYR1 gene although most were normal 
variants of the RYR1 gene sequence observed in the general population. Fourteen 
of the polymorphic sequences resulted in loss or gain of a restriction endonuclease 
site. The other four of these changes caused amino acid substitution in which only 
one of these, Gly24S to Arg, segregated with malignant hyperthermia susceptibility 
in a single family. In addition in this potentially causative gene seven more amino
acid changes have been reported in MHS and CCD families. These are listed in 
table 1.1. These mutations are clustered in two regions, between exons 6 and 18 
and around exon 45 (Phillips and MacLennan 1995). Despite a few families 
reported to show co-segregation of MH susceptibility with the pig mutation 
Cl 840T (Hogan et al 1992; Moroni et al 1995) it was not found in 100 unrelated 
MHS individuals from the UK (Hall-Curran et al 1993). In addition it has been 
reported in MHN individuals diagnosed by the European IVCT protocol as normal 
that the Cl 840 to T mutation is observed (Hartung 1994.). The C487T base 
substitution is another mutation which is reported in the RYR1 gene in two MHS 
and one CCD families (Quane et al 1993), the point mutation resulting in the 
amino acid substitution Arg153 to Cys. The C742 to A mutation was first described 
by Gillard et al (1992). Co-segregation of C742 to A with MH susceptibility 
appeared only in a single family and was proposed as a pathological mutation.
This mutation has not been detected in European MHS families (data of EMHG, 
May 1996). The G1021A mutation reported by Quane et al (1994a) causes 
malignant hyperthermia susceptibility. This is the most common mutation observed 
so far in the European population and accounts for 7-10% of MHS individuals 
(Heytens et al 1995). Amino acid substitution, Ile40^  to Met resulting from 
nucleotide substitution, C1209G was reported by Quane et al (1993) in single CCD 
family. Beside these mutations Quane et al (1994b) reported another mutation in 
the RYR1 gene at A 1565 which causes a transversion to C in a single MHS/CCD 
family. Zhang et al (1993) reported the G7301T point mutation in the skeletal 
muscle ryanodine receptor gene. This base exchange cause amino acid conversion 
of Arg2434 to His. It was found in only one CCD family. There are no further
reports detecting this mutation in MHS or CCD families. In an effort to identify 
new mutations the G7297 to A base substitution is reported by Keating et al (1994) 
in three CCD families. This point mutation causes conversion of Gly2433 to Arg 
and together with the Arg2434 to His mutation may indicate a second cluster of 
MHS/CCD mutations in the RYR I gene. In conclusion, taken together, the linkage 
and mutation data seem to confirm that molecular lesions in the RYR1 gene may 
give rise to MH in humans in at least some families, and may be supposed that one 
mutation is not sufficient in MH induction in some cases or on the other hand a 
combination of more than one mutation, or involvement of a mutation and other 
factors is not impossible.
1.10.2.2 RYR I gene and other disorders
The RYR1 gene in addition to being a candidate for malignant hyperthermia 
is involved in other diseases as a possible candidate e.g. CCD and myotonic 
dystrophy. Myotonic dystrophy is an autosomal dominant disorder for which the 
causative gene has been localised on chromosome 19q 13.2-13.3 (Harley et al 1991; 
Brunner et al 1989). The RYR1 gene has been excluded as a candidate gene for 
myotonic dystrophy based on recombination between the two loci (MacKenzieef 
al 1990).
However strong co-segregation of RYR 1 and CCD with no recombination 
and a lod score of 11.8 have confirmed linkage between these two genes and the
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Table 1.1 RYR1 gene mutations. The eight putative RYR1 gene mutations found 
in MH susceptible and CCD patients are listed in following table. As it is shown 
some mutations are very rare and observed in single cases and also all mutations 
are common between MHS and CCD families.
Base change 
at cDNA
Amino Acid 
change
Status Frequency References
C487 to T Arg 163 to Cys MHS and 
CCD
3-5%
1%
Quane et al (1993) 
Fletcher et al (1995b)
G742 to A Gly248 to Arg MHS single family Gillard et al (1992)
<o•4—»
o
Gly 341 to Arg MHS - 10% Quane et al (1994a)
C 1209 to G Ile403 to Met CCD single family Quane et al (1993)
A 1565 to C Tyr522 to Ser CCD / MHS single family Quane et al ( 1994b)
C 1840 to T Arg614 to Cys MHS -5%
2%
Gillard et al (1991) 
Fletcher et al (1995b)
G7297 to A Gly2433 to Arg MHS / CCD 
MHS
3-5%
4%
Keating et al (1994) 
Philips et al (1994)
G7301 to A Arg2434 to His CCD single family Zhang et al (1993)
disease (Mulley et al 1993). These studies and the fact that patients with CCD are 
apparently prone to develop malignant hyperthermia may indicate that MHS and 
CCD are causally related or allelic.
1.10.3 Heterogeneity in MH
The term “genetic heterogeneity” is used when the same phenotype is 
caused by defects in different genes such that at least two genes would be involved 
in the same phenotype. Following the mapping of MHS to 19q 12-13.2, further 
studies revealed lack of linkage between MHS and polymorphic genetic markers 
either within the RYR1 gene or very close to it in many families (Ball et al 1992, 
Deufel et al 1992; Levitt et al 1992). In European MH pedigrees from the UK, 
Germany, Belgium and Scandinavia heterogeneity is considered to account for up 
to 50% of families investigated (Ball et al 1993; Deufel et al 1992; Fagerlund et al
1992). These important findings confirm that RYR I, or a gene in the region of q 12- 
13.2, is not the only possible MHS causative gene. Therefore MH exhibits both 
allelic heterogeneity (different predisposing mutations in the same gene) and locus 
heterogeneity (mutation in different genes).
There are many other candidate genes which encode proteins involved in 
Ca2+ regulating levels and membrane stability by regulating fatty acid metabolism 
or IP3 levels in skeletal muscle. In the following section putative genes which are 
supposed to be involved in MH susceptibility will be detailed. The findings based 
on linkage between MH susceptibility and other genes, DHPR subunits and 
SCN4A are considerable.
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1.10.4 Identification o f further MHS loci
Since all cases of malignant hyperthermia are not genetically linked to 
defects in the skeletal muscle sarcoplasmic reticulum calcium release channel gene 
then identifying a gene or genes related to MH susceptibility in non 19-linked 
families is important. The search for other possible defective candidate genes has 
followed two approaches, firstly by the investigation of genes which encode the 
proteins involved in Ca2+ level and IP3 level regulation. This approach has been 
successful in finding interesting candidates genes or regions such as on 
chromosome 7q 11,23-q21.1 (lies et al 1994). Secondly a genome search is being 
undertaken to investigate the linkage relationships of MH with polymorphic 
markers distributed throughout the entire human genome.
1.10.4.1 Genomic search approach
Such a project has been undertaken by the European Malignant 
Hyperthermia Group firstly in collaboration with the Genethon Institute near Paris 
and more recently in collaboration with the Berlin-Buch Genome Centre. To 
permit genomic searching, large IVCT tested non 19q linked families (with more 
than one recombinant in each family) are required. It is important that they have an 
unambiguous MH crisis in at least one index case, exhibit a clear pattern of 
autosomal dominant inheritance and are sufficiently large to generate a lod score of 
more than +3.
For this collaborative work, eleven pedigrees (Genethon, 7 families and 
Berlin-Buch, 4 families) have been included in a systematic linkage study using
polymorphic microsatellites markers covering the entire human genome. To date 
one new MHS locus (MHS4) located on chromosome 3ql 3.1 with a lod score of 
over +3 has been identified by this study (Sudbrak et al 1995). This linkage has 
only been found in a single German family.
1.10.5 Candidate genes
1.10.5.1 RYR2 and RYR3 genes
In addition to the RYR1 gene, two further ryanodine receptor genes have 
been identified, RYR2 and RYR3 (Sorrentino and Volpe 1993). These three distinct 
genes express different isoforms in specific locations. The RYR3 gene appears to 
be widely expressed in several tissues including spleen, lung, kidney, skeletal 
muscle (with a level of 100-fold lower than those of RYR1 and RYR2 in skeletal 
and cardiac muscles respectively), stomach, and some smooth muscles (Ogawa
1994). The gene for has RYR3 recently been reported to be localised to 
chromosome 15 in the region 15q 14-q 15 (Sorrentino et al 1993). Linkage studies 
between RYR3 and MHS did not detect any evidence for an MH locus in this 
region in three non-19 linked German MHS families (cited from West 1996).
1.10.5.2 The DHPR genes
A possible second causative candidate for MH susceptibility on 
chromosome 17q 11,2-q24 was reported by Levitt et ai m 1992 and indicated a 
locus MHS2. In this region there are two subunit genes, p and y (CACNLB1 and 
CACNLG) the subunits of 1 ,4-dihydropyridine receptor (DHPR), and in addition 
the locus encoding another plausible candidate adult skeletal muscle sodium
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channel (SCN4A)(01kers et al 1992). There is only one report in which the 012/6 
subunit of the DHPR probably is involved in malignant hyperthermia susceptibility 
(lies e ta l 1994).
1.10.5 2.1 ai-subunit
The a i subunit of the dihydropyridine receptor is a particularly interesting 
candidate for MHS because it functions as a voltage sensor for excitation- 
contraction coupling, and depolarising muscle relaxants such as suxamethonium 
can trigger an MH crisis via this subunit. It may interact with/?Fi?/ in triggering 
calcium release from the sarcoplasmic reticulum. It is a tissue specific gene and 
three kinds of polypeptide are reported in brain, cardiac muscle and skeletal 
muscle. The genes encoding the brain (CACNL1A2) and cardiac isoforms 
(C AC N LIAI) of DHPR ai-subunits have been localised on human chromosomes 3 
and 12p 13 respectively (Seino e ta l 1992; Powers et al 1992). The skeletal muscle 
ai-subunit (CACNL1A3) is located on chromosome Iq31-q32 (Gregg et al 1993a). 
This subunit comprises a 175 kDa peptide which contains the binding-site for Ca2+ 
channel antagonists, 1,4 dihydropyridine, phenylalkylamines, and benzothiazepines 
(Takahashi 1987; Catterall et al 1988). The ai-subunit is the central component of 
the DHPR complex, forms the ion pore structure, functions as a voltage sensor 
(Miller 1992) and when expressed in mammalian cells functions as a calcium 
channel (Perez-Reyes e ta l  1989; Mikami e ta l  1989). The ai-subunit is necessary 
for both slow calcium currents and voltage sensing in excitation-contraction 
coupling. Investigation of the ai-subunit of human skeletal muscle DHPR reveals
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that it is comprised of five segments, I, II, III, IV and linker. Sequencing the cDNA 
segments reveals that the oti subunit has a cytoplasmic II-III loop, a transmembrane 
segment (IS3), and an IS3-IS4 linking peptide (IS3/IS4-IS4). These are the main 
highly specialised components which are critical in E-C coupling (Nakai et al 
1994, Zhang et al 1994; O’Brien e ta l 1995). Any abnormality in either of these 
regions might alter the pharmacological sensitivities and gating properties of the 
SR Ca2+ release channel. This study showed no difference in molecular structure 
of these peptides between MHS and MHN patients which are not linked to 
chromosome 19q. This study with others studies may exclude the ai-subunit as a 
causative gene in malignant hyperthermia susceptibility. In a survey, linkage 
between MH and the locus encoding the a  1-subunit, CACNL1A3 on chromosome
1 in the region of Iq31-q32 has been excluded in nine European MH families in 
which there was also no evidence for linkage to other MHS loci including the 19q 
and 17q regions (Sudbrak et al 1993) although tight linkage between this gene and 
HypoPP has been reported (Elbaz et al 1995).
1.10.5.2.2 p and y-Subunits
A second possible candidate locus for MH susceptibility (MHS2) was 
reported by Levitt et al (1992) on chromosome 17q 11,2-q24. Three possible 
candidate genes are located in this area. They are the adult skeletal muscle sodium 
channel (SCN4A) and subunits of Pi and y of the skeletal muscle dihydropyridine 
receptor.
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The DHPR [3-subunit gene (CACNLB1) is localised on chromosome 
17q 11,2-q24 (Gregg et al 1993b), in the region which is proposed as a candidate 
for MHS2. This gene has been excluded as a second candidate for malignant 
hyperthermia susceptibility (SudbrakeJ al 1993) for reason which are described in 
section 1.10.5.3.
The DHPR y-subunit (CACNLG) is one the five polypeptides that make up 
the dihydropyridine receptor. In humans the CACNLG locus (y gene) is tightly 
linked to the growth hormone gene at chromosome 17q23. This region also 
contains the adult skeletal muscle sodium channel gene (SCN4A). This gene is
12.5 kb in length and consists of four exons encoding a 222 amino acid 
transmembrane protein which is expressed only in skeletal muscle (Powers et al
1993). In a mutation screening study in the CACNLG, three mutations were found 
(Lynch et al 1995). Two of them were rare variants with no amino acid alteration 
and the other one although it caused a Gly to Ser change was also detected in 
normal samples and so is not pathological. In addition the y-subunit as a candidate 
for malignant hyperthermia susceptibility was excluded by Ilese? al (1993). These 
studies demonstrated no MH causative mutation in the y-subunit gene of DHPR.
1.10.5 .2.3 o^/S-subunit
The gene encoding the CLifo subunit (CACNLA2) of the DHPR is located on 
chromosome 7q21-q22 (Powers et al 1994). These two subunits result from the 
cleavage of a single precursor protein and are linked together by disulphide bonds. 
They may be involved in the regulation of calcium current density and together
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with [3-subunit pronouncedly increase the voltage-sensitivity of channel activation 
and inactivation. Evidence for linkage between markers flanking this gene and 
malignant hyperthermia susceptibility was observed in one large three-generation 
European family (lies et al 1994). Subsequent studies have not repeated this 
observation in 30 non-19, non-17 linked MHS families studied by the European 
Malignant Hyperthermia Group (West 1996).
1.10.5.3 Adult skeletal muscle sodium channel (SCN4A)
In searching for further MHS genes a region on chromosome 17q has been 
implicated. This region showed linkage with MH susceptibility in five small North 
American and South African pedigrees. The adult skeletal muscle sodium channel 
gene is located in this region and Olckers et al (1992) proposed it as a candidate 
gene for MH susceptibility. Three point mutations in this gene have been 
identified in patients with myotonia fluctuans, two additional mutations cause other 
unique forms of myotonia and another 11 mutations have been identified within the 
same gene to cause hyperkalaemic periodic paralysis or paramyotonia congenita. It 
is confirmed that mutation in this candidate gene is associated with 
suxamethonium-induced masseter muscle rigidity (MMR), whole body rigidity and 
an abnormal IVCT (Vita et al 1995). But it is generally considered that there is no 
supporting evidence for the role of SCN4A in malignant hyperthermia susceptibility 
and the report on linkage of malignant hyperthermia to the markers in the region 
17q 11.2-q24 is probably due to misdiagnosis of HyperPP as MHS (Iaizzo and 
Lehmann-Horn 1995).
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1.10.5.4 The hormone-sensitive lipase
The hormone sensitive lipase gene (L1PE) is another candidate gene which 
may be involved in malignant hyperthermia (Levitt et al 1990). This hypothesis is 
based on the abnormal metabolism of free fatty acids in MHS skeletal muscle. 
These fatty acids originate from triglycerides in skeletal muscle (Fletcheret al 
1989). In MHS samples high levels of free fatty acid (two and half times the 
normal levels) are detected in human muscle homogenates (Cheah 1983; Fletcher 
et al 1986) and similar results have been obtained using isolated mitochondria from 
pigs. This increase in the concentration of free fatty acids can enhance the release 
of Ca2+ induced Ca2+-release from sarcoplasmic reticulum by lowering the 
threshold and causing a reduction in the Ca2+ uptake by the sarcoplasmic reticulum 
(Fletcher et al 1990). In addition there is excessive heat production as a result of 
the uncoupled oxidative metabolism. The role of hormone-sensitive lipase in free 
fatty acid mobilisation from stored triglycerides is crucial. It is regulated by 
hormonal and neuronal factors (Holm et al 1988). Hormone-sensitive lipase 
(LIPE) is activated by catecholamines and inactivated by insulin. If this 
inactivation did not occur in MHS individuals then the resulting increase in free 
fatty acids would cause disruption of muscle metabolism (Levitt et al 1990).
During a hyperthermic crisis catecholamines are elevated which stimulates 
LIPE and this results in free fatty acid production (Levitt et al 1990). The LIPE 
gene has been mapped on chromosome 19q 13.1-13.2 (Holm et al 1988; Levitt et al
1995). Based on this background the LIPE gene has been proposed as a candidate
gene in MH families which are linked to chromosome 19q (Levitt et al 1990; 1995/ 
Liu et al 1993).
1.10.6. Genetic diagnosis o f  malignant hyperthermia
A genetic method for use in diagnosis should establish a procedure for 
screening patients or persons who are at risk of malignant hyperthermia 
susceptibility. If a genetic method is proved, it may be possible to provide a cheap, 
rapid, accurate and non-invasive screening test for those who are at risk. On the 
other hand the useful indication should be to find affected families in which 
susceptibility is associated with the MH gene. A possible way for finding MH 
patients probably can be carried out with a non invasive, accurate and rapid DNA 
test. These are based on using the potential DNA tests in MH diagnosis is by 
finding mutations in the RYR I gene and other candidate loci. But before mutation 
analysis can be performed, linkage analysis is necessary to determine linkage of 
MH in each family. Of course linkage analysis in small families is less reliable for 
determining linkage between markers and malignant hyperthermia susceptibility. 
But compared with small families, the risk in large families is lower and once the 
allele of a marker which is associated with MHS is identified by linkage analysis, it 
can be used directly in diagnosis of the genetic disorder in individual members of 
affected families. But it should be remembered that linkage analysis is not 
absolutely reliable in diagnosis of MH cases and it probably will not be without 
false diagnoses.
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1.11 Aims of this project:
The main goal of this project has been to establish a genetic procedure to 
identify individuals susceptible to malignant hyperthermia. If a genetic method is 
found, it may be possible to provide a cheap, rapid, accurate and non-invasive 
screening test for those who are at risk of malignant hyperthermia susceptibility.
Two approaches have been adopted. Firstly genetic linkage analysis has 
been used to identifying the chromosome (haplotype) and region on the 
chromosome that carries the defective gene in a particular family. Secondly, 
mutation analysis has been performed on one candidate gene.
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Chapter two
Human gene mapping
In gene mapping the location of a disease locus can be detected by using 
physical methods such as in situ hybridisation and somatic cell hybrids and linkage 
analysis.
2.1 Physical methods
The somatic cell hybrid method (Szybalski and Szybalska 1962; 
D ’Eustachio and Ruddle 1983) is based on the fusion of cultured cells and 
formation of heterokaryons from different species (human and rodents, usually 
mouse and hamster). The development of methods to hybridise human with mouse 
cells allowed the assignment of many genes to specific chromosomes and the 
construction of a human linkage map by Ephrussi and Weiss (1969). In situ 
hybridisation or FISH (fluorescent in situ hybridisation) is another technique in 
physical mapping and based on using a DNA probe which is labelled by 
incorporation of modified nucleotides (such as biotinylated nucleotides) or reporter 
molecules. Following hybridisation of the probe to metaphase chromosomes, after 
denaturation, the chromosome preparation is incubated in solution containing 
fluorescently labelled affinity molecules which bind to the reporter on the 
hybridised probe. The results of FISH can be observed by fluorescent microscopy.
Mapping of genes using associated chromosomal aberrations such as 
deletions, translocations or inversions especially in human cancers is another
technique in physical methods. Some chromosomal aberrations affect more than a 
single gene and so cause a complex phenotype syndrome to appear. Sometimes a 
specific disease is regularly associated with a specific aberration (deletion in 
Duchenne muscular dystrophy disease or some syndromes like Cri du chat which is 
caused by deletion in chromosome 5p). This method was involved in the initial 
identification of the gene responsible for FAP (familial adenomatous polyposis) 
gene mapping in which a possible tumour suppressor gene is defective. In tumour 
cells the high incidence of particular aberrations such as deletions and translocation 
is not unusual. Finding the correlation between specific disorders and related 
genes may contribute to gene mapping.
Gene mapping became a practical possibility using linkage analysis based 
on the segregation of alleles from many co-dominant polymorphic loci which can 
be analysed at the DNA level. This is based on segregation of two loci or more, 
using RFLPs (Restriction Fragment Length Polymorphisms) (Botstein et al 1980) 
and hypervariable markers (VNTRs). The genetic map distance between two genes 
is estimated by the number of cross over events on a single chromosome strand 
(chromatid) between two loci during meiosis as a proportion of the number of 
opportunities for observing these events. Here gene mapping based on linkage 
analysis is generally described.
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2.2 Linkage analysis
2.2.1 Introduction
Two distinct ways for finding the genetic locus which gives rise to a genetic 
disorder can be supposed. The first one is based on previous knowledge of 
biochemistry and physiology of the disease. For example the haemoglobin and 
phenylalanine hydroxylase loci are candidate loci for haemoglobinopathies and 
most cases of phenylketonuria (PKU) respectively (a few percent of PKU cases are 
due to mutation in the dihydrobiopterin synthetase or dihydropteridine reductase 
gene).
The second approach does not require any knowledge of the biochemical 
nature of the trait or the nature of alterations in DNA responsible for the trait and 
isolation of a specific gene is not required. This method is dependent on genetic 
linkage. It uses many genetic markers at known locations on all the chromosomes 
to examine them in a collection of families with the condition. This process is 
known as genomic search. Finding a marker that co-segregates with the condition 
when statistically it is significant can identify the probable location of the disease 
gene close to the marker locus. Further searching within the candidate region is 
necessary to identify the related gene or genes which may be expressed in the 
relevant tissues and finding probable mutations in a particular gene which are 
associated with the condition. This process is known as positional cloning. This 
approach has been successfully applied in diseases where their causation previously 
was not clear, like cystic fibrosis (Tsui et al 1985; White et al 1985).
Genetic linkage analysis is a method that allows the localisation of genes in 
the absence of any information about the biochemical defects that cause such 
disorders. It has been particularly useful for the mapping of disease gene loci. 
Linkage analysis is a technique that uses polymorphic markers to find the 
chromosomal location of a disease causing gene. The method relies on availability 
of markers (proteins or DNA) which detect polymorphisms. The existence of 
polymorphisms in linkage analysis is very important and it means when two or 
more alleles are at significant frequency in the population where the rarer allele has 
a frequency greater than 1%. It is based on the investigation of the segregation 
patterns of the alleles of a large number of polymorphic DNA markers distributed 
throughout the entire genome with the disease phenotype in affected families. 
Indeed using the linkage analysis approaches to human disorders was started with 
the successful identification of linkage between the loci for colour blindness and 
haemophilia on the X chromosome (Bell and Haldane 1937). The technique relies 
on the meiosis events in diploid germ cells. Before explanation of gene 
segregation during meiosis the brief description below is not without benefit.
2.2.2 Principle o f  linkage analysis
In 1903 Sutton and Boveri independently proposed the chromosome theory 
of hereditary and according to their theory the chromosomes carry the hereditary 
factors or genes (as cited in Goodenough and Levine 1974). As it was clear that 
the genes are located in a linear fashion on the chromosomes ( Morgan, Bridges 
and Sturtevant 1913, as cited in Vogel and Motulsky 1979) then it was logical that 
the genes on the same chromosome will be transmitted together. But
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cytogenetically it is known that during meiosis certain chromosome segments are 
exchanged between homologous chromosomes (Bateson, Punnett, Saunders 1908, 
as cited in Vogel and Motulsky 1979). Based on Mendel’s law the chance of 
assortment and transmission of genes of paternal and maternal origin should be 
equal. The two terms, “coupling” ( genes are localised in a doubly heterozygous 
parent on the same chromosome AB/ab) and “repulsion” (when they are localised 
on homologous chromosomes Ab/aB) were introduced. But for these two aspects 
Morgan and his colleagues used the “linkage” term and they supposed that these 
are two features of the same phenomenon observed in the fruit fly, Drosophila 
melanogaster.
These events (coupling and repulsion) of genes assortment are based on 
gametic cell division or meiosis. Meiosis comprises two divisions, meiosis I and II 
which via different processes produce haploid cells (fig 2.1). The main difference 
between these two division is the distribution of gametic materials (chromosomes) 
to daughter cells with similar copies of DNA. The main events in meiosis I from 
the point of view of linkage occur in prophase with formation of bivalents 
(homologous pairs of maternal and paternal chromosomes come together) and 
synapsis. The conformation of the synaptonemal complex between homologous 
chromosomes permits recombination (crossing-over ) between bivalents. Crossing 
over was first proposed by Morgan (1910, as cited in Vogel and Motulsky 1979) to 
explain the formation of recombinant combinations of genes that were shown to be 
linked by genetic data. It is caused by breaking in sister chromatids (after 
replication each parental chromosome consist of two chromatids which are called 
sister chromatids, fig 2.1) at chiasmata, these are physical connection points
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Fig 2.1 Segregation and recombination between alleles at loci A and B during 
meiosis and gametogenesis.
After replication of parental chromosomes the chromosomes come close together 
during prophase of meiosis I and via chiasma formation and crossing over between 
chromatids may yield new combinations of chromosomes. Cell division in meiosis I 
results in two diploid cells with duplicated recombinant chromosomes. Cell division 
in meiosis II results in four haploid cells with unique recombinant chromosomes. 
Depending on the distance between loci the frequency of formation of recombinants 
(A1-B2 and A2-B1) or non-recombinants (A l-B l and A2-B2) haplotypes will vary.
between chromatids from different parents that are believed to be the cytogenetical 
sites of recombination and were first reported in amphibians. This results in 
exchanging the chromatid fragments in a reciprocal fashion. In addition double 
cross overs can occur between two, three, and four chromatids in a bivalent. Direct 
cytogenetical evidence that homologous chromosomes exchange parts during 
crossing over was first obtained in 1931 by Stern in Drosophila melanogaster and 
Creighton and McClintock in maize (as cited in Vogel and Motulsky 1979). In 
each chiasma two of the four chromatids in the bivalent are involved. The location 
of crossing over is not random and it is supposed that there are preferential sites 
due to the existence of interference and recombinational hotpoints.
During meiosis the alleles of loci on different homologous chromosomes 
undergo independent assortment (Mendel’s laws), i.e. they will be inherited 
together with a probability of 0.5, whereas loci close together on the same 
chromosome tend to be inherited together with probability greater than 0.5.
Linkage between two loci is measured by the recombination fraction (RF or 
9), which estimates the distance separating the two loci. The recombination 
fraction is defined as the proportion of recombinant offspring. It is used to 
estimate the distance between two or more loci in constructing genetic maps (Ott 
1991). The recombination fraction can be expressed as:
total number of recombinants
RF = -------------------------------------------------------------------------------------
total number of recombinants and non recombinants
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Since the recombination fraction is an estimate of an absolute value of the 
genetic distance it is important to know the error involved in its estimation. The 
standard error (SE) of a recombination fraction is expressed by below equation 
where the n>30 :
The percentage RF is presented in centi-Morgan (cM) as an estimate of the genetic 
distance or map distance between two loci for short distances (< 10 cM). This 
distance physically for example, 1% recombination, corresponds to a genetic map 
of 1 cM or 1 map unit. This correlation is not accurate for larger values of 
recombination fraction (Haldane 1919). Then for longer distances the linear 
relationship between recombination fraction and genetic distance breaks down 
mainly because of multiple cross-overs occurring (between two loci) and 
interference, a phenomenon which reduces the chance of a cross-over event 
occurring in the close vicinity of another cross over. Mapping functions have been 
proposed for relating recombination fractions (0) with genetic map distances. In 
human genetic linkage analysis the mapping function which is commonly used is 
the Kosambi function but other map functions have been proposed where the 
estimation of genetic map distances show differences between these methods. For 
example, in Haldane’s map function 0 =0.27% translated to 39 cM but in 
Kosambi’s mapping function this 0 value is equal to 30 cM (cited from Terwilliger 
and Ott 1994).
SE = RF
recombination fractionxnon-recombination
total number of offspring (n)
RF indicates the likelihood that two linked loci will be separated by a cross 
over during meiosis. On the other hand RF is the probability that a gamete 
produced by a parent is a recombinant. The two, three or more unlinked alleles on 
the same chromosome are equally transmitted to the same or to different gametes 
duration meiosis. Figure 2.1 shows a simple method of gene segregation in one 
tetrad, one pair of replicated homologous chromosome in gametogenesis of germ 
cells. Recombination events that occur at random positions between paired 
homologous chromosomes at meiosis make it more likely that loci located close 
together rather than more distant loci, are inherited together (fig 2.1). For instance 
we can assume the alleles of Al and B 1 (from A and B loci) are closely linked 
together with a high chance of segregation to the same gamete. So during meiosis 
the probability for co-segregation of A l-B l alleles to one gamete will be greater 
than the A1-B2 combination or haplotype. The haplotype is a set of different genes 
or markers received by an individual from one parent on one chromosome. Then 
the A l-B l combination will appear more frequently amongst the offspring but if 
not, the combination of A1-B2 or A2-B1 will be possible.
On the other hand, in the segregation of unlinked alleles the production of 
new recombinant or non-parental gametes is 50% but this rate will be altered for 
linked genes or markers and close genes will appear together more frequently than 
50%. In this method of genetic linkage analysis, two genetic markers are said to be 
linked if they segregate together in pedigrees more often than by random chance.
If an allele of a DNA marker is linked to a disease gene they will tend to co- 
segregate during meiosis, owing to the fact that meiotic recombination occurs
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infrequently between closely linked loci. If a specific marker is close to a disease 
gene they co-segregate together; if not the frequency of recombination between 
two markers can indicate their distance. Thus simple segregation of alleles can be 
used as a background in linkage analysing three.
2.2.3 Markers used fo r  linkage investigations:
Using markers in human genetics research and diagnostics may be referred 
to the 1910-1960 period during which the blood groups and were helpful. In the 
period up to 1960’s gene mapping studies had been carried out using blood group 
and phenotypic markers. After that HLA (human leukocyte antigen) tissue types in 
1970 were used although these were limited to a specific chromosome. The use of 
RFLPs (restriction fragment length polymorphisms) in 1979 (Solomon and Bodmer 
1979) as a tool in genetic analysis was an important step in the development of 
linkage markers (cited from Botstein et al 1980). These markers were found to be 
associated with disease and may be of value in diagnosis and gene mapping 
(Solomon and Bodmer 1979). Subsequently Botstein et al (1980) proposed RFLPs 
as the solution to the marker problem for genetic analysis in humans. These 
markers, although first discovered in yeast strains, but rapidly introduced in human 
as markers in haemoglobinopathies (Maniatis et al 1978; Kan and Dozy 1978). 
DNA VNTRs (variable number of tandem repeats) or minisatellites in 1985 
(Jeffreys et al 1985; Nakamura et al 1987) and DNA STRs (short tandem repeats) 
or microsatellites in 1989 (Weber and May 1989) were introduced as markers in 
molecular genetic with higher numbers of alleles in comparison with RFLPs.
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A marker’s usefulness for linkage analysis depends on the number of alleles 
and their gene frequencies which determine its degree of polymorphism. The 
degree of polymorphism may be measured using two parameters, the 
heterozygosity and polymorphism information content or PIC value. These 
measurements depended on two factors, the number of alleles and allele frequency. 
Botstein et al (1980) introduced the PIC value for a genetic marker in place of 
heterozygosity for using in linkage analysis. Heterozygosity simply estimates the 
frequency of heterozygotes for a genetic marker in a population but the PIC value 
estimates the frequency of informative matings for that marker. For example in an 
A lA 2xA lA 2 mating half of the progeny are heterozygous (A 1A2) and so they are 
not informative for linkage analysis because they could have inherited the Al allele 
from either parent. But using markers having more than two alleles the chance of 
informative meioses will increase as heterozygous matings of the type 
Al A2xA3A4 will occur which are fully informative. Markers with multiple alleles 
show higher heterozygosity and PIC comparison with RFLPs. The RFLPs or 
restriction site polymorphisms have usually two alleles with low PIC and a 
maximum heterozygosity of 0.5 if the their alleles have equal frequency. But the 
introduction of VNTRs provided markers with multiple alleles and therefore most 
people are heterozygous for different alleles and so their PIC value can be very 
high. Values of PIC from a marker with several common alleles (VNTRs) can 
reach to 0.99 in comparison with the maximum PIC value of 0.375 for an RFLP 
marker with only two alleles. The PIC and heterozygosity will increase where the 
alleles have equal population frequencies. This can be described for two alleles of
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an RFLP marker with frequencies of 0.5 and 0.5, or 0.46 and 0.56, or 0.03 and 0.97 
where the PIC values of the first two loci are more than third one.
Using PCR as a technique in DNA amplification of microsatellites using 
small amounts of DNA (about lOOng compared with 1 Ojug for RFLPs) of was 
another advantage of STRs. With concern to the last two groups of markers 
(minisatellites and microsatellites) these will be described as follows.
The human genome contains repeated DNA sequence families which are 
composed of tandem and individual unit repeats. These segments are generally 
non-coding sequences interspersed in all chromosomes and are more likely to be 
present in introns or between genes. These tandem repeats include satellite DNA, 
minisatellites and microsatellites. Satellite DNA’s (“satellite” means the highly 
repetitive non-transcribed DNA) are long segments found in the centromere area of 
some chromosomes and are not suitable for linkage analysis. Minisatellites are 
long arrays of tandem repeats and are not common in all chromosomes; the 
majority of these are found in or near the centromere and telomeres.
Microsatellites are found in large numbers of very simple repeats, and are highly 
informative sequences.
After using PCR in DNA amplification in 1985, discovery of these repeats 
in 1989 was an important step in molecular biological techniques and caused rapid 
development in molecular genetics. These short repeats are found in the genomes 
of most eukaryotes except yeast. These sequences, compared with minisatellites or 
variable number tandem repeats (VNTRs), are more common and contain short 
motif in repetition. These are small tandem repeats which are simple in sequence
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(l-4bp) and interspersed throughout the genome (e.g. WUT1.9, chapter three). The 
number of copies of the repeat units at any chromosome position usually varies 
from person to person (or chromosome to chromosome) so different lengths of 
these repeat sequences are present in the population. These segments are usually 
non-coding DNA with specific genetic map locations and so these loci are being 
used increasingly in gene mapping and genetic diagnosis (Weber and May 1989; 
Hearne et al 1992). They are used for amplifying the region containing the 
sequence of interest by using the polymerase chain reaction. The length of the 
repeat units or alleles found on the pair of chromosomes in each individual may 
then be resolved by gel electrophoresis.
In linkage analysis the DNA markers used are generally either sequence 
variations giving rise to restriction fragment length polymorphism (RFLPs) or 
polymorphic short tandem repeats (STRs) commonly CA dinucleotide repeats. 
RFLPs normally have two detectable alleles, one of which contains the specific 
restriction enzyme site while the other one lacks this site. These markers due to 
poor informativeness usually are of limited value in genetic analysis
In linkage analysis a useful microsatellite or marker should be typable using 
an easily available source of DNA such as epithelial cells in mouth washes, or 
white blood cells in venous blood samples and as well as it must be inherited in a 
simple codominant pattern. It must reveal a polymorphism, that is the existence of 
two or more alleles at significance frequency in the population under investigation. 
The usefulness of the marker depends on its informativeness. A marker is 
informative when it is possible to distinguish the two alleles passed to offspring
66
(figs 2.2 and 2.3 show phase known and unknown in two and three generation 
pedigrees respectively). The alleles of a marker are not of value when their 
frequencies are close to zero or one; the locus is then not very useful since then 
there is a good chance that both parents in a family will be homozygous for the 
same allele. Then a more polymorphic allele is more suitable for linkage analysis. 
It should have a known chromosomal location and preferably sub-chromosomal 
location. Finding suitable markers in genome mapping is an important step which 
is stated from early this century and usually many attempts were carried out to 
guess the total length of haploid genome and the number of markers (qualified 
markers) which are needed for this purpose. Following this idea and based on the 
estimation of total length of the haploid genome which is supposed to be 3300 cM 
(Renwick 1969) it was estimated that 200-300 markers spaced at 10 cM intervals 
are needed for the entire mapping of the human genome 3x10 ; bp (Solomon and 
Bodmer 1979). But Botstein e ta l (1980) proposed that 150 markers would be 
needed for entire genome mapping with 20 cM intervals. The map of markers for 
human genetic linkage is rapidly improving. The first DNA polymorphism map to 
cover the genome was published in 1987 by Donis-Keller et al and had an average 
spacing between markers of 10-15 cM. However recently a comprehensive genetic 
map of the human genome was published by the Genethon group (Dib et al 1996). 
This map consists of 5 264 short tandem (AC/GT)n repeat polymorphisms. The 
map spans a sex-average genetic distance of 3 699 cM and the average interval size 
is 1.6 cM which identify 2 335 resolved map location.
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Fig 2.2 Segregation of alleles in a phase known three generation pedigree.
Segregation of alleles A l  and A2 at locus A, B1 and B2 at locus B in a three 
generation family. In this family phase in the doubly heterozygous parent, II.2 can 
be determined from the grandparents, as II.2 must have receivedA/ and B1 alleles 
from his father, 1.1 and A2 and B2 alleles from his mother, 1.2 and therefore the 
phase is defined with A1B1 in “ coupling ” or on the paternally derived 
chromosome.
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Fig 2.3 Segregation of alleles in a phase unknown two generation family at loci 
A and B.
In this two generation family the phase of the doubly heterozygous parent, 1.1, is 
unknown. It is equally likely that 1.1 carriesA/ and B1 on the same chromosome as 
A l  and B2. Therefore it is not possible to define which of his offspring are 
recombinant.
2.2.4 Computation o f lod scores
To assess genetic linkage in humans, especially when the three-generation 
pedigrees are not available then it is not possible to count recombinants so a direct 
estimation of recombination fraction is not possible. For this reason an indirect 
statistical approach is used which is based on maximum likelihood estimations. 
This method was introduced by Morton (1955) and it can combine the linkage data 
from phase known and unknown sources in lod scores calculation. Then in 
following this method is described.
A likelihood ratio, L is estimated by computing the ratio of the likelihood
of the two loci being linked at a defined genetic recombination fraction (0) against
likelihood of the two loci being unlinked (0 = 0.5) or on the other hand
L(0)= L(0)/L(O.5) or,
likelihood of linkage at a given value of 0
L = ---------------------------------------------------------------------
likelihood that two loci are not linked (0 = 0.5)
In linkage analysis this “ L ” ratio is called odds ratio or odds fo r  linkage. The
introduction of the lod score method made the analysis of human linkage data
practical (Morton 1955). In many two generation families there is no information
on the phase of the double heterozygote. Using lod scores has the advantage that
information from phase known and phase unknown linkage data can be combined.
Evidence for linkage is expressed statistically as a maximum likelihood expression
as a logarithm to base ten of the odds on linkage (lod) and indicated by “Z”.
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Likelihood of linkage at a given value of 0
Z = logio -------------------------------------------------------------------------------
Likelihood that two loci are unlinked (0 = 0.5)
or Z(0) = LogloL(0) = logio[L(0)/L(O.5)]
Lod scores are used in confirming or refuting the linkage between markers and 
assignment into regions or candidate gene. One example of a lod score calculation 
for a three generation pedigree showing segregation of an autosomal dominant 
disease and an assumed locus as illustrated in fig 2.4 is carried out as following:
In the second generation, in individual II. 1 who is doubly heterozygous the phase is 
known and alleles 3 (from the test locus) and D (from the disease locus) are 
transmitted from his father, 1.1, and alleles 2 and N (normal allele of disease locus) 
from his mother individual 1.2.
In the third generation, the alleles of 3 and D are transmitted together to 
individuals, III. 1, III.3, III.5, III.8 and III. 10 as parental combinations of alleles or 
non recombinants. However individual III.6 has inherited alleles 2 and D from her 
father and so is a recombinant type. The lod scores could be calculated as 
following:
Chance of individual II. 1 transmitting allele 3 to III. 1 (III. 1 and eight more
individuals of third generation are non-recombinant) is Vi and
chance for transmitting of alleles 3 and D if are linked is ViX( 1 -0) (the 1-0 =
non-recombination fraction) and if are unlinked is V2XV2
then likelihood of observing the haplotype of III. 1 is Vix( 1 -Q)IViXVi.
The likelihood of observing individuals III.2 to III.5 and III.7 to III. 10 are
identical to III. 1. In individual III.6, who is recombinant chance of linkage
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Fig 2.4 One sample of a three-generation family used in lod score calculation.
Based on the marker segregation the lod score calculation is carried out at three 
different value of recombination fraction or 9 = 0.05 and 9 = 0.1 (see text).
between alleles 2 and D is V2X(Q) and if they are unlinked is VixVi 
and likelihood is equal to V ix^M xV i. The likelihood for whole family is 
equal to
L(0) = L (m .lfx L (III .6)1 = [(1 - 0 ) /1/2 ]9x [ ( 0 ) /1/ 2]  1 and so is equal to 
L(0) = [2(l-0)]9x(20)' and lod score is equal to: Z = Iogio L(0) 
= log,o [ 2 ( 1 - 0 ) ]9x ( 2 0 ) '.
For this family the calculation of lod scores with two hypotheses, (a) when the RF 
(0) is 0.05 and second (b) when the RF is 0.1 is followed as below: 
for (a) L = [2( 1 -0.05)]9x2(0.5)' = 32.268
Z = logio L(0)=+1.508
(b) for the second situation when 0 = 0.1 the chance for linkage is 90% and for 
recombination is 10%. Then as (a) L = [2(1-0.1)]9x2(0.1)' = 39.671x and logio for 
L which is indicated by “Z” is equal to +1.598 which is the maximum lod score.
A lod score of zero means the assumptions of linkage or non-linkage are 
equally likely [logio (1) = 0]. This level of statistical proof is derived from a 
Bayesian calculation which assumes a prior probability of linkage of any two loci 
on the human genome to be 1 in 50. Lod scores are usually calculated for 
recombination fractions of 0.00, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 
and 0.50. The lod scores at recombination fraction of 0.00 and 0.01 show very 
close linkage and up to 0.40 represent loose linkage.
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2.2.5 Practical considerations
In linkage analysis the size of pedigree is important as well as the number 
of generations. For instance in a two generation family segregation between the 
disease gene and marker may be difficult to interpret because in the phase unknown 
double heterozygote it is not clear which two alleles were received as a haplotype 
from one parent. This problem probably will be removed in the third generation.
In fig 2.3 in the first generation it is not clear which markers are syntenic in 1.1, 
A1B1 or A1B2 but in the second generation in fig 2.2 the phase will be known and 
the identification of recombinant and non-recombinant offspring is unambiguous. 
Finally despite the importance of human genetic analysis in clinical applications 
and preventive diagnosis it is faced by some problems. The long generation times, 
small family size, limitation in crosses and non-paternity can be problems.
2.2.6 Two point analysis
In two point linkage analysis, pedigree data are used to check whether two 
loci are genetically linked, to estimate the recombination fraction between the two 
loci and to evaluate the support for this linkage. In this manner evidence for 
linkage is considered significant when the lod score is +3 or more and a lod score -
2 or less is taken as evidence against linkage at that recombination fraction. The 
lod score can be calculated for any value of the recombination fraction or “ 0 “ 
between 0.00 (complete linkage) and 0.5 (no linkage, 50% recombination).
In this project linkage analysis between hypervariable microsatellite 
markers and disease locus for MH susceptibility was done by using the LINKAGE
computer programme (version 5.1) (Terwilliger and Ott 1994). The LINKAGE 
programme estimates the likelihood of linkage between gene disease and makers.
There are a few programmes for linkage analysis and lod score calculation. 
Two of these are LIPED (for Likelihood in PEDigrees )and LINKAGE. Both 
programs calculate the likelihood of linkage from family pedigree data given the 
various parameters such as recombination fraction and gene frequencies. The 
LIPED programme is designed for pairwise analysis loci (two point analysis), 
while the LINKAGE programmes are not limited in the number of loci that may 
jointly be analysed. LIPED is written in FORTRAN but the LINKAGE 
programme is in the Pascal language. The major difference between these two 
programs is in definition of penetrance, while LIPED uses penetrance in a general 
sense the LINKAGE program use the penetrance as the probability of being 
affected given a genotype (based on affection status locus) and inducing liability or 
penetrance class. The LINKAGE package consists of several analysis programmes 
such as MLINK, ILINK and LINKMAP which calculate two point or multipoint 
likelihoods in human pedigrees. MLINK calculates lod scores for given set 
parameter values such as a set of recombination fractions in interlocus intervals. 
ILINK estimates recombination fractions, but LINKMAP program assumes a fixed 
map of markers and calculates likelihoods for a new locus at various points in each 
interval along the known map. ILINK is a program for two point analysis and only 
estimates the maximum likelihoods. In linkage analysis based on the pedigree 
drawing the MLINK option (using Cyrillic package version 2.0 which is used for 
pedigree drawing and published by Cherwell Scientific publishing Ltd 1996)
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automatically creates two files, PRE files for pedigree and DAT files for linkage 
analysis (Ott 1991).
2.2.7 Multipoint analysis
The next step in linkage analysis is multipoint analysis, using two, three or 
more markers and disease status. In multipoint analysis the closely linked markers 
which may be informative in different individuals in the pedigree are analysed then 
a more definitive lod score may be obtained. In two point linkage analysis when an 
individual may be informative for one marker but others in the same pedigree may 
be uninformative or homozygous and vice versa for other markers, pairwise lod 
scores cannot combine information from more than two loci. This situation can 
affect the results in two point analysis but in multipoint analysis this disadvantage 
does not arise. The other advantage of this analysis method is that it is useful in 
establishing the order of a certain set of linked loci on a chromosome.
2.3 Genetic diagnosis of diseases
In genetic diagnosis for an inherited disease (here MH) it is necessary to 
follow the following steps :
2.3.1 Linkage studies
Finding marker(s) on known chromosome which are closely linked to 
disease locus and study of association of these markers with disease phenotype in 
family members. In this step using pedigrees for following the transmission of 
disease and linkage analysis method is a prerequisite. Having distinguishable and
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informative alleles in progenies and a clear mode of inheritance in marker selection 
are important. In the following pedigrees the examples for informative and 
uninformative markers are presented. This method is fully described in section 2.2.
2.3.2 Identification o f the candidate gene
The next step is identifying the region in which the causative gene is 
located, using flanking markers and results of linkage analysis may give rise to the 
determination of a possible abnormal gene. Once a linkage region has been 
identified it has to be searched for candidate genes either by screening candidates 
indicated by other studies for example in physiology, biochemistry, pharmacology 
etc. or by positional cloning strategies.
2.3.3 Identification o f  mutations associated with the disease
When the gene is recognised, sequencing and screening for causative 
mutation(s) and following the mutation(s) in susceptible and normal individuals 
will be necessary (some polymorphism in genes which are normal does not mean a 
mutation and these base changes need not result in alteration of gene function).
The search for existence and co-segregation of causative mutation in people who 
have suffered the specific disease and lack of this mutation are essential at this 
step.
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2.3.4 Determination o f the causative nature o f a mutation
After these last steps and making enough results the next important step is 
introducing the mutant candidate gene into a line of normal animals and then 
analysing the results from the transgenic line.
2.4 Malignant hyperthermia and genetic methods
In genetic analysis of malignant hyperthermia two methods, the DNA-based 
test for MH diagnostic and linkage programme for linkage analysis were used as 
briefly described as below.
2.4.1 Using the linkage programme
For two point linkage analysis, lod scores were calculated using the MLINK 
option of the LINKAGE program (Version 5.1) on a personal computer (DX4 486 
100MZ). Linkage contains different ability to calculate recombination fractions, 
likelihood, lod scores with two alleles or more in two point and multipoint analysis 
in two generation or three generation. The MLINK program which is used in this 
study has the ability to calculate the lod score and risk analysis with two or more 
loci. This programme in two point analysis calculates the likelihood of the data on 
two alternative assumptions, when two loci are linked at a given recombination 
fraction, and when two loci are unlinked. But in multipoint analysis using a few 
loci and the disease locus together with different locations for the MH locus 
between the marker loci. Pedigrees were created using the Cyrillic programme,
version 2.0. Penetrance for MH susceptibility was taken to be 0.98 allowing for 
2% false positive rate in IVCT, and it was taken as 0.02 (a false negative rate or 
frequency of phenocopies) for all individuals typed as MHN. All untested 
individuals were given the disease status unknown and the frequency of MH allele 
for the disease gene in population assumed to be 0.0001. MHE (malignant 
hyperthermia equivocal) individuals were assigned unknown status (i.e., they do 
not contribute to the lod score in used pedigrees). These are the recommendations 
of the European Malignant Hyperthermia Group; Genetics Section and agreed at 
their meeting in July 1991.
Finally the principle drawback with this method is that due to genetic 
heterogeneity in MH, only large pedigrees with many members already diagnosed 
by the IVCT are able to be analysed in this way.
2.4.2 Mutation analysis
In human to date eight mutations in RYR I gene are reported in MH and 
CCD patients. Probably these are related and causative to some degree in CCD 
and MH susceptibility but no mutation for other candidates are reported. Although 
it is predictable using DNA-based test for MH diagnosis in human (as in pig) but 
now there is no evidence to supporting this idea as the relation between RYR/ 
causative mutations and MH susceptibility is ambiguous.
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Chapter three
Materials and methods
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3.1 Patients and families
Patients came from well characterised families ascertained through the UK 
Malignant Hyperthermia Investigation Unit at Leeds except family AN2. All 
probands (except very young probands, under ten years old or deceased probands), 
and their at risk relatives were investigated by MH Unit using the IVCT. Prior to 
1984, the static halothane, dynamic halothane and caffeine tests were also used. 
However each of these tests was not used for every patient and sometimes 
additional tests such as a dynamic caffeine test was used. Patients were classified 
as MH positive or MH negative. Since 1984 all patients have been tested using the 
European IVCT protocol (EMHG 1984, 1985). On the basis of IVCT patients 
were classified as MHS, MHN and MHE. MHS patients were those whose 
biopsies responded to exposure to caffeine, 2mM (or less) and halothane, 2% (or 
less) by generating a contracture (0.2gr). MHN patients were those whose biopsies 
responded to neither caffeine nor halothane at the stated concentrations. MHE 
patients were those whose biopsies responded to either caffeine or halothane (see 
section 1.7.2).
In a few cases, patients characterised as MHE on the basis of IVCT were 
known to have experienced a hyperpyrexic response to anaesthesia. These patients 
were nonetheless considered MHE for the study of linkage analysis (see 2.4.1). 
This allowed general uniformity with European practice.
Male Female
□
MHN
o
MHN
1 3  3
MHE(h) MHE(h)
0
Deceased
SH : Static halothane test 
SC : Static caffeine test 
DH : Dynamic halothane test
Fig 3.1 Key to Figures 3.2 to 3.9 and description of symbols used in pedigrees.
Black symbols showing 0.2g contracture (positive responses or MHS) using specific 
concentrations of halothane and caffeine. Half-blacked symbols show 0.2g tension 
using specified concentration of halothane, described MHE(h) and blank symbols are 
normal or have no response using threshold concentrations (MHN).
0
Deceased
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Fig 3.2 Pedigree of family LMH03 showing results of IVCT diagnosis.
This four-generation pedigree, LMH03 composed of 18 individuals which, are tested . 
by the IVCT. Two of them are MHE and show positive contracture to halothane 
only. The first proband IV.7 is a nine year old male. He developed severe masseter 
spasm during anaesthesia with succinylcholine. Post-operatively he developed 
marked myoglobinuria with a serum creatine kinase level of 2850 units per litre. His 
paternal grand mother had died unexpectedly during anaesthesia for a hysterectomy 
when aged 46. The second proband of this family IV. 1 is a great nephew of the 
above grand mother. He developed an increasing heart rate after one hour of 
anaesthesia followed by arrhythmia and asystole. He had muscle rigidity and a 
temperature of 40C prior to death when aged 14. Previous linkage analyses with 
markers from chromosome 19q, 17q, 7q, 3q, and lq have excluded linkage with 
these candidate gene regions (Dr J. Curran, pers. comm.).
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Fig 3.3 Pedigree of family LMH07 showing results of IVCT diagnosis. This 
family comprises three MHS, two MHN, two MHE(h) and three individuals who are 
not tested by IVCT. The proband, III.2 is a young female who expressed clinical 
MH reaction during anaesthesia using suxamethonium. Her sister and her mother 
are normal and it appears that the disease allele is inherited from her father who is 
MHS. The proband’s uncle (II.3) and cousin (III.3) are both MH^,). It would 
appear that the MHE(h) status of the uncle represents a susceptibility diagnosis 
because he has an MHS daughter, III.4. This family is excluded from chromosome 
19q linkage (Dr J. Curran pers. comm.).
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SC 3mM 
DH 2 0%
SC 32mM 
DH > 2 0%
SC 3mM 
DH 2 0%
SC 32mM 
DH > 2 0%
SC 4mM 
DH > 2 0%
SC 3mM 
DH > 2.0%
Fig 3.4 Pedigree of family LMH12 showing results of IVCT diagnosis. The
LMH 12 family includes 10 individuals tested. Three are MHEd,,, two MHS and four 
MHN. The proband of this family is MHE using halothane test. He showed clinical 
reactions (such as hyperpyrexia) triggered by halothane. This tamily with one MHS 
recombinant is excluded from chromosome 19q markers using linkage analysis (Dr 
J. Curran per. comm.).
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SC  2 mM 
DH 1 .0%
SC 3m M 
DH 1.0%
SC > 4 mM 
DH > 2 .0%
SC > 3mM 
DH > 2 .0%
SC > 4mM 
DH > 2 .0 %
SC > 4mM 
DH > 2 .0%
Fig. 3.5 Pedigree of family LMH15 showing results of IVCT diagnosis. This 
family is composed of three MHS, one MHE(h) and seven MHN individuals. The 
proband of this family IV.2 is MHE(h) by IVCT despite the clinical reaction during 
anaesthesia. In a dental extraction he presented the muscle spasm and raised CK 
with halothane and suxamethonium. His father and his brother are MHS although 
his sister is normal. His uncle, III.3 is MHS but his three children are MHN.
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SC 3mM 
DH > 2 0%
SC> 4mM 
DH > 2 0%
SC 3mM 
DH > 2.0%
SC 2mM 
DH 1.0%
SC
DH
4mM
1 .0%
SC 4m M 
DH > 2 0%
SC > 4mM 
DH 2.0%
Fig. 3.6 Pedigree of family LMH16 showing results of IVCT diagnosis. III.5 is
the proband. She developed muscle spasm and jaw rigidity after induction of 
anaesthesia with suxamethonium for tonsillectomy. She proved to be MHS by IVCT 
testing but her father has no positive response to caffeine but halothane induced 
positive contracture using her muscle biopsy. Thirteen people have been tested by 
IVCT in this pedigree with three MHS and 6 MHE(h) individuals identified.
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SC1.5mM SC 2m M SC 2mM
DH 1 0% DH 0 5% DH 0 5%
Fig. 3.7 Pedigree of family LMH17 showing results of IVCT diagnosis. The
first proband in family LMH 17 is IV.4 who is not tested but his mother with two his 
brothers are MH susceptible by IVCT testing. During anaesthesia he developed 
tachycardia and increased in body temperature after isoflurane, thiopentone and 
fentanyl. The second proband of this family, IV. 1 was anaesthetised for a broken 
nose when she was 12 years old. During general anaesthesia using halothane and 
suxamethonium she developed masseter muscle spasm and raised CPK, 26 000 unit 
per litre and myoglobinurea. When she was old enough, her MHS status was 
established using in vitro contracture testing. Apparently the second proband is 
affected by disease gene through her father who is not a relative of this family.
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1:1
Not tested
- o
l:2
Not tested
O
11:1 
Not tested
£11:1 
SC > 2.0% 
SC 3m M 
DH > 2.0%
■O
II: 2 
Not tested
D ~
ll:3 
Not tested
;rs
ll:4 II.5 l!:6
SH 0.5% SH 4.0% Nottested 
SC 4mM SC 4mM
III.2 III3 III: 4
Nottested SH 4.0% SH 2.0% 
SC 8mM SC 8mM
*  III.5 III 6
SH 0.5% SH > 30% 
SC 2mM SC 8m M 
DH 30%
I
11:7
SH 1.0% 
SC 2mM 
DH > 2%
ll:8 
Not tested SH
SC
DH
III.7 
SH 0 50% 
SC 1.5mM 
DH 0.50%
n
III8 III9
SH 0.5% SH 2.0%
SC 0.5mM SC 3mM
DH 0 5% DH > 2.0%
Fig. 3.8. Pedigree of family LMH18 showing results of IVCT diagnosis. The 
proband III.5 was recognised during anaesthesia for squint because she developed 
rigidity with suxamethonium. After administration of drug her temperature 
increased from 37 to 38.6°C in 20 minutes and CK increased to 8 700 units post 
operatively. The proband’s mother is M H ^h) with a strong response to halothane in 
IVCT but not to caffeine. Thirteen members of this family were screened by IVCT 
with 7MHS, 2 MHE(h), 4MHN individuals and five people not tested.
I
II. 9 
0.5% 
1mM 
0.5%
111:10 
SH 2.0% 
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DH 1.0%
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Fig 3.9 Pedigree of family AN2.
The IVCT for this family has been carried out according to the European protocol at 
Antwerp, Belgium. This family is a three-generation family with 15 individuals of 
whom fourteen have been tested by the IVCT. This family as LMH03 has been 
excluded from 19q, 7q, 3q, lq candidate gene regions and investigated using markers 
from chromosome 2p.
For this study families were selected for linkage analysis on the basis of 
size and clear MHS/MHN results and for mutation analysis all families were 
investigated. In figures 3.1 to 3.9 the pedigrees of MH susceptible families 
investigated for linkage are shown with their IVCT results for all individuals 
tested.
3.1.1 CCD families
Details of seven MH/CCD families using IVCT are described below (table 
3.1). Three pedigrees of CCD families are shown in Figures of 3.10 and 3.11
3.1.2 Families and samples used in mutation screening
242 families have been investigated for three RYR1 mutations, C487T,
G 1021A and C1840T. The IVCT results of these families are listed in table 3.2.
3.2 Methods
3.2.1 Preparation o f DNA samples
Genomic DNA was extracted from whole blood samples according to 
salting out procedures for fresh blood and a phenol-chloroform extraction method 
for frozen blood samples.
3.2.1 A Blood samples
Blood samples were collected by venepuncture. 10ml of blood was 
collected into 15ml polypropylene tubes contained anticoagulant. DNAs were 
either extracted within 12 hours of blood collection or samples were frozen at 
-80°C.
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CCD
Fig 3.10 Pedigree of CCD family used in m utation screening. This family is very 
small and has not been entered in linkage analysis. The numbered individuals have 
been tested using IVCT and vice versa. The individuals with black and blank 
symbols are MHS and MHN respectively. The individuals with no number have not 
been tested.
92
jA 2586 2937
CCD
Fig 3.11 Two samples of CCD families. These families are entered in mutation 
analysis for C487T and G 1021A mutations. The results show no mutation in these 
two families. The individuals with black and blank symbols are MHS and MHN 
respectively.
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Table 3.1. The IVCT results of seven CCD families used in mutation 
screening. S and D, symbols are used for static and dynamic halothane 
respectively. The quantities of halothane and caffeine are the amount required to 
induce 0.2g of muscle tension.
Family Number Halothane Caffeine Status Relation­
ship
Bar-Lan 2379 0.5% (S)/0.5% (D) ImM MH+ve/CCD Proband
2499 >2%(S) />2%(D) 32mM MH-ve Sister
Gib-Mir 529 2%(S) <8mM MH+ve/CCD Proband
614 4%(S) 16mM MH-ve/CCD Son
1976 >2%(S) / >2%(D) >4mM MH-ve Daughter
Jon-Nor 3076 2%(S) 2mM MHS/CCD Proband
Mas-Boo 2954 >2%(S) / >2%(D) 4mM MHN/CCD Proband
Pay-Nor 2176 0.5% (S)/0.5% (D) 0.5Mm MHS/CCD Proband
2449 >2%(S) / >2%(D) 4mM MHN Sister
2451 0.5% (S)/0.5% (D) ImM MHS/CCD Father
Sel-Dar 2586 0.5% (S)/0.5% (D) 0.5mM MHS/CCD Proband
2936 0.5% (S)/ 1%(D) 1.5mM MHS/CCD? Father
2937 0.5%(S) / 0.5%(D) 0.5mM MHS/CCD? Sister
Smi-Tam 742 2% 4mM MHE/CCD? Relative
1776 0.5% (S)/0.5% (D) 4mM MHS/CCD Proband
1843 0.5%(S) / 0.5%(D) 2mM MHS Daughter
1844 >2%(S) / >2%(D) 32mM MHN Daughter
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Table 3.2. IVCT results of individuals used in mutation screening.
The star (*) shows heterozygoute individuals for G1021 to A mutation.
Pedigree
identification
Identification 
number of 
individuals
Threshold contraction 
(0 .2b ) 
halothane caffeine 
% mlYT
MH
status
AIN-BON 2136 1 0.5 MHS
AKH-OXF 3174 >2 >2 MHN
ALC-BUR 3161 >2 4 MHN
3162 >2 3 MHN
ALL-STA 2796 >2 4 MHN
AMO-SUR 2723 1 1.5 MHS
BAM-MIL 2654 >2 4 MHN
BAN-LIN 3150 2 2 MHS
BAR-BAR 1567 1 1.5 MHS
1606 >2 >4 MHN
1633 0.5 2 MHS
1751 0.5 2 MHS
3159 1 1.5 MHS
BAR-LAN 2379 0.5 1 MHS
2499 >2 32 MHN
BAW-SON 2658 >2 3 MHS
BEA-DOR 2866 >2 4 MHN
BEA-EXE 1502 1 3 MHE
1533 >2 >4 MHN
BEA-WIL 2646 >2 4 MHN
BIR-MID 1569 2.0 3 MHE
1614 >2 32 MHN
2338 >2 3 MHN
BLA-AEV 2698 1 1.5 MHS
BLA-ARM 2748 0.5 2 MHS
3033 1 2 MHS
3170 2 3 MHE(h)
BLA-DER 2631 1 1.5 MHS
BLA-DEV 2801 >2 4 MHN
2811 >2 3 MHN
BLA-DON 2781 >2 4 MHN
BLE-MID 2142 >2 4 MHN
continued
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Table 3.2 continued
BOO-SUN 2694 1 1.5 MHS
BOU-BIR 2686 >2 32 MHN
BOW-CLN 2975 2 2 MHS
BOW-OWL 3192 1 2 MHS
BRA-TIN 2789 >2 3 MHN
BRA-DER 2831 >2 4 MHN
BRE-NDR 2692 >2 4 MHN
BRI-BAN 2684 >2 4 MHN
BRO-DER 2722 >2 4 MHN
3038 1 2 MHS
BRO-GLA 2687 >2 3 MHN
BRO-MID 2805 >2 4 MHN
BRO-NOR 2771 >2 3 MHN
BUL-LON 2855 >2 4 MHN
2794 >2 4 MHN
BUR-BUG 2749 >2 32 MHN
BRO-PON 3194 >2 32 MHN
BUR-LYN 2778 >2 32 MHN
BUT-WAR 3090 2 2 MHS
CAN-CHI 3156 1 2 MHS
CAR-LLA 2860 2 1.5 MHS
3075 1 2 MHS
CAT-TEN 3094 1 1.5 MHS
CHE-LON 2754 >2 32 MHN
CLA-PAI 2264 2 1 MHS
COL-IOW 2262 >2 32 MHN
COU-LIN 2758 >2 32 MHN
CRA-SKE 3173 >2 32 MHN
CRE-BUC 2850 >2 32 MHN
CRO-HCD 2714 >2 4 MHN
CUM-ABE 2879 2 2 MHS *
DAV-NOT 2851 >2 4 MHN
DAV-SWA 2753 >2 4 MHN
DIC-EDI 2810 2 2 MHS
2847 >2 32 MHN
DON-CRO 2200 >2 4 MHN
DOR-SHE 2929 >2 32 MHN
continued....
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Table 3.2 continued
ECT-PRE 2713 >2 4 MHN
ELL-PLY 2691 1 2 MHS
FAI-BOS 2247 >2 3 MHN
FEA-BUC 2804 2 2 MHS
FID-LEE 2924 0.5 0.5 MHS
FIS-PRE 2650 0.5 1 MHS
2705 1 1 MHS
2706 >2 4 MHN
2728 1 1.5 MHS
2894 2 1.5 MHS
3191 >2 4 MHN
FOR-ESS 2148 2 2 MHS
2149 >2 3 MHN
2884 0.5 0.5 MHS
FOX-BLA 713 0.5 2 MHS
1227 2 3 MHE
1298 2 2 MHS
2337 0.5 0.5 MHS
2685 >2 3 MHN
GAM -DON 2637 1 1.5 MHS
GAM -HAN 2701 0.5 1.5 MHS
2978 1 2 MHS
3099 0.5 1 MHS
GIB-HUD 529 2 -VE MHS
614 4 16 MHN
GIB-MIR 1976 >2 32 MHN
GIL-LEI 3068 1 2 MHS
GRA-IOW 2786 >2 4 MHN
GRA-STO 2680 >2 32 MHN
HAK-BLA 2842 >2 >3 MHN
HAL-CRO 2710 1 1.5 MHS
HAL-SUN 2667 2 2 MHS
3176 >2 4 MHN
HAM-LEE 2735 >2 4 MHN
HAN-DER 2699 >2 3 MHN
HAR-BRA 3177 >2 32 MHN
HAR-CAR 2841 >2 32 MHN
HAR-NOT 2769 >2 32 MHN
HAY-WIG 2761 >2 32 MHN
HEY-WIG 2800 >2 32 MHN
HIN-BUR 2651 2 2 MHS
continued....
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Table 3.2 continued
HIN-SOT 2832 0.5 1.5 MHS
HOP-DUN 2776 1 1.5 MHS
2861 2 32 MHN
HOW-SHR 2834 >2 4 MHN
HUN-LOW 3178 >2 >3 MHN
HYD-DUR 2822 1 1.5 MHS
INK-BRI 2147 1 1.5 MHS
2196 1 1.5 MHS
2251 >2 32 MHN
2627 >2 4 MHN
IRV-KIR 3163 >2 4 MHN
JAC-SOM 2157 0.5 1.5 MHS
JEF-BIR 742 2 4 MHS
JON-CAR 2632 >2 32 MHN
2633 >2 32 MHN
3139 2 2 MHS
JON-DOR 2835 >2 32 MHN
JON-GLA 2648 >2 32 MHN
2767 >2 4 MHN
JON-NOR 3076 2 2 MHS
JON-WIG 2137 >2 4 MHN
KEL-POR 2568 0.5 1 MHS *
2709 >2 3 MHN
KIN-BRI 2774 1 1.5 MHS
KIN-CDR 2682 >2 32 MHN
KYN-BAS 2673 0.5 1 MHS *
2729 2 2 MHS
2807 2 3 MHEh
2808 >2 32 MHN
2809 >2 4 MHN
2907
LAN-BIR 2561 0.5 1.5 MHS
LAN-SHE 2813 >2 32 MHN
LAT-COK 2688 >2 4 MHN
LEA-SUS 2134 0.5 0.5 MHS *
2236 MHS *
2235 1 1.5 MHS *
LEE-NOR 2144 1 3 MHEh
LEG-TOR 2732 >2 3 MHN
3083 1 2 MHS
3179 2 2 MHN
3181 >2 32 MHN
IEW-EAS 2693 >2 32 MHN
continued
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Table 3.2 continued
LEW-MIL 2840 >2 >2 MHN
LIN-PIN 2606 0.5 0.5 MHS
2629 0.5 0.5 MHS
2708 0.5 1 MHS
2900 0.5 1.5 MHS
LIN-SOT 2918 0.5 1.5 MHS
LIT-BAT 2675 >2 32 MHN
LOA-BRI 3188 1 2 MHS
LOO-HAL 2661 >2 4 MHN
LYN-LON 2736 2 1.5 MHS
MAC-GUI 2976 0.5 1.5 MHS
3160 >2 4 MHN
MAI-LON 2765 2 2 MHS
MAR-LLA 2133 >2 4 MHN
M AS-BOO 2954 >2 4 MHN
MCB-GLA 2166 0.5 1.5 MHS
3166 >2 2 MHS
MCL-SCO 2836 2 1.5 MHS
3167 >2 4 MHN
3169 1 2 MHS
MCM -ANT 2674 >2 3 MHN
2854 1 2 MHS
MCM-GLA 2168 1 1.5 MHS
MCM-UTT 2730 >2 4 MHN
MEA-LEE 3096 1 1.5 MHS
MIL-BOU 2268 >2 4 MHN
MIN-BIR 3091 1 2 MHS
MIT-DUR 2945 2 2 MHS
M OB-CAT 2138 2 32 MHEh
M UB-GLA 2669 1 0.5 MHS
MUL-GLA 2843 >2 32 MHN
2844 0.5 1 MHS
M UR-NEW 2161 0.5 1 MHS *
NAR-W AT 2712 1 1.5 MHS
3072 0.5 1.5 MHS
NAU-FIF 2552 0.5 0.5 MHS
2696 1 2 MHS
2697 >2 32 MHN
NEW-BRI 2657 >2 3 MHN
NEW-WAR 2136 >2 32 MHN
ODO-CHE 2659 >2 4 MHN
OHA-STO 2703 >2 4 MHN
continued,
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Table 3.2 continued
ORW-BLA 2830 >2 32 MHN
PAL-LEE 2638 >2 3 MHN
2750 >2 4 MHN
2784 >2 4 MHN
PAL-PET 2653 >2 4 MHN
PAR-BUE 2754 >2 32 MHN
PAR-ORE 2165 >2 32 MHN
PAT-LIN 2644 >2 32 MHN
PAY-NOR 2176 0.5 0.5 MHS
2449 >2 4 MHN
2451 0.5 1 MHS
PER-LEI 3057 0.5 1.5 MHS
PIN-LEE 2681 >2 3 MHN
PIN-NLE 2864 >2 4 MHN
POP-BAR 1437 >2 4 MHS
1826 2 3 MHEh
1852 1 2 MHS
1879 >2 >4 MHN
PRE-DUN 2770 >2 32 MHN
2791 >2 4 MHN
PRI-BAN 2825 >2 4 MHN
QUA-M AN 2949 >2 32 MHN
2950 1 2 MHS *
2988 >2 1.5 MHS *
RIC-DEW 2654 >2 4 MHN
RIC-MDI 3064 1 1.5 MHS
RIL-STO 2883 1 1.5 MHS
3016 1 2 MHS
ROB-BIR 900 >3 8 MHN
954 2 1.5 MHS
ROO-RED 2782 >2 4 MHN
ROW -HAN 2865 >2 32 MHN
3029 >2 4 MHN
ROW -MAN 2816 0.5 0.5 MHS
ROW-PON 2757 >2 32 MHN
ROW-STO 2162 1 2 MHS
2180 0.5 1 MHS
2536 0.5 1 MHS
3104 0.5 1.5 MHS
RUD-CAR 2550 0.5 1.5 MHS
RYA-LEE 2888 1 1.5 MHS
SAB-DON 2727 >2 4 MHN
continued,
1 0 0
Table 3.2 continued
SAW -GLA 2772 >2 32 MHN
SEL-DAR 2586 0.5 0.5 MHS
2936 0.5 1.5 MHS
2937 0.5 0.5 MHS
SHA-CAM 2780 >2 32 MHN
SHB-DON 2785 >2 32 MHN
SHO-MIR 2150 0.5 1 MHS
2641 >2 3 MHEh
2662 >2 3 MHN
SIM-MAC 2768 >2 3 MHN
SIM-SUS 3051 0.5 1 MHS
SLA-ROT 2733 >2 3 MHN
SMI-BOL 2649 >2 32 MHN
2790 >2 32 MHN
SMI-GLA 2756 0.5 0.5 MHS
2826 1 1 MHS
SMI-TAM 1776 0.5 2 MHS
1843 0.5 2 MHS
1844 >2 32 MHN
SPO-GRI 2799 >2 4 MHN
SPO-GRU 2140 >2 4 MHN
SQE-SHE 2652 >2 4 MHN
STA-BAT 3175 >2 32 MHN
STA-DER 2742 >2 3 MHN
STE-GEW 2634 1 2 MHS
2635 >2 3 MHN
2636 >2 4 MHN
STR-ESS 2556 0.5 0.5 MHS
STR-HAR 2738 2 2 MHS
SUS-CLE 2678 2 2 MHS
SUT-BAS 2766 >2 4 MHN
3143 1 2 MHS
3013 1 2 MHS
SUT-SAU 2664 1 1 MHS
TAY-LEI 2737 >2 >2 MHN
TER-LIN 2990 1 1 MHS
TEW-DON 2715 1 1.5 MHS
2824 2 3 MHEh
2891 1 2 MHS
2915 2 2 MHS
3077 1 2 MHS
THD-BRA 2679 >2 4 MHN
TIM-FYL 2852 >2 4 MHN
continued
Table 3.2 continued
1 0 1
TIM-ROT 2163 0.5 1.5 MHS
TIN-NEW 2630 >2 3 MHN
2642 >2 4 MHN
TOO-WOO 2145 >2 4 MHN
TOT-COR 2702 >2 32 MHN
UNS-HUD 2856 0.5 0.5 MHS
2858 >2 3 MHN
VER-SOM 2270 0.5 1.5 MHS
2704 >2 3 MHN
VET-POR 2716 >2 4 MHN
WAL-PRE 2153 0.5 1.5 MHS
2175 >2 32 MHN
W AR-LAN 2583 2 1.5 MHS
2731 1 2 MHS
2814 >2 >2 MHN
W AR-NOR 2504 2 2 MHS
W EA-HAR 2798 >2 32 MHN
WEB-WOB 2717 >2 3 MHN
WEB-WOK 2643 >2 4 MHN
WEL-BEV 2828 >2 32 MHN
WHI-AUS 3109 0.5 1 MHS
W HI-DUD 2655 2 2 MHS
WHI-HAR 2139 >2 32 MHN
W IL-BLA 2740 >2 32 MHN
WIL-GLA 2660 >2 32 MHN
2720 >2 4 MHN
WIL-HUN 2829 1 2 MHS
3164 1 2 MHS
WIL-WHI 2151 1 1 MHS
2739 1 2 MHS
W OO-BRA 2683 0.5 0.5 MHS
2792 0.5 0.5 MHS
2793 >2 32 MHN
2862 0.5 1.5 MHS
WRO-SEL 3102 0.5 1.5 MHS
1 0 2
3.2.1.2 DNA extraction from fresh blood
Fresh venous blood samples (10 ml) were collected in 15ml polypropylene 
heparinised or EDTA tubes. After spinning at 900g for 5 minutes, the buffy layer 
containing white cells was removed with a pipette and placed in a 30ml 
polypropylene tube containing 20ml lysis buffer (0.86% ammonium chloride) and 
incubated for 15 minutes at 37°C. After centrifugation at 900g for 15 min the 
pellet was washed twice with lysis buffer and re-suspended in 5 ml STE (lOOmM 
sodium chloride, 1M Tris-HCl pH 7.8 and 500mM EDTA) with 1% SDS and 50pl 
proteinase k (lOmg/ml, Boehringer Mannheim). The mixture was incubated 
overnight at 37°C. After incubation 2.5ml 7.5M ammonium acetate was added and 
the mixture placed on ice for 40 minutes. Samples were centrifuged for 30 minutes 
at 1300g and then the supernatant transferred to a fresh 15ml tube. Two volumes 
of cold ethanol (4°C) were added and mixed by inverting the tubes several times 
until the DNA precipitated. The precipitated DNA strands were hooked out using 
a bent Pasteur pipette, and placed in 1.5ml microcentrifuge tubes containing an 
appropriate volume, usually 100-500pl, of 1XTE (1M Tris-HCl pH 7.6, 500mM 
EDTA) depending on the yield of extracted DNA. Finally before using or storage 
of samples they were rotated at room temperature for at least 2 hours to dissolve 
the DNA.
3.2.1.3 DNA extraction from frozen blood
When the blood samples were more than 12 hours old or had been frozen 
the phenol-chloroform method was used. The phenol extraction removes the
proteins and RNA, the chloroform removes any traces of phenol which may inhibit 
later reactions, of course phenol can cause severe chemical burns on skin and will 
damage clothes. 10ml blood samples in either heparin or EDTA were mixed with 
10ml of lysis buffer (0.86% ammonium chloride) and incubated at 37°C for 30 
minutes. After spinning at 1300g for 30 minutes pellets were resuspended in 1% 
SDS and 50|il proteinase k (lOmg/ml) samples were incubated at 37°C overnight. 
An equal volume of equilibrated phenol was added to the DNA sample mixture (in 
30ml polypropylene tube) and after shaking well but gently and centrifuging 
(1300g) for 5 minutes the upper aqueous layer was removed to a 13ml 
polypropylene tube. This extraction step was repeated with phenol and then using 
chloroform instead of phenol. After the final chloroform extraction the upper layer 
was transferred to a 30ml tube and two volumes of ethanol were added and mixed 
by inverting the tubes several times until the DNA precipitated. The precipitated 
DNA strands were hooked out using a bent Pasteur pipette and placed in 1.5 ml 
microcentrifuge tubes containing usually 100|Ltl to 500[il of IX TE depending on 
the yield of extraction. Then before using or storage of samples they were rotated 
at room temperature for at least two hours to dissolve the DNA.
3.2.1.4 Quantitation o f  DNA
For quantitation of extracted DNAs and to confirm that the extraction has 
been successful, from both methods the DNA samples were run on 0.8% agarose 
gels.
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3.2.2 Gel electrophoresis
3.2.2.1 Agarose gel electrophoresis
Gels, dependent on the size of DNA samples, were prepared with different 
concentrations of agarose (Boehringer Mannheim GmbH) and electrophoresis was 
carried out as described in Sambrook et al (1989). For different percentage (n% = 
n gram agarose/100ml gel volume) of normal agarose gels, the appropriate weight 
agarose, with IX TBE (Tris base, boric acid, 500mM EDTA) were used. The 
mixture placed in a conical flask in a microwave oven and heated on full power for 
about 2 min until the agarose had completely dissolved then 5|il of lOmg/ml 
ethidium bromide was added. The mixture then was poured into trays with a well 
former in place and left to set. Gels were set in different sizes of trays (dependent 
on the size and number of samples, tray 10x8.5 cm or 15x20 and tanks 18.5x10 cm 
or 35x17 cm) and running of samples after mixing with loading buffer (0.5mM 
xylene cyanol, ImM bromophenol blue, 20% Ficoll 400) was performed in 
horizontal electrophoresis tanks (Bio-RAD mini sub, DNA cell). For gel running a 
Bio-RAD (model 250/2.5) power supply with appropriate voltage (depend to the 
size of DNA fragments between 70- lOOv) and time (50-80 min) was used. Then 
DNA bands were visualised in UV light and photographed with photographic 
equipment (UVP inc) using Upp-110HA (Sony) film.
3.2.2.2 Electrophoresis of extracted DNA
The extracted DNA samples were run on 0.8% agarose gel which was 
prepared (1XTBE, ethidium bromide (Sigma) 0.5pg/ml with care because of
mutagenicity), and after gel setting the samples (5pl) were run at 80 volts for 40-60 
minutes ( fig 3.12).
3.2.2.3 Acrylamide gels
A 19:1 mix of acrylamide : bisacrylamide was used (Fison) to make 100ml 
of 6% gel containing 1XTBE, 7M urea, (to keep the samples denatured), 1ml 10% 
freshly prepared ammonium persulphate (lg  / 10ml water) and 40pl TEMED 
(Sigma) and swirling gently to mix. Gels were prepared as described in Sambrook 
et al (1989) with some slight modifications. Glass plates (sho rt: 33x39 cm and 
long 33x42cm) were washed with soapy water, rinsed with distilled water, and then 
one plate siliconised on its inner surface with siliconising agent (Sigmacoat,
Sigma). This plate was then rinsed with 95% ethanol. Two 0.4mm spacers were 
placed along the long edges of one plate and the second plate placed on top and the 
plates sealed together with tape. The gel mixture was prepared and immediately 
using the barrel of a 60ml syringe was poured carefully into the gel mould (~
60ml). The flat edge of a sharkstooth comb (Gibco/BRL) was used to make a 
straight edge at the top of the gel and then butterfly clips applied around this area to 
ensure that the comb did not leak.
After gel polymerisation the comb was inverted to make the sample loading 
spaces. Then gel was placed in a sequencing gel rig (model S2, Gibco/BRL) and 
connected to a power supply (3000xi, Bio-RAD) and 1XTBE was used in both the 
upper and lower buffer chambers. The gel was pre-run before sample loading for 
30 min. at 60W until the gel reached approximately 50°C. Prior to loading the
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1 2 3 4 5 6 7 8
Fig 3.12 DNA extraction.
Some samples of extracted DNA are shown in lanes 1 to 7. Lane 8 shows a 123bp 
DNA ladder. The molecular weight of the genomic DNA samples can be greater than the 
last band(4200bp).
samples an equal volume of loading buffer was added to the PCR product and it 
was denatured for 3min at 94°C and then 2-5 |nl was loaded into each lane. The gel 
was run at a constant power of 60W for an appropriate time dependent upon the 
sample size. After running the gels were fixed in 10% methanol (for dehydration 
and to remove any unbound urea which could cause fuzzy bands) and transferred 
with care from the glass plate to a sheet of 3M chromatography paper (Whatman). 
The gel was covered with Saran wrap and placed into a gel dryer (model 58, Bio- 
RAD) under vacuum at 80°C for 30-60min before exposing the sensitive films 
(blue sensitive x-ray film GRI Ltd) for 2-72 hours depending upon the level of 
radioactive incorporation determined using a Geiger monitor). Finally after 
exposure the film processing was carried out using developer (Ilfospeed, Ilford) 
and fixer solutions (Hypam fixer, Ilford).
3.2.3 PCR methods
3.2.3.1 Labelled PCR
Amplification of all microsatellite repeats of chromosome 19 were carried 
out in a thermocycler (Perkin-Elmer Cetus & Biometra trio-thermoblock) in a total 
volume of 20 |il, reaction buffer, containing 1.5-2mM MgCl2 0.25 mM dNTPs 
(dCTP, dGTP, dTTP and dATP Promega / Pharmacia), 50ng genomic template 
DNA, l-2}iCi [a  -32 p]dATP (lOmCi \ ml (3000 Ci / mmol), Amersham Life 
Science ), 0.25U Taq DNA polymerase (5 Unit/ ljxl, Promega), 0.5mM each 
primer (Genetic Research) and l(il containing 50ng genomic DNA was added. The 
reactions were covered with a drop of light mineral oil (Sigma). The samples were
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denatured at 94°C for 5 minutes. Then amplification was carried out for 30 cycles 
at certain conditions (tables 3.3 to 3.7). After a final extension step at 5 min at 
72°C an equal volume of loading buffer (2X formamide loading buffer : 950|il 
deionised formamide, 200|J,1 5XTBE, 0.1 mg bromophenol blue and 0.1 mg xylene 
cyanol) was added. The samples might be stored frozen or heated to 95°C for 3min 
and then placed on ice. Alleles were separated using 3-5|ll each sample on 6% 
polyacrylamide gels as described in section 3.2.2.3. This used method of gel 
running was the same for all microsatellites except WUT1.9 which was amplified 
non-radioactively and resolved on low melting agarose gels (2% Metaphor agarose 
or 2.5% Nusieve in 1XTBE) instead of polyacrylamide gels.
3 .23 .2  PCR for mutation detection
The PCR condition for amplification of candidate region in mutation 
screening using mentioned primers (table 3.8) were carried out in 25|ll volumes 
contain lOmM Tris-HCl, 1.5mM MgCh, 200fiM dNTP, 0.5|iM each primer, 50- 
lOOng of genomic DNA, 0.25-0.5 U Taq polymerase (Promega). Then the 
reactions were covered with a drop of mineral oil. The reactions were processed 5 
minutes for initial denaturation at 94°C and 30 cycles (94°C, 1 min, 58°C 1 min, 
and 72°C 1 min). The products had a final extension stage at 72°C for 10 minutes.
3.3 Primers
Primers were obtained from different suppliers (Pharmacia and Oswel) and 
used for two purposes, microsatellite amplification for linkage analysis and
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amplification of RYRI gene regions for mutation screening. Some primers for 
amplification of chromosome 19q, 7q, 3q and lq regions in linkage analysis are 
intragenic and the others are intergenic. The second group of primers are 
intragenic sequences used for mutation detection. These mutations are C487T,
G 1021A and C1840T. All primer sequences are shown in tables and are written in 
the 5' to 3' direction and primers for different chromosomes are described 
separately. These primers with sequences, location, size and PCR conditions are 
summarised in tables and figs in sections 3.4.1 and 3.5.1 for linkage analysis and 
mutation detection respectively.
3.4 Linkage analysis
3.4.1 Primers used fo r linkage analysis
3.4.1.1 Primers fo r  linkage analysis of chromosome 19q
Seven pairs of primers (forward and reverse primers) were used to amplify 
D19S49, D19S191, D19S220, WUT1.9, RYRI, D19S47 and D19S178 for 
chromosome 19q linkage analysis. Figure 3.13 shows the location of these markers 
on chromosome 19q. This figure is adapted from Ashworth et al (1995) Levitte et 
al (1995), Weber et al (1993), Weissenbach et al (1992), Matise et al (1994). 
Details of these primers are listed in table 3.3. Three samples of chromosome 19q 
markers, RYRI, D19S178  and WUT1.9 are shown in figures 3.14, 3.15 and 3.16.
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1 1 0
19p telomere 
13.3
13.2
13.1
12
11
11
12
13.1
13.2
13.3
13.4 
19q telomere
I
I
14
D19S179
D19S49
—  GPI
2 - 2.2
D19S191 -  D19S220 —  D19S190 
-RYR1 —  WUT1.9
4.6-8
D19S47
D19S178 
LIPE*
Fig 3.13 Chromosome 19q microsatellites used in linkage analysis.
The localisation of the eight markers used and their genetic distances are illustrated 
in this figure. The GPI and LIPE genes were not entered in linkage analysis but are 
illustrated because these loci have been related to malignant hyperthermia 
susceptibility.
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Lanes
Fig 3.14 Autoradiograph of allele segregation using the chromosome 19q 
RYRI  microsatellite marker. Two alleles, 1 and 2, are observed. These alleles 
are shown in lanes 1 to 8. Lanes 1, 3, 7 and 8 show allele 2, lanes 2, 4 and 5 
show two alleles and lane 6 is a control and shows no DNA.
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1 -4
2 
3
4 —>
5—>
—
Fig 3.15 Autoradiograph of allele segregation of the chromosome 19q 
marker, D19S178. Five alleles of this marker are observed in lanes 1 to 9. Lane 
1 contains two bands, 1 and 4, lane 2 two bands, 1 and 5, lane 3 two bands, 2 and
3, lanes 4 and 5 contain bands 4 and 5, lane 6 shows only band 3 and lanes 7, 8 
and 9 contain the same bands, 4 and 5.
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Lanes 1 2  3 4 5  6 7 8  9 10
Fig 3.16 Autoradiograph of chromosome 19q marker, WUT1.9.
Four alleles of this marker are observed in lanes 1 to 10. Lanes 2, 5 and 6 are 
homozygote for allele 2 and lanes 3, 9 and 10 show two alleles, 1 and 3. Lane 1 
shows alleles 2 and 3 but lane 4 shows alleles 1 and 2. Lane 7 shows no DNA.
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3.4.1.2 Primers fo r  chromosomes 7q, 3q, 2p and lq
These primers with details and PCR conditions are described in tables 3.4 
(for chromosome 7q), 3.5 (for chromosome 3q), 3.6 (for chromosome lq) and 3.7 
for chromosome 2p respectively. In addition these loci are shown on fig 3.17 for 
chromosome 7q (Matise et al 1994; lies et al 1994; Gyapay et al 1994; Dib et al 
1996). One sample of allele segregation for chromosome 7q markers, D7S849 is 
shown in Figure 3.18.
Markers for chromosome 3q are illustrated in fig 3.19 (Matise et al 1994; 
O’Connell et al 1994; Gyapay et al 1994; Sudbrak et al 1995; Dib et al 1996) and 
one sample of allele segregation for D3S1302 marker is represented in Figure 3.20.
Chromosome lq markers (Gyapay et al 1994; Dib et al 1996) and one 
sample of allele segregation for D1S252 marker are shown in figs 3.21 and 3.22 
respectively.
Primers and PCR conditions for chromosome 2p and also one sample of 
allele segregation for D2S139 marker are represented in table 3.7 and fig 3.23 
respectively.
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Fig 3.17 Chromosome 7q markers which were used in haplotype segregation 
and linkage analysis.
* : Indicates the markers used by lies et al (1994).
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Lanes
Fig 3.18 Autoradiograph of allele segregation of chromosome 7q marker, D7S849.
Four alleles for this marker are observed which are shown in lanes 1 to 3. Lane 1 shows 
bands 2 and 4 and lane 2 shows bands 1 and 3. Lane 3 is homozygous for band 3.
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Fig 3.19 Chromosome 3q markers which were used in linkage analysis.
* : Indicates markers used by Sudbrak et al (1995) from the region 3ql3 in mapping 
a further malignant hyperthermia susceptibility locus.
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Fig 3.20 Autoradiograph of chromosome 3q marker, D3S1302.
Four alleles are shown in lanes 1 to 8. Lanes 1, 3 and 6 show bands 3 and 4 but 
bands 2 and 4 are observed in lanes 2, 5 and 8. Lane 7 contains two bands, 1 and
4.
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Fig 3.21 Chromosome lq  markers used in haplotype segregation and linkage 
analysis.
The REN  gene encodes the ai-subunit of the calcium channel dihydropyridine 
receptor. It is proposed as a candidate gene in malignant hyperthermia susceptibility. 
The D1S249  marker is close to region lq 3 1 where the REN gene is located.
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Fig 3.22 Autoradiograph of allele segregation of the chromosome 
lq  marker, D1S252.
Five alleles of this marker are shown in lanes I to 7. Lane 6 is control 
with no DNA. The alleles are numbered at the left hand side of the 
photograph.
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Fig 3.23 Autoradiograph of chromosome 2p allele segregation.
The D2S139 marker shows four alleles which are observed in different lanes. Lanes 6 
and 7 have no DNA but different alleles are observed in lanes 1 to 10.
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3.5 Mutation screening in RYR1 gene
Three mutations, C487T, G 1021A and C1840T were investigated using 
genomic DNA samples from MHS, MHE and MHN individuals. Screening was 
carried out using PCR amplification and restriction enzyme digestion. The 
conditions and primers used are described in table 3.8.
3.5.1 Primers fo r mutation screening
Details of primers used for amplifying genomic DNA in the region of three 
RYR1 gene mutations investigated in this study are shown in table 3.8.
3.5.2. T substitution at C487
This survey was carried out by amplification of the 76 base pair fragment 
which spans the region of the C487T mutation (table 3.8) (Quane et al 1993). By 
restriction analysis due to base substitution (mutant sequence) the specific site for 
the 5.stUI restriction enzyme (Bio-lab) is absent. The normal specific site for 
enzyme action is :
I
5 ' .... CGCG.....
3 '.... GCGC.....
t
The C487 to T mutation (CGCG—>CGTG) deletes a BsrtJI restriction site 
and so in mutant samples there is no cleavage with this enzyme. Normal 
individuals yield two bands at 44 and 32bp. Mutation carriers yield three bands, 
two at 44 and 32bp from their normal RYR] allele and a 76bp fragment
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corresponding to the uncleaved PCR product. 15j_ll of the 76bp PCR product was 
digested using 2 units Zfa/UI (New England, Bio-Labs) in a total volume of 20)il 
using the IX manufacture’s buffer (New England, Bio-Labs). Digests were 
performed at 60°C for 2 hours. 10-15pl samples of digestion products were mixed 
with loading buffer (0.5mM xylene cyanol, ImM bromophenol blue, 20% Ficoll 
400) and resolved on 4% agarose gels (3% low melting high resolution agarose and 
1 % normal agarose) at 70 volts for 50-60 minutes. DNA was stained with 
ethidium bromide and viewed with ultraviolet light and photographed. An 
example of a gel for typing the C487T mutation is illustrated in fig 3.24.
3.5.3 G1021 to A
At nucleotide 1021 the normal G is converted to an A jn  mutated samples. 
This mutation does not change any known restriction sites Then the diagnosis of 
heterozygous individuals was possible using single-stranded conformation 
polymorphism (SSCP) (Quane et al 1994). Therefore a primer (Adeokun et al 
submitted 1997) was designed to create a restriction site. This forward primer 
includes a base substitution C for A at position 1019. This change creates a 
specific site (CCGG) for Msp I (restriction enzyme) digestion in the normal PCR 
products (1021G) which is absent in products generated from the mutant 1021A 
(CCAG) DNA.
1001 GCCCCCCTGAGATCAAGTACGG \ CAGCATGTGGCCTCAGGACTG 1061
5 ' GCCCCCCTGAGATCAAGTCC (engineered primer) GTCGTACACCGGAGTCCTGAC
130
L anes 1 2  3 4  5 6 7 8 9 10 11 12 13 14 15
Fig 3.24 C487T mutation screening.
The 76 nucleotide PCR product yields a 44 and a 33 nucleotide fragments from 
C487 (normal) chromosomes after Bst UI enzyme digestion; the 76 nucleotide 
fragment is not digested from 487T chromosomes. This mutation was not 
observed in UK MH families. Lanes 5 and 9 ave no DNA and lane 14 shows a
1 Obp ladder.
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At position 1019 in engineered primer A at normal sequence is changed to 
C and this substitution creates CCGG sequence which is specific site for Msp I 
restriction enzyme.
Restriction site
I
CCGG
GGCC
t
PCR was performed as table 3.8. PCR products were digested by using 
Msp I restriction endonuclease enzyme(Bio-Lab). 2-3 units of enzyme in IX buffer
2 (50mM NaCl, lOmM Tris-HCl, lOmM MgCl2, ImM DTT and pH 7.9)(New 
England, Bio-Labs) was added to 1 5(ll1 PCR product and incubated at 37°C for 2 
hours. The 62bp products were cleaved in 21 bp and 41 bp fragments in normal 
G1021 alleles but three bands, 21 bp, 41 bp and 62bp in mutation carriers of 1021A 
alleles. 10-15(Lil of digested products were analysed on 4% agarose gel (3%
Nusieve and 1% normal agarose) at 70 volts for 50-60 min. DNA was stained with 
the ethidium bromide and viewed with ultraviolet light and photographed. An 
example of a gel for typing the G 1021A mutation is illustrated in fig 3.25.
3.5.4 Pig mutation (substitution o f C1840 to T)
Genomic DNA was amplified using primers (Genosys) which hybridise at 
nucleotides 1808 and 1881 (table 3.8) and generate a fragment of 74bp. The 
C1840T mutation deletes a Rsa\ restriction site (GTAC—>GTAT) and so in mutant
samples there is no cleavage with this enzyme. The specific restriction site for 
Rsa 1 is :
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Lanes 1 2  3 4 5 6 7  8 9 10 11 12
Fig 3.25 G1021A mutation screening.
The 62 nucleotide PCR product yields a 43 nucleotide fragment from G1021 
chromosomes after Mspl digestion; the 62 nucleotide fragment is not digested 
from 1021A chromosomes. Lanes 3, 9 and 11 are heterozygous for 1021 mutation 
(G base substituted by A), Lane 6 has no DNA but the others lanes show normal 
sequence for the 1021 mutation
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5 GTAC 3
3 CATG 5
T
Due to the lack of a restriction site in mutant chromosomes, MHS samples 
generate three bands, 74, 41 and 33bp but two bands, 41 and 33 from normal DNA. 
10|il of the 74bp PCR product was digested using 1 (ill of /foal (Promega) IX 
buffer. Digests were performed at 37°C for two hours. The 10-15|ll of digested 
products were mixed with loading buffer (Xylene cyanol; bromophenol blue, Ficoll 
400) and run on 4% agarose, a mix of 3% Nusieve (Flowgen) and 1 % normal 
agarose (Boehringer Mannheim) at 70 volts for 50-60 minutes. DNA bands were 
stained with ethidium bromide and viewed with ultraviolet light and photographed. 
An example of a gel for typing the C1840T mutation is illustrated in fig 3.26.
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Fig 3.26 C1840T mutation screening.
The 74 nucleotide PCR product yields 41 and 33 nucleotide fragments from 
C l840 chromosomes with Rsal digestion. The 74 nucleotide fragment is not 
digested from 1840T chromosomes. This mutation was not observed in screened 
samples from UK MH families. Lanes 6, 11 and 12 show no DNA. The marker 
used is lOObp ladder.
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Chapter four
Results and Discussion of Linkage Analysis
Because of heterogeneity individual families are considered independently 
as chromosome 19q linked and non 19q linked.
The probable MHS gene candidate RYR] and two distal flanking markers 
(.DI9S47  and D19S178) and four proximal flanking markers ( D19S49, D19S191, 
D19S220  and WUT1.9) were typed in four families.
For chromosome 19q six families, LMH07, LMH12, LMH15, LMH16, 
LMH17 and LMH18, which had been investigated by IVCT were studied. Details 
of typing these seven microsatellites (for families LMH07 and LMH12 the 
microsatellites were different as the major part of marker typing for these two 
families had been previously carried out by Dr J. Curran) and their haplotypes for 
chromosome 19q 13.1 are summarised for each of these pedigrees in figures 4.1 to 
4.6. However, families used in the project will be discussed in the following 
results. The investigated families are classified as results achieved using markers 
from chromosomes 19q, 7q, 3q, lq and 2p.
4.1 Linkage analysis of MHS with markers from chromosome 19q
Family LMH07 composed three MHS, two MHE, two MHN and one 
person who is not tested using IVCT. Eight individuals have been typed for six 
chromosome 19q linkage markers (D19S179, DI9S191, WUT1.9, RYR1, D19S190
and D19S47) in family LMH07. Results of marker segregation are shown in fig
4.1 The high risk haplotype 2-2-3-2-2 is shared between MHS and MHE 
individuals and one MHN, III. 1. This individual, excluding the most proximal 
marker D19SI79, has inherited the high risk haplotype despite that she showed no 
contracture responses using 3% halothane and 2mM caffeine. In addition the 
proband III.2 is a recombinant fo rD19S47 the most distal marker used. Despite 
the similarity in haplotypes in MHS and MHE individuals the lod scores for this 
family mostly are low for 19q region markers except for D19S179 which is +0.6 at 
0 = 0.00. Lod score results for this pedigree are listed in table 4 1.
Family LMH07 was first surveyed for chromosome 19q markers (some 
parts of this practical work for chromosome 19q markers for this family was 
carried out by Dr J. Curran) and excluded as a chromosome 19-linked family.
Family LM H 12 has been investigated for linkage between MH 
susceptibility and markers (DI9S191, WUT1.9, RYR1 and D19S47) from 
chromosome 19q 13.1. The pedigree of family LMH 12 showing segregation of 
these markers is illustrated in fig 4.2. The proband, III.3, had positive contracture 
to halothane but he is negative for caffeine contracture in IVCT and so is classified 
as MHE(h). In addition IVCT indicated MHE<h) status for his sister, III. 1 and his 
uncle, II.3. His father II. 1 and another uncle II.5 are MHS. The high risk 
haplotype, 1 -3-2-6 is observed in two MHS and one MHN, III.2 individuals but it 
is not shared with MHE(h> individuals and the reminding MHN individuals.
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n -
1:1
Not tested
o -------------- --------------1
11:1
IVCT
11:2
IVCT
D19S179 2 2 1 2
D19S191 3 4 1 2
WUT1.9 2 2 2 3
RYR1 1 2 2 2
D19S190 1 2 2 2
D19S47 4 1 4 3
c
II :1
i
*  lll:2
IVCT IVCT
D19S179 2 1 2 2
D19S191 4 2 4 2
WUT1.9 2 3 2 3
RYR1 2 2 2 2
D19S190 2 2 2 2
D19S47 1 3 1 4
- o
l:2
Not tested
i
II :3 
MHE 
2 3
2
3
2
2
3
II :4 
Not tested 
2 2
4
1
2
2
3
£
III.3 
MHE 
2 2
III.4 
MHE 
2 2
2
3
2
2
3
4
2
2
2
2
Fig 4.1 Marker segregation of chromosome 19q in family LMH07.
The markers used are D19S179, D19S191, WUT1.9, RYR1, D 19S190 and D19S47  
respectively. Although the III. 1 is MHN, she received high risk haplotype 2-2-3-2-2-
3 except with recombination for D19S179. The high risk haplotype is shared 
between MHS and MHE individuals. The individuals III.3 and III.4 although are 
MHE and MHS respectively but they inherited the same haplotype from their father. 
Maybe for these persons it can be concluded that the maternal genotype has additive 
effects on susceptibility.
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LOD SCORES
Recombination 
fraction—» 
Marker s i
0.00 0.05 0.1 0.15 0.2 0.25 0.3 0.5
D19179 0.60 0.50 0.42 0.33 0.25 0.17 0.11 0.00
D19S191 -0.35 -0.23 -0.16 -0.11 -0.08 -0.06 0.04 0.00
WUT1.9 -0.33 -0.20 -0.12 -0.07 -0.04 -0.02 -0.01 0.00
RYR] 0.10 0.07 0.05 0.30 0.01 0.00 0.00 0.00
D19S190 0.10 0.09 0.07 0.05 0.04 0.03 0.02 0.00
DJ9S47 -0.32 -0.18 -0.09 -0.04 -0.01 -0.00 0.00 0.00
Table 4.1 The two point lod scores results of linkage analysis between 
chromosome 19q markers and malignant hyperthermia susceptibility in family 
LMH07
III.2 is a definite MHN with no positive response to halothane and caffeine 
using high concentrations. In LMH12 the lod score for all markers are -0.00 at0 = 
0.00. These results are shown in table 4.2. Based on this results and lod score 
calculation the suggestion for lack of linkage to chromosome 19q 13.1 and 
exclusion of it is not impossible.
In family LM H 15 twelve persons were tested for marker segregation 
analysis. The proband of this family IV.2 is MHE(h) but his haplotype is similar to 
the other MHS individuals III.2, III.3 and IV. 1 (fig 4.3). Where data exist the high 
risk haplotype (4-5-2-3-2-3-5) is common between all four MHS individuals and it 
is not transmitted to the three MHN offspring of III.3 and the MHN daughter of
III.2. The two point lod score results for this family are mostly positive at0 = 0.00 
except for D19S178 although they are not very significant. These results are 
shown in table 4.3. Apparently, despite the incomplete results the co-segregation 
of chromosome 19q haplotypes associated with the MH susceptibility looks almost 
significant and acceptable.
In family LMH 15 as shown in fig 4.3 the marker haplotype, 4-5-2-3-2-3-3 
shared between MHS and MHE individuals shows no recombination. These 
linkage data also suggest that the individual II.3 who is not tested by IVCT may be 
MHS or perhaps MHE because she carries the high risk haplotype which appears to 
co-segregate with MH susceptibility. Therefore it may be suggested that the high 
risk haplotype is transferred from II.3 to subsequent generations.
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Fig 4.2 Marker segregation of chromosome 19q in family LMH12.
The used markers are D19S191, WUT1.9, RYR1, and D19S47  respectively. The 
proband of this family, III.3, is MHE and he presented weak responses to halothane 
(at 2%). Apparently the haplotype 1-3-2-6 is shared between MHS individuals and 
MHN III.2 but is not observed in MHE persons. Perhaps it is possible to conclude 
that the MH gene in this family is not linked to chromosome 19q markers.
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LOD SCORES
Recombination 
fraction—> 
Markers i
0.0 0.05 0.10 0.15 0.20 0.25 0.30 0.5
D19S191 -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 0.00 0.00
WUT1.9 -0.00 -0.00 0.00 -0.00 0.00 0.00 0.00 0.00
RYR1 -0.00 -0.00 -0.01 -0.00 -0.00 -0.00 -0.00 0.00
D19S47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Table 4.2 The lod scores of family LM H12 resulted from linkage analysis of 
chromosome 19q markers and malignant hyperthermia susceptibility.
Based on the lack of high risk haplotype in MHN individuals it may be 
concluded that in this family the MH gene is linked to chromosome 19q despite the 
low two point lod scores which are presented in table 4.3. The low lod scores 
result in part from the MHE status of individual IV.2, who despite the good 
contracture on expose to halothane (1% halothane for static and dynamic tests, fig 
3.5) and inheritance of high risk haplotype is entered in analysis as unknown status 
(50% chance for being susceptible compared to 98% for MHS individuals). But if 
we assume the IV.2 individual is MHS the lod scores will significantly increase as 
shown in table 4.3a. In addition to the incomplete haplotypes and the 
homozygosity of some markers, D19S19J and D19S220 also affect informativeness 
and reduce the lod scores.
The LM H 16 family (fig 4.4) as well as family LMH 15 has a shared 
haplotype and a clear co-segregation of the 19q3.1 haplotype with MHS 
susceptibility, 1-6-5-1-2-4-4. This high risk haplotype is observed in MHE, (II.4 
and II.6) and MHS individuals. Despite the good and common high risk haplotype 
shared in MHS and MHE(h) individuals one recombination is observed in III.2, who 
has no positive contracture at 2% halothane and 4mM caffeine concentrations.
This high risk haplotype with one recombination for D19S178 marker is shown in
III.2. She has two MHE(h) sisters and her mother is affected (MHS). It seems 
unlikely that this is due to an error in IVCT typing because III.2 showed no positive 
contracture at more than 2% halothane and 4mM caffeine whereas her MHS 
mother II.2 has good contracture in 1% static halothane and 0.5% dynamic 
halothane as well as in 2mM caffeine.
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Fig 4.3 Marker segregation of chromosome 19q in family LMH15.
The markers used are £>79549, D19S191, D19S220, WUT1.9, RYRI, D19S47  and 
D19S178 respectively. Apparently the high risk haplotype for this family is 4-5-2-3- 
2-3-3 which is common (although not completely) between MHS and MHE 
individuals. This haplotype is not observed in MHN individuals. Individual II.3 
who is not tested by IVCT possibly is not MHN as she inherited the haplotype which 
co-segregates with susceptibility to malignant hyperthermia.
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LOD SCORES
Recombination 
fraction—> 
Markers^
0.00 0.05 0.10 0.15 0.2 0.25 0.3 0.5
D19S49 0.87 0.74 0.60 0.47 0.36 0.25 0.16 0.00
D19S191 0.05 0.04 0.03 0.02 0.01 0.01 0.00 0.00
D19S220 0.12 0.10 0.09 0.07 0.05 0.04 0.03 0.00
WUT1.9 0.26 0.22 0.17 0.13 0.09 0.06 0.04 0.00
RYRI -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D19S47 0.73 0.61 0.49 0.38 0.28 0.20 0.12 0.00
D 19178 -0.11 -0.03 0.00 0.02 0.03 0.03 0.02 0.00
Table 4.3 The results of two point linkage analysis between MH and markers on 
chromosome 19q in family LMH15. As shown in table despite the segregation of 
high risk haplotype only two markers D19S49 and D19S47  have high lod scores. 
Although the lod scores are not very significant there is no reason for excluding of 
this family from chromosome 19q.
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LOD SCORES
Recombination 
fraction—> 
Markers^
0.00 0.05 0.10 0.5
D19S49 1.62 1.44 1.26 0.00
DJ9S191 0.14 0.11 0.09 0.00
D19S220 0.31 0.27 0.23 0.00
WUT1.9 0.56 0.48 0.40 0.00
RYR] -0.02 -0.01 -0.01 0.00
D19S47 1.17 1.02 0.88 0.00
D 19178 -0.52 -0.12 0.01 0.00
Table 4.3a The results of two point linkage analysis between MH susceptibility 
and chromosome 19q markers in family LMH15. As shown in table if assume the 
IV.3 is MHS the lod scores will increase significantly.
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Furthermore, in this family the MHE(h) individuals, II.4 and II.6, have MHS 
progeny III-4, III-5 (proband) who show good contracture to halothane and 
caffeine. Linkage analysis for LMH 16 show low lod scores (two point) for 
chromosome 19q markers and are mostly negative except for D19S178  for which 
the lod score is +0.92 at 0 = 0.00 (two point lod scores at table 4.4).
The D19S178 marker is reported to be close to the LIPE gene which is a 
candidate in malignant hyperthermia susceptibility (Levitt et al 1995). Support for 
a close relation between MH locus and D19S178 is observed in LMH 16. For the 
MHN individual III.2 carrying the high risk haplotypes a few alternative 
explanations will be considered. The lack of penetrance due to modifying genes, 
misclassification and/or mislabelling are the simplest suggestions for this apparent 
recombinant. RYR I gene mutation analysis can be useful for this individual since 
if these mutations are observed in LMH 16 family. The low lod scores, for two 
point analysis for this family can be due to allele homozygosity and lack of fully 
informative meioses and MHE(h) individuals otherwise when the MHE individual 
supposed to be MHS the lod scores are increased (table 4.4a).
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Fig 4.4 M arker segregation of chromosome 19q in family LM H 16.
The markers used are D19S49, D19S191, D19S220, WUT1.9, RYRI, DJ9S47  and 
D19S178  respectively. The high risk haplotype 1-6-5-1-2-4-4 is shared between 
MHS and MHE individuals with one recombination for individual III.2 who is 
MHN. This person has not shown any contracture using high amounts of halothane 
and caffeine.
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LOD SCORES
Recombination 
fraction—» 
Markers^
0.00 0.05 0.10 0.15 0.20 0.25 0.3 0.5
D19S49 -0.64 -0.37 -0.23 -0.15 -0.10 -0.06 -0.03 0.00
D19S191 -0.63 -0.36 -0.22 -0.14 -0.09 -0.05 -0.03 0.00
D19S220 -0.38 -0.08 0.01 0.04 0.04 0.03 0.02 0.00
WUT1.9 -0.41 -0.11 -0.01 0.02 0.02 0.02 0.01 0.00
RYR1 -0.43 -0.12 -0.11 0.03 0.04 0.04 0.03 0.00
DJ9S47 0.40 0.33 0.26 0.19 0.14 0.09 0.05 0.00
D 19178 0.92 0.80 0.67 0.55 0.42 0.31 0.20 0.00
Table 4.4 The results of pairwise linkage analysis between MH susceptibility and 
chromosome 19 markers using family LM H 16. The lod scores are given in 
different recombination fraction. As it is shown despite the clear high risk 
haplotype in MHS individuals and lack of in MHN persons there is not a 
significant lod score.
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LOD SCORES
Recombination 
fraction—» 
MarkerssL
0.00 0.05 0.10 0.15 0.20 0.25 0.3 0.5
D19S49 0.62 0.53 0.43 0.34 0.25 0.17 0.10 0.00
D19S191 0.66 0.56 0.46 0.36 0.27 0.18 0.11 0.00
D19S220 1.21 1.07 0.93 0.78 0.63 0.48 0.33 0.00
WUT1.9 1.16 1.03 0.89 0.74 0.60 0.45 0.32 0.00
RYRI 1.13 1.00 0.86 0.73 0.60 0.45 0.32 0.00
D19S47 0.47 0.40 0.32 0.24 0.17 0.11 0.07 0.00
D19178 -0.65 -0.19 -0.05 -0.00 0.01 0.01 0.00 0.00
Table 4.4a The results of pairwise linkage analysis between MH susceptibility and 
chromosome 19 markers using family LM H 16 when assume the MHE and III.2 
individuals are MHS. The lod scores are given in different recombination fraction. 
With this situation the lod scores for main markers (D19S220 , WUT1.9 and RYRI 
significantly is increased. As it is shown the high risk haplotype in MHS 
individuals is more acceptable.
Family L M H  17 is composed of two parts with two different probands and 
two different haplotypes which segregate with MH susceptibility. In the right part 
or large section except for one marker, D19S49 in individual III.7 the same 
haplotype co-segregates with the MHS phenotype. So except for D19S49 
individual III.7, there are no recombinants out of six opportunities for 
recombination. Recombination between D19S49 and RYR1 is not unexpected 
because D19S49 is the most proximal marker of this linkage group and because of 
the distance, approximately 14 cM between D19S49, and the main linkage group of 
markers, D19S191 , to RYR1 (fig 3.13). Thus simple inspection suggests that in this 
part o f pedigree MHS is linked to RYR1.
In the left hand part of the pedigree the IV. 1 is the MHS proband with 
contracture responses at low concentration of halothane and caffeine. But she has 
inherited susceptibility to MH from her susceptible father who is not related to the 
right hand side of family as shown in fig 4.5 and appears probably affected by 
different haplotype which is not common in MHS individuals of this family. She 
probably has inherited the high risk haplotype, 2-1-1-2-1-4-5 which may be is high 
risk haplotype in the relatives of III.2.
The other proband of this family, IV.4 although not tested by IVCT, has 
inherited the similar high risk haplotype, 4-4-4-2-2-3-5 which is common to all the 
MHS individuals in the right hand side of the pedigree. His two brothers, IV .2 and
IV .3 show strong contracture responses to halothane (0.5%) and caffeine (fig 3.7). 
In linkage analysis apparently the lod scores for three m arkersD /9S797, D19S220  
and D 19S47  are around 1 although the lod score for the other
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Fig 4.5 Marker segregation of chromosome 19q in family LMH17.
The markers used are D /9549, D19S191, D19S220, WUT1.9, RYRI, D19S47 and 
D19S178  respectively. This family shows co-segregation of the high risk haplotype 
with malignant hyperthermia susceptibility. The shared haplotype with one 
recombination for D19S49 at individual III.7, is 4-4-4-2-2-3-5.
four markers D19S49, WUT 1.9, RYR1 and D19S178  at 0 = 0.00 are negative. The 
lod score results are presented in table 4.5. Based on the results and condition of 
IV. 1, the suggestion of another locus is not impossible although other reasons such 
as a different haplotype of chromosome 19q like independent pedigree, cannot be 
rejected. However, in an explanation of this family based on the two genes model 
in MH susceptibility the lod score calculation without individual IV -1 will be 
increased as presented in table 4.5a.
In conclusion family LMH17 like family LMH15 may be supposed to be a 
19q-linked family and the low and minus lod scores using two point method 
referred to un-informativeness of some primers (tables 4.5 and 4.5a).
In family L M H  18 haplotype analysis has been carried out for 9 
individuals, one MHN, four MHS, two MHE and two individuals who have not 
been tested by IVCT. Markers D19S49, D19S191, D19S220, WUT1.9, RYR1, 
D 19S47  and D19S178  co-segregate with the MHS phenotype through the entire 
pedigree, and support linkage between the MHS locus in MHS and MHE 
individuals and the 19q 13.1 region. In LMH 18 the high risk haplotype, 1-1-4-1-2- 
3-2 is shared between MHS individuals and this looks to be a 19q linked family 
based on the results of a two point lod scores analysis presented in table 4.6.
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LOD SCORES
Recombination 
fraction—> 
M arkers 4-
0.00 0.05 0.10 0.15 0.20 0.25 0.3 0.5
D19S49 -0.73 -0.27 -0.11 -0.04 -0.00 0.01 0.02 0.00
D19S191 0.75 0.67 0.59 0.49 0.39 0.29 0.19 0.00
D19S220 0.83 0.74 0.64 0.53 0.42 0.31 0.21 0.00
WUT1.9 -0.39 -0.29 -0.21 -0.16 -0.11 -0.07 -0.04 0.00
RYRI -0.16 -0.13 -0.10 -0.07 -0.05 -0.04 -0.02 0.00
D 19S47 0.95 0.82 0.70 0.57 0.44 0.19 0.20 0.00
D19S178 -0.18 -0.06 -0.01 0.01 0.02 0.02 0.02 0.00
T ab le  4.5 The results of two point linkage analysis between MH and markers on 
chromosome 19q 13.2 in family L M H  17. As shown in the table the two markers 
D19S191 and D19S220  closer to the RYRI gene have higher lod scores with MH 
locus as well as the distal locus D19S47.
154
LOD SCORES
Recombination 
fraction—> 
M arkers^
0.00 0.05 0.1 0.15 0.2 0.25 0.3 0.5
D19S49 -0.48 0.07 0.03 0.07 0.07 0.04 0.01 0.00
D19S191 1.00 0.95 0.87 0.77 0.65 0.52 0.40 0.00
D19S220 1.22 1.13 1.09 0.89 0.75 0.61 0.46 0.00
WUT1.9 -0.33 -0.26 -0.20 -0.15 -0.11 -0.07 0.04 0.00
RYR1 -0.17 -0.14 -0.11 -0.08 -0.06 -0.04 -0.03 0.00
D19S47 1.32 1.20 1.03 0.87 0.69 0.52 0.36 0.00
D19S178 0.06 0.20 0.24 0.24 0.21 0.17 0.13 0.00
T ab le  4.5a The results of two point linkage analysis between MH locus and 
markers on chromosome 19q in family L M H  17 without individual IV. 1. As 
supposed the lod scores is increased when the individual IV. 1 is not entered in 
calculation.
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The high risk haplotype order shows (fig 4.6) no recombination with MH 
susceptibility in MHS patients and one MHE(h) individual (II.4). Individual III.4 
who is MHE(h) has inherited a different haplotype from her mother MHE(h) 
compared with her MHS sister, III.5. This haplotype is not observed in MHS or 
MHN individuals (except for D19S49 and D19S191). The proband’s mother (11.4), 
is MHE(h) and she has the same haplotype as MHS individuals. This situation may 
arise for different reasons. For example despite the proband’s mother (II.4) being 
MHE(h) she shows strong positive contracture responses to halothane at 0.5% as 
well as her daughter, III.5 but the situation for III.4 using IVCT is different. He 
shows contracture at 2% halothane which is close to the border between MHN and 
MHE and he does not show any positive response at concentrations of caffeine 
under 8mM which is a high concentration. These concentrations of halothane and 
caffeine suggest doubt about the assignment of the status for III.4 and the condition 
for making a strong decision in classifying III.4 as MHN or MHE^)- An alternative 
explanation may be described by the same gene with different high risk haplotypes 
if we suppose that the individual II.3 is MHS. Another possible explanation 
involves two causative genes but the probability of this is lower compared to above 
explanations because of lack of enough data for this family and also low frequency 
of MH individuals, although finding of two genes in one family is not impossible. 
The lod scores at 0 = 0.00 for three markers, D19S220, D19S47  and D19S178  are 
positive, +1.05, +1.4 and +1.17 respectively as presented in table 4.6 . Apparently 
the low lod scores are related to markers which are not informative (RYRI).
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D19S49 3 
D19S191 5 
D19S220 4 
WUT1.9 3 
RYR1 2 
D19S47 3 
D19S178 1
Fig 4.6 M a rk e r  segregation  of chrom osom e 19q in LM H 18 family.
The markers used arzD 19S49, D19S191, DI9S220, WUTJ.9, RYRI, D19S47  and 
D19S178 respectively. Except for individual III.4 (MHE), the high risk haplotype, l- 
I -4-1-2-3-2 is shared between MHS and M H E individuals. This individual 
presented weak responses to halothane and caffeine at 2% and 8mM respectively (fig 
3.8) and is probably not MH susceptible.
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LOD SCORES
Recombination 
fraction—» 
Markers 4-
0.00 0.05 0.10 0.15 0.20 0.025 0.30 0.5
D19S49 0.17 0.12 0.08 0.05 0.03 0.01 0.00 0.00
D19S191 -0.37 -0.09 -0.00 0.03 0.04 0.03 0.02 0.00
D19S220 1.05 0.91 0.77 0.63 0.50 0.35 0.23 0.00
WUT1.9 -0.09 0.30 0.36 0.35 0.030 0.24 0.16 0.00
RYR1 0.34 0.30 0.23 0.19 0.14 0.10 0.06 0.00
DJ9S47 1.40 1.25 1.09 0.92 0.75 0.57 0.40 0.00
D19S178 1.17 1.03 0.89 0.74 0.60 0.44 0.30 0.00
T able 4.6 Lod score table of two point linkage analysis between MH locus and 
chromosome 19 markers of family L M H  18. The two markers, DJ9S220 and 
D19S47  which are rather close to RYR1 marker have relatively high lod scores 
compared with other markers and then may close linkage between the MH locus 
and these two loci.
In conclusion it may be supposed that family LM H 18 is 19-linked and 
probably that individual III.4 is not MH susceptible.
4.2 Conclusion of Chromosome 19q Results
In conclusion it is probable that MH susceptibility is linked to RYRI in 
families LM H15, LMH16, LM H17 and LMH18. There is not strong evidence for 
exclusion of these families from the 19q region using two point and multipoint 
linkage analysis.
Based on these results a few points should be considered. In general, 
although the marker segregation looks to show a correlation with MH locus on 19q 
in LMH15, LMH16, LMH17, LMH18 the high number of MHE^h) individuals with 
haplotypes similar to MHS individuals, but entered in the calculations as 
“unknown status”, result in a reduction of lod score information. In addition 
homozygosity for some markers especially for RYRI and WUT1.9 also results in 
lod score reduction. The decision in classification of sample as MHS, MHN or 
MHE(h) is another factor, and misclassification in IVCT or molecular genetic 
analysis or mislabelling of samples (maybe in LMH 16 and LMH 18) can be 
involved in linkage analysis.
The other point which cannot be ignored is the size of families, and the 
number of generations available for analysis. Perhaps spreading of the search to 
more members o f the pedigrees and completing of haplotypes especially for new 
IVCT typed members of pedigrees could give rise to increased lod scores and make 
interesting haplotypes.
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In the other part of the linkage analysis, for non 19 linked families the 
LM H07 and LM H12 families at a brief glance appear not to be linked to the 
chromosome 19q markers. The linkage analysis results provide less support for 
linkage of MH susceptibility to chromosome 19q in family LMH07. This family 
shows one M HN recombination using chromosome 19q markers. A ltogether the 
results of this investigation for linkage to chromosome 19q are inconclusive. With 
concern to discussion for the mentioned pedigrees (LMH 15, 16, 17 and LM H 18) 
this suggestion is not impossible (of course the situation for LM H 12 is different).
In family LMH 12 there is clearer evidence that MH susceptibility is not linked to 
RYRI gene. However acceptance of linkage of LMH 12 to 19q gives rise to two 
cases which do not follow this conclusion. In LM H 12 the individual II.5 who is 
MHS with a different haplotype from the high risk haplotype and individual III.4 
who is M HN with the high risk haplotype, 6-1-2-4 are two cases with a low 
probability against this explanation. If we arrange the haplotype 1-3-2-6 for MHS 
individuals then there will not be any difficulty in conclusion and excluding it from 
chromosome 19 markers and the description of the marker distribution.
In family LMH07 despite the common haplotype between MHS and MHE 
individuals based on the marker segregation and lod scores, linkage to 
chromosome 19q needs more evidence to be more clear. In LMH07 the 
appearance for linkage to 19q are more acceptable than the LMH12. The high risk 
haplotype is shared between susceptible individuals. But the high level of 
homozygosity for D19S179, D19S190 and RYRI and the recombination in III. 1 
may exclude this family from chromosome 19q although for the reason described
for the III-2 in LM H 16 this is not impossible. In summary the exact conclusion 
for LMH 12 for linkage to chromosome 19q needs more attempts and more 
evidence but supposing linkage of LMH07 to chromosome 19q may be possible 
with reasonable features and clear situation.
4.3 Linkage data with other chromosomal regions, 7q, 3q, lq  and 2p
Four families LMH03, LMH07, LMH 12 and AN2 have been identified as 
non 19-linked families as a result of these investigations and previous studies 
(families LM H07 and LMH 12, data are shown in figures 4.1 and tables 4.2; family 
LM H03 by Dr. J. Curran and AN2 by EMHG). The families LMH03 and AN2 
have been investigated previously for marker segregation using markers from 
chromosom es 19q, 17q, 7q and 3q and excluded from these candidate regions. In 
this study family LM H07 is investigated for chromosome 3q and 7q and LM H 12 
was studied using markers from chromosomes 7q, 3q and lq. The two other 
families LM H03 and AN2 were investigated using markers from chromosome 2p 
as a part o f a genomic search.
4.3.1 Linkage analysis with markers from  chromosome 7q
In families LMH07 and LM H12 marker segregation for six markers 
(.D7S675, D7S634, D7S660, D7S849, D7S524, D7S515) from chromosome 
7ql 1.23-q21.3 close to the CACNLA2 locus are illustrated in figs 4.7 and 4.8 for 
LM H07 and LM H 12 respectively. In family LMH07 the haplotypes are varied to 
different alleles and there is not a shared high risk haplotype between MHS or even 
M HE individuals.
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Fig 4.7 Marker segregation of chromosome 7q in family LMH07.
The markers used are D7S675, D7S634, D7S660, D7S849 D7S524 and D 7S5I5  
respectively. There is no high risk haplotype that co-segregates with malignant 
hypertherm ia susceptibility and using two point linkage analysis shows no linkage to 
chrom osom e 7q (table 4.7).
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LOD SCORES
Recombination 
fraction—» 
M arkers^
0.00 0.05 0.1 0.15 0.2 0.25 0.3 0.5
D7S675 0.05 0.04 0.03 0.02 0.01 0.01 0.00 0.00
D7S634 -0.36 -0.21 -0.13 -0.07 -0.04 -0.01 -0.00 0.00
D7S660 -0.32 -0.12 -0.02 0.01 0.03 0.04 0.03 0.00
D7S849 -0.32 -0.10 -0.00 0.03 0.05 0.05 0.04 0.00
D7S524 0.36 0.30 0.23 0.18 0.13 0.08 0.05 0.00
D7S515 -0.32 -0.26 -0.20 -0.14 -0.10 -0.06 -0.03 0.00
Table 4.7 The two point linkage analysis results of chromosome 7q markers and 
M H susceptibility in family LM H 07. Except for the locus D7S524 most lod scores 
are negative or close to zero.
In conclusion as results are shown (fig 4.7 and table 4.7) there is no 
evidence of linkage between MH susceptibility and markers from chromosome 7q.
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In family L M H  12 (fig 4.8) the MHS individual II. 1 has three children, two 
III. 1 and III.3 (proband) are MHEh) and one is MHN (III.2). They have all 
inherited the same haplotype (3-3-3-1-3-3) from their father. In addition the 
daughters of II-3 (MHE) who are both MHN have received different haplotypes 
from their father. This means that there is no common 7q marker haplotype which 
co-segregates with MH susceptibility in this family. Simple inspection of the 
pedigrees reveals that there is no common haplotype in MHS individuals in either 
pedigree. The results of chromosome 7q marker linkage analysis in the family 
LM H 12 using two point lod score calculation, are summarised in tables 4.8.
Then for these two families there is no evidence to support linkage between 
MHS and markers from chromosome 7q. Although for excluding the MH 
susceptibility locus from chromosome 7q the lod score of -2 is required. These 
results are consistent with 27 other non 19-linked families data from European MH 
centres which are reported in EMHG (Genetics Section) meeting in 1995. But they 
are contrary to the observation of lies et al (1994) who found good evidence for 
linkage to this region o f chromosome 7q in a single three-generation MHS family 
from central Europe. The candidate region on chromosome 7q (lies et al 1994) 
was mapped between q l 1.23 to q21.1 using the D7S849 and D7S524, D7S492, 
D7S634, D7S660, D7S669, D7S675, D7S644 and D7S630 markers (fig 3.13) with 
a maximum lod score of +2.91. The co-segregation of marker D7S849  which is
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D7S675 3 3 
D7S634 3 2 
D7S660 3 2 
4 
3 
2
D7S849 1 
D7S524 3 
D7S515 3
Fig 4.8. Marker segregation of chromosome 7q in LMH12 family.
The markers used are D7S675, D7S634, D7S660, D7S849 D7S524 and D7S515 
respectively. Allele segregation using these markers does not show co-segregation 
with susceptibility to m alignant hyperthermia.
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LOD SCORES
Recombination 
fraction—> 
M arkers-i
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.50
D7S675 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
D7S634 -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D7S660 -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D7S849 -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D7S524 -0.00 -0.00 -0.00 0.00 0.00 0.00 0.00 0.00
D7S515 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
T ab le  4.8 The two point lod scores of linkage analysis between chromosome 7q 
markers and MH susceptibility in family LM H 12. As with family LM H07 most of 
the lod scores are low and there is no significant suggestion of linkage between 
MH susceptibility and chromosome 7q markers in this family.
1 6 6
close to a gene encoding the a 2/8 subunit of DHPR (dihydropyridine receptor) and 
MH susceptibility resulted in a claim for another MHS locus in this region.
4.3.2 Linkage analysis with markers from chromosome 3q
Allele segregation for chromosome 3q markers, D3S1271, D3S1302, 
D3S1278, D3S3654, D3S1309, D3S1303, D3S1279 and D3S3638  in families 
LM H07 and LMH 12 were investigated for linkage analysis between these markers 
and the MH susceptibility locus (D3S1279 was not typed in family LMH07).
Haplotype analysis for eight markers of chromosome 3q which span the 
region 3q 11-1 to q23 (fig 3.19) shows no common high risk haplotype and no 
association with the MH locus in either family (figs 4.9 and 4.10). M arker 
segregation for chromosome 3q in comparison with the results of chromosome 19q 
markers have not a specific haplotype in family LMH 07 as well as markers of 
chromosome 7q. In family LMH07 both III. 1 and III.2 have inherited the same 
haplotype from their father. The proband III.2 has two recombination (for 
D3S1302 and D3S1303 markers) and III. 1 shows one crossing over for D3S1309. 
The daughters of MHE(h) individual, II.3, have inherited the same the haplotype (1- 
1-2-2-6-1-3) from their father although one of them is MHE (III.3) and the other 
one is MHS (III.4). Based on these observations it is unlikely that the MH locus in 
LM H07 is linked to chromosome 3q. Pairwise lod score data between MHS and 
these markers supports this conclusion (table 4.9).
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Fig 4.9 M a rk e r  segregation  o f ch rom osom e 3q in fam ily LM H 07.
The markers used arc D3S1271, D3S3654, D3S363S, D3SI302, D3SI278, D j S I30 j 
and D3S1309  respectively. This family does not show any correlation between MH 
susceptibility and the segregation of these m arkers.
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LOD SCORES
Recombination
fraction-4
M arkers-l
0.00 0.05 0.1 0.15 0.2 0.25 0.3 0.5
D3S1271 -0.49 -0.36 -0.30 -0.22 -0.15 -0.10 -0.06 0.00
D3S3654 0.16 0.14 0.11 0.09 0.06 0.04 0.03 0.00
D3S3638 -0.34 -0.21 -0.13 -0.08 -0.05 -0.03 -0.01 0.00
D3S1302 -0.34 -0.23 -0.16 -0.12 -0.08 -0.06 -0.04 0.00
D3S1278 -0.41 -0.37 -0.31 -0.24 -0.18 -0.12 -0.08 0.00
D3S1303 -0.32 -0.18 -0.11 -0.07 -0.05 -0.03 -0.02 0.00
D3S1309 0.16 0.13 0.11 0.08 0.06 0.04 0.03 0.00
T able 4.9 The two point linkage analysis results between MH susceptibility and 
chromosom e 3q markers in family LM H 07. As shown in the table the lod scores 
are low and do not provide any evidence for linkage o f MHS to chromosome 3q.
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In family LM H 12 eight chromosome 3q markers (D3S1271, D3S1302, 
D3S1278, D3S3654, D3S1309, D3S1303, D3S1279, and D3S3638) have been 
investigated. The results are presented in fig 4.10. As with the last pedigree 
(LMH07, fig 4.9) there is not a common haplotype in the MHS individuals. 
Individuals III. 1 (MHEh), III.2 (MHN) and III.3 (MHEh) have inherited the same 
haplotype form their father II. 1 who is MHS. Furthermore the daughters of II.3 
have received different haplotypes from their MHE(h) father although both are 
MHN. This simple inspection indicates that MHS is not linked to 3q 13.3 in this 
family. Lod score analysis support this conclusion for different markers. A t0  = 
0.00 the most lod scores are near to zero and as listed in table 4.10 there is no 
significant result for linkage to chromosome 3q.
The chromosome 3q 13.1 region in a collaborative genome search by the 
EM HG (Genetic Section) using hypervariable microsatellites was reported to be 
linked to MH susceptibility in one German family which had previously been 
excluded from 19q linkage and linkage putative MHS loci on 17q and 7q (Sudbrak 
et al 1995). In this present project using these eight chromosome 3q markers there 
was no correlation between 3q markers and MHS locus. These results agree with 
other results for 18 non 19-linked families reported in EMHG (Genetics Section) 
meeting from European centres in 1995. Of course this piece o f work, although it 
covers the candidate region, cannot exclude the supposed MHS locus from this 
region because of the high distance between markers and since only eight marker 
were used for long arm of chromosome 3q.
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Fig 4.10 Marker segregation of chromosome 3q in LMH12 family.
The markers used are D3S1271, D3S3654, D3S3638, D3S1302, D3S1278, D3S1303, 
D3S1309  and D 3SI279  respectively. Allele segregation using these eight markers 
does not show co-segregation of a high risk haplotype with malignant hyperthermia 
susceptibility.
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LOD SCORES
Recombination 
fraction —> 
M arkers sL
0.00 0.05 0.10 0.15 0.20 0.25 0.3 0.5
D3S1271 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D3S3654 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
D3S3638 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00
D3S1302 0.03 0.02 0.02 -0.00 0.00 0.00 0.00 0.00
D3S1278 0.01 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D3S1303 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D3S1309 -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D3S1279 0.02 0.02 0.01 0.01 0.00 0.00 0.00 0.03
Table 4.10 Two point lod scores for linkage analysis between chromosome 3q 
markers and MH susceptibility using eight markers in family LMH12. These 
results do not provide evidence for linkage of MHS to chromosome 3q markers in 
this family.
172
4.3.3 Linkage analysis with markers from chromosome lq
In family LMH 12 six chromosome lq markers (D1S248, D1S252, D1S194, 
D1S196, DIS191 and D1S249) have been typed which span the region from 1 q 12 
to 1 q32 .1. The segregation of these markers is shown in fig 4.11. No significant 
haplotype is associated with MH susceptibility locus. Haplotype analysis in the 
progeny of II. 1 shows a similar order for III. 1 and III.3 who are M H ^h> and MHS 
respectively. The great distance between the marker loci (fig 3.21) is likely to 
result in a high rate of crossing over between them as observed in pedigree LM H 12 
and shown in fig 4.11.
The gene encoding the (Xi subunit of DHPR (a candidate protein in MH 
susceptibility) is located at Iq31-q32 very close to the D1S249 locus used in this 
analysis. The lod scores for pairwise linkage analysis between MH susceptibility 
and these markers on chromosome lq  are presented in table 4.11 and all around 
zero at 0 = 0.00 and therefore indicate that there is no linkage between MHS locus 
and these lq  marker loci. These results are consistent with other results for four 
non 19-linked families reported in Genetics Section of EM HG meeting in 1995.
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Fig 4.11 Marker segregation of chromosome lq  in family LMH12.
The used markers ar&D1S248, DIS252, D1S194, D1S196, D1S191, and D 1S249 
respectively. As observed for chromosomes 7q and 3q there is no co-segregation 
between susceptibility to MH and the candidate region on chromosome lq.
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LOD SCORES
Recombination 
fraction—> 
M arkers xl
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.5
D1S248 0.02 0.02 0.01 0.01 0.00 0.00 0.00 0.00
D1S252 -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D1S194 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D1S196 -0.00 -0.00 -0.00 -0.00 -0.00 0.00 0.00 0.00
D1S191 -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
D1S249 -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 0.00
T ab le  4.11 The two point lod scores of linkage analysis between chromosome lq  
markers and MH susceptibility in family LM H 12. The lod scores are very low and 
can not be used in proving or excluding the MH locus from this family.
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4.3.4 linkage analysis with markers from chromosome 2p
Preliminary results from the genomic search project (collaborative project 
of the European M alignant Hyperthermia Group, Genetic Section) suggested that 
there may be an MH susceptibility locus on chromosome 2p. Genotyping of two 
candidate markers, D2S398 and D2S139 was carried out for two families, AN2 and 
LMH03 which had been excluded from linkage to chromosomes 19q, 17q and 7q 
indicated by the genomic search.
For these two markers there is no common haplotype in MHS individuals; 
however, a shared haplotype is not expected since the distance between these 
markers, approximately 80cM is very great. The D2S398 and D2S139 markers are 
not linked to MH susceptibility locus in family LM H 03. The LMH03 yields 
negative lod scores for both markers, -3.23 and -5.18 D2S139 and D2S398 
respectively at zero recombination fraction and low positive lod scores at 0 = 0.15 
and more (table 4.12).
In family AN2 one allele of the D2S139 marker (allele 2) is co-inherited 
with MH susceptibility except with one recombination in individual 11.12 who is 
MHN (fig 4.13). The lod scores for linkage between MHS and this marker in 
family AN2 are presented in table 4.13 and the high lod score is approximately 1 at 
0 = 0.00 although it is -2.20 for D2S398 and then this excludes close linkage to 
MH susceptibility locus. Based on the results in family AN2 typing o f more
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Fig 4.12. Segregation of chromosome 2 markers in LM H 03 family.
The markers used are D2S139 and D2S398. Allele segregation using two markers 
shows no shared haplotype between MH susceptible individuals.
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LO D  SC O R ES
Recombination 
fraction—> 
Markers!-
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.5
D2S139 -3.23 -0.54 -0.13 0.05 0.13 0.016 0.15 0.00
D2S398 -5.18 -1.45 -0.84 -0.52 -0.33 0.21 -0.13 0.00
T ab le  4.12 Lod scores of two point linkage analysis between MH susceptibility 
locus and chromosome 2 markers D2S139 and D2S398 in family L M H  03.
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D2S398 1 4  1 4
S v S l  “ ) there was no c o n a t io n  o f m arkers used wUh MH
su scep tib ility .
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LOD SCORES
Recombination 
fraction—> 
M arkers^
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.5
D2S139 0.99 0.90 0.80 0.70 0.59 0.47 0.35 0.00
D2S398 -2.20 -1.18 -0.76 -0.51 -0.34 -0.22 -0.13 0.00
Table 4.13 Lod score results of linkage analysis between MHS and two markers 
from chromosome 2p, D2S139 and D2S398 in family AN2.
markers close to D2S139 seems to be necessary to demonstrate or exclude linkage 
of MHS to chromosome 2p in this family.
4.4 Conclusion of linkage data with other chromosomal regions
In conclusion regarding the linkage data of this project for chromosomes 
7q, 3q and lq  and chromosome 2, despite the reports by lies et al 1994 (for 
chromosome 7q with lod score less than 3) and Sudbrak et al 1995 (for 
chromosome 3q with lod score more than 3) there was no evidence to support their 
finding in UK families. Although except for chromosome 2p (for LMH03 and 
AN2 families) there is not strong evidence (lod score -2) to exclude these families 
from chromosomes 7q ,3q and lq. In addition linkage analysis in two families 
LMH07 and LMH 12 using chromosome 7q markers two more UK MH families 
have been investigated and no linkage was found to chromosome 7q (EMHGGS 
1995).
Furthermore investigation for linkage between MH susceptibility and 
chromosome 7q markers using 27 MH European families have shown no linkage 
for this candidate region. In addition, further studies in MH units (European 
countries) using chromosome 3q markers for 18 MH families gave the same results 
as UK families, namely lack of any linkage to the proposed candidate region. This 
project’s result for chromosome lq  agree with an investigation of four more 
European M H families which reported no linkage to the lq candidate region 
(EM HG Genetics Section, 1995). There is no considerable m arker segregation or 
lod score for chromosome 2p except for one marker (AN2 family, fig 4.13).
180
Finally although it is not possible to exclude the families LM H07 and LMFI12 
from candidate regions on chromosomes 7q, 3q, lq and LMFI03 and AN2 from 
chromosome 2 as well as there in is not possible evidence to suppose any linkage 
to these candidate regions.
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Chapter five
Results and Discussion of Mutation Detection in RYR1 gene
5.1 Results of Mutation detection
5.1.1 C487 substitution to T
31 unrelated MHN, 102 unrelated MHS and 2 unrelated M HE individuals 
were tested for this mutation. These data are shown in table 5.1. There is no 
evidence for the presence of the C487 to T mutation in UK MH population.
Furthermore this survey was carried out in 9 MHS, 2 MHN and 2 M HE 
individuals diagnosed as having central core disease (CCD). This mutation was 
not detected in CCD individuals. These results are presented in table 5.2.
5.1.2 G1021 to A mutation
100 unrelated MHS individuals, 130 unrelated MHN individuals and also 
four unrelated M HE individuals from UK MHS families were investigated for the 
presence of the G 1021A mutation. The results of this investigation are shown in 
table 5.3. This mutation is recognised in 10 patients from six different MHS 
families who were heterozygous for the G1021 site. In addition 11 MHS / CCD, 6 
MHN / CCD and 3 MHE / CCD samples were tested for this mutation. There was 
no mutant individual in the CCD families. These results are summarised in table 
5.4. Three of seven families who are heterozygote for G1021A mutation are 
shown in figs 5.1 and 5.2.
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G-A
(a)
F am ilie s : Qua-Man
(b)
Kel-Por
Fig 5.1 Two pedigrees which are heterozygous for G1021A mutation.
G-G and G-A genotypes respectively show normal and mutant sequences for the 
G 1021A mutation. This base substitution was observed in individuals who are 
susceptible to malignant hyperthermia. The individuals with number have been 
tested by IVCT and unnumbered individuals have not been IVCT tested
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Fig 5.2 Pedigree of family Lea-Sus which segregates for malignant 
hyperthermia susceptibility and the G1021A mutation.
The individuals with number have been tested using IVCT and vice versa.
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Table 5.1 Results of C487T mutation detection in UK MHS families.
This mutation is not observed in 102 MHS, 31 MHN and 2 M HE individuals.
MH status C487T
heterozygotes
C487
homozygotes
Total
MHS 0 102 102
MHN 0 31 31
MHE(h) 0 2 2
Total 0 135 135
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Table 5.2 Results of C487T mutation detection in UK MH/CCD families.
MH status C487T
heterozygotes
C487
homozygotes
Total
MHS 0 9 9
MHN 0 2 2
MHE(h) 0 1 1
Total 0 0 12
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Table 5.3 Results of G1021A mutation screening in British MH families in the 
RYRI gene.
MH status G1021A
heterozygotes
G1021
homozygotes
Total
MHS 10 134 144
MHN 0 157 157
MHE(h) 0 10 10
Total 10 301 311
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Table 5.4 Results of G1021A mutation screening in British MH/CCD families 
in the RYR1 gene.
MH status G1021A
heterozygotes
G1021
homozygotes
Total
MHS 0 10 10
MHN 0 6 6
MHE(h) 0 1 1
Total 0 17 17
5.1.3 C 1840to  T results
38 samples from MH families (20 MHS, 15 M HN and 3 M HE and 
unknown status) were tested for the C1840T mutation. This mutation was not 
detected in any of the individuals tested. The results are summarised in table 5.5.
5.2 Mutation analysis study
The mutation detection for three known mutations of the RYRI gene 
(C487T, G 1021A and C1840T) from the eight potentially causative mutations 
reported in the RYRI gene (in MHS and CCD individuals, table 1.1) was carried 
out using DNA samples from different MHS families and also from CCD patients 
with or without MHS. Some of these families (MH families) had been shown to 
have an M H locus linked to 19q.
5.2.1 C487T mutation
The search for the C487T mutation was followed using 135 samples from 
MHS, M HE(h) and MHN individuals. This mutation may be causative in CCD 
induction and MH susceptibility (Quane et al 1993). This mutation is reported 
(Quane et al 1993) in one MHS family and one CCD family. The results of this 
work in UK samples tested for this mutation revealed no mutant sample in MHS, 
MHN, M HE and CCD samples (table 5.1). This mutation in a survey of 48 Danish 
MHS families is reported in only one family (Fagerlunde? al 1994). The frequency 
of this mutation in MH families is low, and supposed to be around 3% in the 
European population (W est 1996) or lower, 1% in the North American population 
(Fletcher 1995).
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Table 5.5 The results of a mutation search (the C1840 to T mutation) in 
different samples from UK MH families.
MH status C1840T
heterozygotes
Cl 840
homozygotes
Total
MHS 0 20 20
MHN 0 15 15
MHE(h) and 
unknown status
0 3 3
Total 0 38 38
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The search for the C 1840T mutation was carried out in some samples from 
MHS and MHN individuals from UK families. The results show no mutant 
samples on enzyme digestion (fig 3.26) consistent with Curran et al (1993) who 
reported no mutant in one hundred British unrelated MHS individuals. There is no 
overlap in these data. Of course the frequency of this mutation is not high and 
supposed to be approximately 5% in European families (West 1996).
Finally it is important to beware of association of this mutation with 
susceptibility to MH as no unity was reported between IVCT results, C1840T 
mutation and susceptibility to MH by Fletcher e/ al 1995; Deufel et al 1995 and 
Serfas et al 1996. These studies describe the correlation between MH 
susceptibility and the RYR1 C1840T mutation with different features. Fletcher et 
al (1995b) reported 18 uneventful anaesthetics in one subject with the/? 17?/ 
C1840T mutation. They supposed that either additional modulating factors must 
contribute to the syndrome or the presence of the C l 840T mutation is not a 
causative factor in MH. However, in another study in pigs it is supposed that the 
presence of the C1840T mutation alone might not be sufficient to consistently 
cause MH in pigs (Fletcher et al 1993). In another family which is reported by 
Deufel et al (1995) the RYR1 C1840T mutation is present in one branch o f the 
family but not in other. In fact there are two independent C1840T transitions in the 
one branch as judged by the flanking 19q haplotypes and homozygosity of one 
individual. In addition there is the further complication that the C1840T mutation 
is also present in an individual who clearly types as MHN. Serfas et al (1996)
5.2.2 C1840T mutation
observed a Canadian family in which there was disconcordance between the RYRI 
C1840T mutation and CHCT (caffeine halothane contracture test) assignment of 
MH susceptibility. They attributed this observation to two errors in the biopsy 
testing.
In summary based on the different reports from different centres it is 
supposed this mutation indicates a geographical distribution (W est 1996).
5.2.3 G1021A mutation
The survey for detection of the G 1021A mutation was carried out using 234 
samples (one hundred samples from unrelated MHS individuals, one hundred thirty 
unrelated MHN samples and four MHEh samples). These results indicate that 10 
individuals from seven unrelated MHS families are heterozygous for this mutation 
and carry a base substitution of A instead G (table 5.3). The pedigrees of these six 
families are small, three of these families are shown in figs 5.1 and 5.2. In addition 
to these MH individuals 17 CCD individuals, ten MHS, 6 MHN and one M HE(h), 
were screened for this mutation. The results from these CCD samples show no 
positive individual for this mutation (table 5.4).
The G 1021A mutation (Gly341 to Arg amino acid substitution) mutation 
perhaps is the most common mutation so far reported in the RYRI gene in MHS 
individuals. However this mutation is observed in one non 19q linked family 
LM H03 (Adeokun et al 1997). In LMH03 the mutation is inherited within the 
pedigree and is only present in MHS individuals but did not show com plete co­
segregation with MH susceptibility. This mutation was not observed in five
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individuals of this family who are MHS. Three different explanations for 
correlation between MH susceptibility and/?}7/?/ G 1021A mutation for this family 
are proposed by the authors. The frequency of this base substitution has been 
estimated to be 10% of all MHS families (Quane et al 1994a) and in comparison 
with the C1840T mutation it has not been observed in MHN samples. The 
association of this mutation with MHS individuals (here in 140 samples) and lack 
of it in MHN individuals (150 samples) as well as similar results in another centre 
in the UK (Adeokun et al 1997) in addition to the reports of Quane et al (1994a) 
strongly indicates a causative role for the G 1021A as a causative mutation in MH 
susceptibility. The interesting point in Adeokun et al (1997) report in LMH03 
family was the co-segregation of this mutation in individuals who show 
chromosom e 19q-linked haplotypes and lack of this mutation in other part of this 
family which does not show linkage to chromosome 19q.
In conclusion in UK families the two RYRI mutations, C487T and C1840T 
are believed to be at very low frequency, less than 3%. The results of investigation 
in European MH families for these two mutations show 3 heterozygotes in 246 
MHS individuals and 22 in 463 MHS individuals for C487T and C1840T 
mutations respectively (European M alignant Hyperthermia Group Genetics 
Section, Dec. 1995). But the RYRI G 1021A mutation is found at greater 
frequency, around 7% in MHS individuals in the UK population (20 mutants in 
400 MH individuals) and probably is a causative mutation in MH susceptibility. In 
CCD patients although the C487T mutation is reported in a few families (Quane et 
al 1994) we could not find any evidence in our samples. These results agree with 
W est’s suggestion (1996) on the geographical distribution of RYRI mutations and
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it may be supposed that approximately between 15 to 20% of M H families (19q 
linked families) carry one of the eight mentioned RYRI mutations (table 1.1). The 
possibility of finding more RYRI mutations which could account for more MHS 
individuals is considerable and necessary.
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Chapter SIX
Conclusion and future work
6.1 Critical points and future work
Two approaches to the elucidation of the molecular defects underlying 
MHS were taken in this project. At first this project started on a logical path which 
is stated from main source or malignant hyperthermia susceptible individuals. 
Using DNA samples of MH families, screening for causative genes or candidate 
loci was continued by linkage analysis. Finding linkage to theR Y R l gene and 
following this path using mutation screening was the next step in the molecular 
analysis of malignant hyperthermia. Although this project finished at this step it 
could have been continued by sequencing of individuals who are susceptible and 
are heterozygous for 7?77?7 mutations proving the relation between MH 
susceptibility and causative mutations.
Ensuring the absence of these mutations in normal people and providing the 
transgenic animals are essential in finding more about the pathogenic role of these 
mutations in malignant hyperthermia susceptibility especially finding more about 
defects in RYR1 gene and malignant hyperthermia susceptibility. Up to now the 
exact mechanism of excitation-contraction coupling and the role of volatile 
anaesthetics and also muscle relaxants in Ca2+ release is not known. Then as an 
interdisciplinary project it needs to be associated with electrophysiology and 
studies on calcium currents in muscle fibres. Although it is reported that some
factors such as the calcium pump are not involved (chapter one) in MH 
susceptibility, as Morgan and Sedensky (1995) reported in C. elegans, mutations 
which are not involved in RYRI may give rise to contractile responses. However, 
following genomic search for MH causative loci, using the new achievements from 
ion channels (especially calcium currents) is necessary. The new survey on 
triggering agent may be another project which can be involved in MH 
susceptibility.
In the second part of this project few points could effect on the results. 
Firstly it may be supposed that the project did not follow a specific path.
Following the chromosome 19q project for the LM H 15, 16, 17 andLM H 18 
families, the choice of families LMH07 and LMH12 for screening the other 
candidate loci was made after excluding 19q for these families. The future work 
for these families may be supposed to be the collection of more data using 
chromosome 19q markers in new members. M arker segregation and linkage 
analysis for these two families, especially for family LMH07, and using markers 
from chromosomes 7q, 3q and lq were ambiguous, more data needs to be entered 
in this project for localisation of the MH locus to candidate regions or exclusion of 
it. The other point which should be considered in future work is more attention to 
the markers for a candidate region which should be based on more data. The study 
using two distantly spaced markers for chromosome 2p was a “ shot in the dark ” . 
The two markers with high distance apart on a big chromosome appears not to give 
rise to reasonable results. Using more markers spread over the candidate region for 
chromosom e 19q especially for LIPE gene could be an interesting study for the
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future in addition to a review of results and completion of these results. The more 
important point in this part is focusing on the IVCT results and making a strong 
decision on classification of MH groups and if it is possible, of course it should be 
possible to draw pedigrees focusing on the IVCT results with less doubts and more 
accurate data.
6.2 G eneral conclusion
A brief review and conclusion of practical work and analysis of results 
make it possible to classify the achievements in two sections, linkage analysis 
results and mutation search. Results of linkage analysis based on the investigated 
pedigrees are classified in two main groups, linkage data with markers on 
chromosom e 19q and linkage data with other chromosomal regions. In the first 
group the families LMH 15 and LMH 17 despite the low lod scores show co­
segregation of high risk haplotypes in MHS and MHE(h) individuals and show 
unambiguous linkage between MHS and markers from chromosome 19q. The 
other three families, LM H07, LMH 16 and LMH 18 show linkage between MHS 
and markers from chromosome 19q in most members with one MHN inconsistency 
in the two first pedigrees and one M HE recombination in LMH18. The LM H12 is 
a family for which conclusion on linkage between MHS locus and markers from 
chromosom e 19q cannot be drawn and this locus is proposed to be unlinked to 
chromosom e 19q. Despite more candidate regions from reports on other 
chromosomes, 7q, 3q, lq and 2p (chapter one), these linkage analysis results do not 
confirm  these candidate loci and do not consistently support any linkage to these 
regions. Families LMH07 and LMH 12 do not show significant lod scores or
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shared high risk haplotypes between MHS and M HE individuals to prove linkage 
to candidate regions on chromosomes 7q, 3q and lq  (only family LMH 12) 
although there is no strong evidence for exclusion of these families from these 
candidate regions. For these two families it is not reasonable to develop more 
linkage analysis using the reported candidate regions. It seems acceptable to 
extend the pedigrees (LMH 15, LMH 16, LM H 17, LMH 18 and LM H07) for further 
linkage analysis. The satisfactory classification of MH individuals using IVCT and 
selection o f appropriate markers for linkage analysis are important for the future of 
this study.
Mutation testing was carried out for three mutations, C487T, G1021A 
C1840T. The C487T was not found in any samples in MHS, M HE and MHN 
individuals in UK MH and CCD families and it might be supposed that the 
frequency of this mutation in UK MH families is less than 3%. The results of the 
C1840T mutation screening were similar to C487T and are consistent with another 
report (Curran et al 1993) from UK families where this mutation was not detected 
in any of the individuals tested. The only RYR] mutation detected in UK M H 
families is the G1021A mutation. The frequency of this mutation is deduced to be 
around 6% in UK MH families. These results are consistent with W est’s 
suggestion (1996) that the MH mutations are geographically distributed.
Finally despite the reports on genetical diagnosis of malignant hypertherm ia 
susceptibility status (Healy et al 1991; 1996; W allace et al 1996), the time for 
using these techniques is too early and using these methods in diagnosis is at high 
risk of misleading diagnoses. This is specially true where the linkage analysis is
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based on IVCT results which are not reproducible and may give false results 
(Hopkins et al 1994; Serfas et al 1996). On the other hand the DNA-based test for 
chromosom e 19-linked families in humans for MH diagnosis as reported by Fujii et 
al (1991) and Otsu et al ( 1991) in pigs is not useable and confident for human. In 
addition lack of co-segregation of RYRI gene mutations with linkage analysis 
results and chromosome 19q haplotypes in some pedigrees are not unusual. The 
report of Adeokun et al (1997) on co-segregation of G 1021A mutation in some 
MHS individuals and lack of co-segregation in others in one pedigree is a good 
example which confirm that DNA tests are not reliable based on present MH 
knowledge (Fletcher et al 1995; Deufel et al 1995). Finally the results presented 
here indicate that more understanding is needed before DNA tests (linkage analysis 
and mutation typing) for MH status diagnosis could be considered reliable. Then 
in conclusion the in vitro contracture testing, IVCT remains the gold standard 
technique in diagnostic methods for MH susceptibility (Ball et al 1991; Larach 
1993).
At the end with confidence based on the biochemical, physiological and 
genetical achievements it is logical to state that the RYRI gene is the main key to 
solve the mystery of malignant hyperthermia susceptibility. This study shows five 
out of six families in addition to the large branch of the LMH03 family (Ball et al 
1993) and the recent report (Curran et al in press) show that more than 60% UK 
families are linked to chromosome 19q and this gives rise to suppose that a defect 
in the RYRI gene is the main reason to causing their malignant hyperthermia 
susceptibility. In rare cases which do not show linkage to chromosom e 19q 
possibly the genetic background and environmental factors can affect the
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phenotype as modifiers, enhancers or inhibitors. Then the main axis for future 
work will be based on finding out more about the RYRI gene and its protein 
product. For example more mutation screening and introducing the mutant gene 
into a line of normal animals to observe whether the transgenic animal develops 
disease. Eventually it will be necessary to find out more about the relationship 
between the calcium release channel and other factors mentioned in chapter one.
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